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Abstract
Macrophages are mononuclear phagocytic cells that have diverse roles within the body.
Tissue specific macrophages, e.g. Kupffer cells, microglia and osteoclasts, have roles
in tissue homeostasis, while circulating macrophages play an important role in the in-
nate immune system. Macrophages detect the presence of pathogen associated molec-
ular patterns (PAMPs) via a range of receptors known collectively as pathogen recog-
nition receptors (PRRs). Detection of pathogens causes the macrophages to become
‘activated,’ during which the macrophages undergo extreme morphological and trans-
lational changes that enable the pathogen to be neutralised and other immune system
components to be recruited. Macrophage activation must be carefully regulated and
promptly resolved, as chronic inflammation is damaging to the host. MicroRNAs have
emerged as one mechanism by which activation is regulated.
MicroRNAs are small, non-coding pieces of RNA that function as a post-transcript-
ional regulatory mechanism. Their action is exerted through binding with a comple-
mentary region in the 3’ untranslated region (3’UTR) of the target mRNA. This bind-
ing, facilitated by the ribonuclear protein complex RISC, prevents successful transla-
tion of the mRNA into its protein product. MicroRNAs have been shown to function
across species, throughout development and during the adult life-span.
In the immune system, microRNAs are known to be required for correct formation
of germinal centres and normal development of B- and T-cells. MicroRNAs have also
been shown to be differentially regulated during macrophage activation with different
stimuli. In particular, miR-155, miR-146a and miR-21 are associated with macrophage
activation by lipopolysaccharide (LPS).
The objective of this work was to further understand the role of microRNAs during
macrophage activation with LPS. Two approaches were adopted. Firstly, the regu-
lation of individual microRNAs in LPS-activated bone marrow derived macrophages
(BMDMs) was characterised by the use of illumina small RNA sequencing. Secondly,
the requirement of the global microRNA population during macrophage biology was
investigated through the use of DGCR8 and Dicer knockout systems.
In keeping with the large number of changes reported in mRNA translation upon
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activation, expression of >400 microRNAs were found to be differentially regulated
by exposure to LPS. Twelve of these microRNAs were chosen for further study (miR-
142-3p, -146a, -15b, -155, -16, -191, -21, -27b, -30b, -322-5p, -378 and -7a). Indi-
vidual knock-down of these microRNAs in the RAW264.7 macrophage-like cell line
mostly demonstrated subtle, rather than dramatic changes to the activation marker
genes studied by RT-QPCR analysis. However, knock-down of miR-146a, -15b, -
155 and -191 were able to significantly alter the expression of the activation marker
genes (Tnf-a, Cox2, Cxcl2, Il-6 and Saa3). Interestingly, knock-down of miR-142-3p,
miR-146a and miR-155 appeared to show cross-regulation of these microRNAs. The
cell index (CI) data suggested that miR-191 and miR-21 influence adhesion in acti-
vated macrophages. Studies with the DGCR8 and Dicer knockout systems showed
that the global microRNA population was required for successful differentiation of
macrophages from embryonic stem cells, and for normal expression of differentiation
and activation markers in bone marrow derived macrophages.
Overall, these results show that dynamic expression of microRNAs is an integral
part of the macrophage response to LPS.
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Lay Summary
Blood is a complex fluid containing many different components. However, the three
main cell types found in blood are red blood cells which carry oxygen around the body,
platelets which enable blood to clot and white blood cells which form the immune
system and function to fight off disease.
In addition to fighting infections, white blood cells also have roles in general tis-
sue/organ maintenance. Careful regulation of white blood cells by the body is required
in both health and disease otherwise serious medical issues can occur. For example,
an over-active immune system response can cause excessive tissue scarring follow-
ing injury and infection, resulting in reduced tissue/organ function following recovery.
It is also associated with chronic/long-term inflammation which can worsen existing
physiological conditions (e.g. atherosclerosis, psoriatic arthritis) and can lead to the
development of auto-immune conditions (e.g. systemic lupus erythematosus (SLE),
rheumatoid arthritis (RA), Sjögren’s syndrome (SjS), Alzheimer’s and multiple sclero-
sis (MS)) and cancer. By comparison, an under-active immune response is associated
with prolonged illness and infection and the spreading of infection throughout the body
(sepsis) and even death.
Macrophages are a type of white blood cell. They are involved in fighting off infec-
tion and then in subsequent wound healing and tissue repair. Macrophages are found
in all tissues in the body and have roles in general tissue maintenance to ensure opti-
mal health of the host/individual. Some of the important functions macrophages are
associated with include normal regulation of reproductive function, neuron survival,
blood pressure, the development of mammary ducts during pregnancy, muscle growth,
metabolism, and the growth and regeneration of bone. Abnormal macrophage func-
tion not only impairs all of these processes but results in a sub-par immune response to
infection (either over- or under-reaction), causing the health problems outlined above.
When macrophages encounter an infection they begin to express different genes to
enable them to change function from a ‘resting macrophage’ focused on tissue main-
tenance to an ‘activated macrophage’ that will attack/neutralise the infection (e.g. re-
leasing toxic molecules to kill the infection and releasing signalling molecules to notify
v
other white blood cells to respond). Turning the appropriate genes on and off is a com-
plex process and has to be carefully regulated to avoid abnormal macrophage function
and its damaging side effects to the host/individual.
Discovered in 1993 in worms, and in a range of other of plant and animal species
by 2001, microRNAs are small molecules made of a substance called RNA that func-
tion to regulate gene expression in all cell and tissue types, and different developmental
stages and functions. Blocking or over-enhancing microRNA function has been found
to be associated with many diseases (e.g. cancer). MicroRNA function is a hugely in-
teresting area of study that is not yet fully understood but contains enormous potential
for the development of future medical tests and treatments.
This work aimed to further understand the role of microRNAs during the normal
macrophage response to infection. Firstly, macrophages were treated with a bacterial
molecule called lipopolysaccharide to mimic an infection and ‘activate’ the macrophages.
Then the microRNAs present in ‘resting’ and ‘activated’ macrophages were identified
and compared. MicroRNAs which were present in different levels in the two states
were short-listed as possibly having a role in macrophage activation. Secondly, 12 se-
lected microRNAs from the short-list were individually removed to determine if they
exerted identifiable effects on the macrophage activation process. Four of the microR-
NAs were found to affect gene expression and two of the microRNAs were found to
affect physical characteristics of the activated macrophages. Finally, we attempted
to create a system in which all microRNAs could be removed from macrophages to
study the requirement of the total microRNA population for normal macrophage func-
tion. Although it was found that the system did not successfully remove all of the
microRNAs, it showed strong potential and future refinement of the system would
likely achieve this goal.
It is expected that future work in this field of study would develop a better under-
standing of the mechanisms behind abnormally functioning macrophages and lead to
treatments for diseases/conditions associated with these cells.
vi
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Macrophages are phagocytic cells of the innate immune system that form the first line
of defence against pathogens. Upon the detection of a pathogen, macrophages initiate a
full immune response, acting to neutralise the invading pathogen and are subsequently
involved in wound healing. The effector functions of macrophages must be carefully
regulated to avoid damage to the host. The most recently discovered mechanism of
macrophage regulation is the microRNA [4, 16, 26].
MicroRNAs are short, non-coding RNA molecules that function as a post-trans-
criptional regulatory mechanism. Initially characterised in C. elegans [149], microR-
NAs have subsequently been found to be encoded in plant, animal and viral genomes
[13, 28, 50]. Across species, the biogenesis and functional mechanisms of microR-
NAs are strongly conserved. First implicated in development of the C. elegans larvae,
microRNAs are now known to function at all stages of development and in most bi-
ological functions within adult organisms. The field of microRNA research is still
expanding; in particular, the clinical potential of microRNAs as bio-markers and ther-
apeutic agents is being explored in detail (see section 1.4.3).
1
1.2 Macrophages
This section provides a general introduction into macrophage biology in order to pro-
vide context for the main body of this project which focuses on the role of microRNAs
during macrophage activation.
Macrophages are the principal cells of the mononuclear phagocyte system (MPS)
which is comprised of mononuclear bone marrow progenitors, circulating monocytes
and tissue macrophages. The MPS is a component of the innate immune system which
is the primary, non-specific arm of the eukaryotic immune response. In this guise
macrophages identify, target and destroy pathogens that have breached the physical
barriers of the host and act to stimulate a full immune response through the recruit-
ment of other immune cells to the site of infection. Although activation is the best
known macrophage state, the resident tissue macrophages are equally important, reg-
ulating several aspects of tissue development and homeostasis. Through steady-state
and reactive roles, macrophage regulation is associated with both health and disease
(reviewed in [282]).
1.2.1 Differentiation of macrophages
Monocytes and macrophages are derived in the bone marrow from haematopoietic
stem cells (HSCs) along the myeloid differentiation pathway (Fig 1.1). The end point
of HSC differentiation is dependent upon the interplay between, and the dynamic ex-
pression of, many transcription factors and cell markers (reviewed in [107]). A pivotal
example of dynamic marker expression during monocyte and macrophage differentia-
tion is the emergence of the macrophage colony-stimulating factor receptor (CSF-1R
or M-CSFR) on the progenitor cells. CSF-1R interacts with the macrophage colony-
stimulating factor (CSF-1) creating a signal/receptor positive feedback loop that specif-
ically drives myeloid differentiation through increased expression of CSF-1R. Cells
which are not exposed to CSF-1 down-regulate the expression of CSF-1R and do not
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Figure 1.1: Macrophage Differentiation and the Haematopoietic System. The
haematopoietic stem cell (HSC) gives rise to two different progenitors: 1) the com-
mon lymphoid progenitor (CLP) which seeds the adaptive immune system (B-cells
and T-cells) and NK-cells; and 2) the common myeloid progenitor (CMP) which can
differentiate into all of the other cell types present in the immune system (dendritic
cells, neutrophils, eosinophils, basophils, mast cells, monocytes/macrophages) and
core blood component cells (erythrocytes and platelets). Macrophages are the final
step in the monocyte/macrophage differentiation pathway which occurs under the in-
fluence of the monocyte growth factor colony stimulating factor-1 (CSF-1). Adapted
from [117].
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follow the myeloid differentiation pathway. A selection of cell markers and transcrip-
tion factors that were measured during this study are described herein (sections 1.2.1.3
and 1.2.1.4).
1.2.1.1 Embryonic macrophages
Macrophages are required during embryogenesis to carry out key functions in organo-
genesis, controlled apoptosis (webbing) and scarless wound healing (reviewed in [124,
206]). Macrophages are able to participate in these functions because they are gener-
ated in the primary stages of development. Embryonic macrophages develop in two
distinct waves of cellular differentiation. Early developmental macrophages are de-
rived from the embryonic yolk sac (YS). These primitive yolk sac macrophages are
a distinct population from the definitive, bone marrow derived, ‘adult’ macrophage
population.
The first wave of macrophage differentiation in the embryo begins during gastrula-
tion when mesoderm cells colonise the yolk sac and become known as haemangioblast
cells. These cells form the blood islands in the YS, producing blast-colony-forming
cells (blast-CFCs) which in turn give rise to the primitive haematopoietic cells, includ-
ing myeloid progenitor cells. The myeloid progenitors then migrate to the fetal liver,
joining HSCs from the aorta-gonad-mesonephros (AGM) to form a haematopoietic
progenitor pool.
Definitive macrophages arise during the second wave of embryonic macrophage
differentiation. These cells are derived from haemangioblasts that migrated to the
AGM and became the first recognisable HSCs. The HSCs migrate to the fetal liver,
multiply and then migrate through the circulatory system to colonise different areas
of the body. The HSCs that migrate to the bone marrow form the major source of
macrophages for the remainder of embryonic development. These AGM-derived HSC
pools persist in the adult, providing haematopoietic progenitors throughout the organ-
ism’s lifetime.
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The biological origins of resident tissue macrophages vary throughout the body.
YS-derived progenitors have not been found to contribute to the adult progenitor (HSC)
pool in the bone marrow. By comparison, microglia are exclusively derived from YS
macrophages, while Kuffper cells and alveolar macrophages demonstrate a mixture of
YS and fetal liver derived cells [82, 152, 168]. Of particular note are the barrier tissues
(skin and gut) in which the majority of resident tissue macrophages are adult cells de-
rived from the bone marrow. The full implications of these different biological origins
on the biological functions of the resident tissue macrophages in the adult organism
are still being elucidated [59, 227, 226, 235].
1.2.1.2 Macrophages in the adult organism
As discussed above, the first ‘adult’ macrophages are derived from AGM-lineage haem-
atopoietic stem cells during development. After birth, the majority of mammalian
macrophages are generated from the HSCs in the bone marrow of the long bones (e.g.
the femur and sternum). Macrophage differentiation in the bone marrow follows sev-
eral distinct steps: haematopoietic stem cell - common myeloid progenitor - granu-
locyte/macrophage progenitor - monocyte - macrophage (Fig 1.1). At the monocyte
stage the cells migrate out of the bone marrow into the circulation, from where the
monocytes can enter the tissues, undergoing terminal differentiation into macrophages
and replenishing the tissue macrophage populations (section 1.2.2). Meanwhile some
cells remain as circulating monocytes, only entering the tissue in a localised manner
in response to inflammatory signals at the site of an infection and becoming activated
macrophages (section 1.2.3).
Differentiation is driven by the dynamic interplay of surface markers, transcription
factors and growth factors. During experimentation, a panel of these well-characterised
molecules from across different macrophage developmental stages were selected as
markers to confirm successful in vitro macrophage cultivation and as output variables,
in order to assess the effects of treatment conditions reported in subsequent chapters of
5
this work. The selected markers and their roles in normal macrophage differentiation
are described below (Fig 1.2).
1.2.1.3 Surface markers
Surface markers are used to identify and distinguish different macrophage populations
and sub-populations. Although useful tools for characterisation, it is important not to
consider surface markers and the sub-populations that they represent as static. There
is a growing consensus that macrophage populations reflect a fluid continuum rather
than fixed end-points (reviewed in [180, 287]) and that there is much variation in gene
expression between individual cells within a population [230].
c-kit Also known as CD117, the proto-oncogene c-kit is a transmembrane tyrosine
kinase receptor with the same general structure as other receptors from this family,
including c-fms (aka CSF-1R, section 1.2.1.5). It is expressed on mesoderm and early
haematopoietic progenitors and is associated with cell survival and proliferation (re-
viewed in [162]). The c-kit ligand has several names: stem cell factor, kit ligand (KL),
mast cell growth factor and steel factor. For the purpose of clarity it is referred to here
as stem cell factor (SCF).
Within the haematopoietic system c-kit expression is mostly limited to progenitor
cells [162] and is found on cells from both myeloid and lymphoid lineages [60]. The
c-kit/SCF interaction is known to play an important role during early haematopoiesis.
The application of SCF causes a dose-dependent expansion of progenitor cells within
the bone marrow [60], while the in vitro application of anti-KIT (anti-SCF) monoclonal
antibodies has been found to decrease the numbers of colony forming cells (CFCs) in
the culture samples [289]. Studies suggest that c-kit expression is high during devel-
opment but decreases with cellular maturation [60]. Expression also varies between
species; c-KIT is present on less than 0.1% of human peripheral blood, but is more
common in mice where it can be detected on approx 50% of monocytes [162].
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CD34 CD34 is a mucin-like cell surface glycoprotein (reviewed in [74]). Expression
of CD34 occurs early in development; it is detected on early haematopoietic precursors
and endothelial cells in the yolk sac and AGM [65, 74]. Also present on stem cells and
myeloid progenitors, CD34 expression is down-regulated with differentiation and, with
the exception of mast cells, not expressed on mature haematopoietic cells [65, 74, 197,
234].
The function of CD34 is as yet unknown, but it is thought to support HSC main-
tenance. In vitro CD34+endothelial cells mediate expansion of CD34+haematopoietic
precursor cells in co-culture, but CD34-/-mutants show only a mild haematopoietic de-
fect. CD34 is also thought to act as an adhesion or anti-adhesion molecule to facilitate
the migration of haematopoietic precursors to the appropriate niche [65, 74].
Bclx BCL-2-like 1 (Bclx) is an anti-apoptotic factor that promotes cell survival (re-
viewed in [35]). It is expressed in the majority of CD34+cells and promotes HSC sur-
vival [220, 292]. Bclx-/- mice die at approximately d13 in utero due to massive apopto-
sis of haematopoietic progenitor cells. Bclx is present on myeloid precursors, periph-
eral blood monocytes and alveolar macrophages but not on polymorphonuclear cells
or blood neutrophils [220]. This indicates that Bclx expression continues to play an
important role in the survival of myeloid cells and the initial stages of haematopoiesis.
uPA Urokinase plasminogen activator (uPA) is a multifunctional extracellular serine
protease which interacts with its receptor, uPAR/CD87, to regulate several different
cellular events including adhesion, surface proteolysis, chemotaxis, fibrinolysis, tis-
sue remodelling and haematopoiesis (reviewed in [138, 177, 264]). UPA expression is
regulated by RUNX1, while increased uPA expression correlates with in vitro differ-
entiation of HL-60, NB4 and THP-1 cells, indicating a role for uPA in haematopoiesis
[138, 199]. UPA-deficient mice display impaired wound healing and inflammatory
responses; 30% fewer peritoneal macrophages were recovered from uPA-/- mice com-
pared to control animals; and inefficient T-cell and macrophage migration resulted in
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the death of uPA-/- mice from pulmonary infections [113, 177, 199].
F4/80 F4/80 is a member of the EGF-TM7 receptor family which is part of a larger
family of tissue adhesion G-protein coupled receptors (GPCRs) that are thought to
have dual adhesion and signalling functions in the immune system. It is not yet known
if F4/80 couples intercellularly with GPCRs and, like most EGF-TM7 receptors, its
ligand remains unidentified (reviewed in [85]). F4/80 is an ortholog of the human
gene EMR1; and while EMR1 is only found on eosinophils, F4/80 is expressed on all
murine macrophage populations ([12] and reviewed in [85, 155]) where it is consid-
ered a marker of macrophage maturation. Therefore, variation of F4/80 expression is
related to developmental stage rather than sub-population: F4/80- progenitors give rise
to F4/80+ monocytes and macrophages [12, 102, 108]. This specificity of expression
is due to the presence of a purine-rich region within the enhancer region that binds the
myeloid associated transcription factor PU.1 [85, 155]. Knockout studies have shown
that although F4/80 is not required for normal macrophage development, it does appear
to play a role in the development of peripheral tolerance [85, 155].
1.2.1.4 Transcriptional changes during macrophage differentiation
Macrophage differentiation is a dynamic process driven by the interconnected expres-
sion of a number of transcription factors and their downstream targets. The expression
of three transcription factors known to be associated with macrophage and myeloid
cell development were measured as part of this study.
PU.1 Considered to be the major myeloid transcription factor, PU.1 (Spi-1) is a
member of the Ets transcription factor protein family. PU.1 expression is restricted to
haematopoietic tissues and varies in a stage- and lineage-specific manner. It is required
for the differentiation and maturation of myeloid and B-cells but not erythroid or T-
cells (reviewed in [51, 68, 75, 215]). While the initial expression of PU.1 in HSCs is
induced by Oct-1 and GATA1, Spi-1 contains a PU.1 binding site which is important
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Figure 1.2: Changes in Gene Expression during Macrophage Differentiation. The
expression of surface markers and transcription factors varies during macrophage dif-
ferentiation with individual genes being turned on or off at different stages along the
maturation process. The expression of RUNX1, uPA, PU.1, c-kit, c-Myb, CD34, CSF-
1R, Bclx and F4/80 during macrophage differentiation are summarised here. Full de-
scriptions of these genes and their functions during macrophage differentiation can be
found in sections 1.2.1.3-1.2.1.5. HSC = haematopoietic stem cell. CMP = common
myeloid progenitor. GMP = granulocyte mononuclear progenitor.
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for the self-regulation of PU.1 expression in myeloid cells. PU.1 has also been found
to promote the expression of almost all other myeloid-specific genes, including CSF-
1 and CSF-1R. Mutation of the PU.1 binding site reduces or ablates PU.1 promoter
function. Deletion of PU.1 prevents the generation of myeloid cells, both in vivo and
in vitro, by disrupting the action of the macrophage growth factor CSF-1. PU.1-/-cells
can expand in response to generic growth factors, but no longer respond to CSF-1
since PU.1 is required to induce expression of its receptor c-fms/CSF-1R. Restoration
of PU.1 expression in vivo and in vitro rescues the ability to form macrophages [68,
75, 197, 215].
RUNX1 Also known as acute myeloid leukemia protein-1 (AML-1), Runt related
transcription factor-1 (RUNX1) is a Runt family transcription factor protein that is
required for normal fetal haematopoiesis, and for lymphogenesis and megakaryocyte
formation in the adult (reviewed in [112, 288]). RUNX1 is constitutively expressed in
all haematopoietic lineages in mammals except erythroid cells [112].
During development, the dosage of RUNX1 must be carefully regulated to ensure
normal haematopoiesis. RUNX1+/-animals can produce early haematopoietic cells in
the YS but prematurely abandon haematopoiesis in the AGM. In RUNX1-/-embryos
normal YS haematopoiesis is observed but there is no sign of definitive haematopoiesis,
resulting in death in utero at approximately d12.5. Conditional deletion of RUNX1
in adult mice was not found to be lethal, instead causing a myeloproliferative disor-
der. RUNX1 deletion or loss of function is also associated with human leukemias
[112, 215, 288].
Most of the genes regulated by RUNX1 are specific to haematopoiesis including
IL-3 and CSF-1R [112, 288]. RUNX1 has a co-factor, CBFb, with which it forms a
heterodimer. DNA-binding to target genes occurs via RUNX1, while CBFb acts to
enhance this interaction. RUNX1-/-and CBFb-/-studies demonstrate matching embry-
onic lethal phenotypes, and mutations in CBFb are also associated with acute myeloid
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leukemia (AML). This shows that heterodimerisation of RUNX1 with CBFb is crucial
for RUNX1 function [112, 288].
c-Myb C-Myb is a homolog of the leukemia-inducing avian retroviral oncogene v-
myb. Correct c-Myb expression is essential for successful haematopoiesis. The c-
Myb-/-genotype is embryonic lethal, and although it can produce low numbers of
haematopoietic progenitors, it fails to produce either erythrocytes or myeloid cells.
The ability of HSCs to develop in the absence of c-Myb suggests that the lack of ery-
throid and myeloid cells in c-Myb-/-mice may be due to a block in differentiation rather
than a failure to produce HSCs. In conditional c-Myb-/-mice, decreased expression of
c-Myb was associated with increased numbers of haematopoietic progenitor cells in
the fetal liver and adult bone marrow. Over-expression of c-Myb was also found to
prevent erythroid and myeloid cell differentiation. The fact that myeloid differenti-
ation is prevented by both over-expression and ablation of c-Myb indicates that its
expression must be properly regulated to ensure normal haematopoietic development.
Several molecules are thought to regulate c-Myb gene expression, including NFkB,
Est-1 and miR-150, while c-Myb protein activity is controlled by post-translational
protein modifications [87].
1.2.1.5 CSF-1 and CSF-1R
Several growth factors are required during macrophage differentiation. In the early
stages of haematopoiesis the more general survival factor IL-3 maintains cell viability;
at later stages the required growth factors become lineage-specific e.g. CSF-1 and GM-
CSF. Colony stimulating factor-1 (CSF-1), also known as macrophage-colony stimu-
lating factor (M-CSF), is a homodimeric glycoprotein that is required for the survival
and proliferation of mononuclear phagocytes. It acts via binding and dimerisation of
its receptor, colony stimulating factor-1 receptor (CSF-1R), which is considered the
archetypal macrophage marker.
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Structure and expression The mRNA generated by the human Csf-1 gene encodes
a 522aa protein precursor. While the 150aa terminal segment of the precursor is re-
quired for biological function in vitro (reviewed in [246]), alternative post-translational
mRNA splicing and proteolytic processing give rise to three isoforms: a secreted gly-
coprotein, a secreted proteoglycan and a membrane-spanning proteoglycan [124, 246].
Produced by a range of cell types, CSF-1 acts both locally and humorally via high
affinity binding to its receptor CSF-1R, which is expressed on myeloid cells. The
CSF-1/CSF-1R complex is then internalised and destroyed (reviewed in [96, 124]).
CSF-1R is expressed on cells of the haematopoietic and trophoblast lineages. It is
one of the earliest macrophage-specific markers to be detected and cells expressing it
are regulated by CSF-1 [124]. CSF-1R is the protein product of the proto-oncogene
c-fms, an ortholog of the sarcoma virus v-fms gene [96, 246]. Structurally, CSF-1R is
a membrane-spanning protein with intrinsic tyrosine kinase activity. The extracellular
ligand-binding domain contains five immunoglobulin (Ig)-like loops, and the cytoplas-
mic portion contains the protein tyrosine kinase (PTK) domain (Figure 1.3) [96, 246].
Signalling The steps in the CSF-1/CSF-1R binding interaction are as follows: re-
ceptor dimerisation, autophosphorylation and signalling, tyrosine dephosphorylation,
internalisation and degradation [96]. CSF-1 mediated dimerisation causes activation
of the CSF-1R tyrosine kinase domain, creating high-affinity Src homology region 2
(SH2) binding sites via transphosphorylation of specific tyrosine residues. Receptor
tyrosine kinases (RTKs) such as Grb2, PI3-kinase, STAT-1 and Src, can bind the SH2
domains, triggering intracellular signalling cascades through tyrosine phosphorylation
of other proteins.
In macrophages CSF-1 induces phosphorylation of GTPase-activating protein (GAP)
which goes on to activate small GTP-binding proteins such as Ras which are required
for proliferation and survival. Specifically, CSF-1 binding causes phosphorylation
of CSF-1R Y809, leading to Ras activation, Ets transcription factor activity and in-
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Figure 1.3: Colony Stimulating Factor-1 Receptor (CSF-1R) Structure. The extra-
cellular domain contains five immunoglobulin (Ig)-like loops which mediate CSF-1-
binding and subsequent receptor dimerisation. Upon activation, the protein tyrosine
kinase (PTK) domain in the cytoplasmic region transphosphorylates specific tyrosine
residues in the cytoplasmic tail, which mediates binding and activation of downstream
signalling molecules. Image from [205].
13
creased c-Myc expression, resulting in cell proliferation [96]. The final step in the
CSF-1/CSF-1R binding interaction is the internalisation of the CSF-1/CSF-1R com-
plex via clathrin-coated pits followed by its degradation by lysosome activity [96].
Function Acting both locally and humorally, CSF-1 controls the mononuclear phago-
cyte population by driving the survival, proliferation and differentiation of myeloid
cells. During development CSF-1 expression correlates with key periods of organo-
genesis indicating that CSF-1, through the regulation of trophic macrophages and their
roles in tissue remodelling, is required for normal development. The multiple devel-
opmental defects that occur in the absence of CSF-1 (e.g. Csf-1op/op mice) confirmed
this theory [124, 246].
Knockouts The best characterised CSF-1-deficient model is the osteopetrotic mouse
(Csf-1op/op). The result of a naturally occurring spontaneous autosomal recessive null
mutation, the op/op mouse produces a biologically inactive isoform of CSF-1. This
lack of biologically active CSF-1 is characterised by several phenological defects: a
severe lack of osteoclasts, mononuclear phagocyte deficiency, low body weight, short
life-span, poor breeding performance, skeletal abnormalities, a lack of teeth and de-
creased sensory processing. Many, but not all of these defects can be reversed by
neonatal injection of CSF-1, suggesting that local, rather than humoral production of
CSF-1 is required for the development of some tissues [246].
Surprisingly, IL-34 can act as a functional CSF-1R ligand [78] despite not sharing
any sequence homology with CSF-1 and having different receptor binding kinetics
[124]. Under normal circumstances the complementary and non-redundant functions
of CSF-1 and IL-34 are determined by differences in temporal and spatial expression;
for example expression of IL-34 in the brain occurs earlier and at a higher level than
expression of CSF-1 [124]. Experimentally, IL-34 has been shown to correct CSF-1-/-
defects when expressed transgenically under the CSF-1 promoter, and macrophages
differentiated in the presence of IL-34 have been shown to develop a M2 phenotype,
14
similar to CSF-1 responsive macrophages[124].
1.2.2 Macrophages in tissue homeostasis
Although best known as cells of the innate immune response, macrophages play impor-
tant roles in tissue development and homeostasis in the guise of professional phago-
cytic cells. Macrophages are involved in several processes including angiogenesis,
regulation of adipose tissue, neuronal patterning and bone morphogenesis. Mature
macrophages constitute 10-20% of all cells and are found throughout the tissues of
the body [206]. Known collectively as tissue macrophages, these cells have become
specialised to the local tissue environment and are anatomically distinct: Kupffer cells
in the liver; microglia cells in the central nervous system; Langerhans cells in the epi-
dermis and osteoclasts in the bone, to name a few. Tissue macrophages are required
for the maintenance of homeostasis, while macrophage depletion impairs both tissue
formation and function [206, 282]. The importance of resident tissue macrophages
for organ development and tissue homeostasis is apparent from CSF-1 and CSF-1R
mutants (section 1.2.1.5).
Tissue patterning and remodelling Developmental tissue patterning and remod-
elling requires apoptosis and subsequent phagocytosis of the dead cells. Ablation of
macrophages during development impairs dead cell clearance and disrupts remodelling
in several tissues including lung, kidney and pancreas. Macrophages are also known
to identify and degrade ejected nuclei during erythrogenesis [206]. PU.1-/-mice ex-
hibit changes to the dermal lymphatic vasculature, and the tissue abnormalities of the
CSF-1op/opmice are well documented (reviewed in [248, 282] and section 1.2.1.5).
Trophic macrophages The requirement of macrophages for the normal regulation of
multiple bodily processes is perhaps most clearly demonstrated in the manifold issues
affecting the macrophage-deficient CSF-1op/opmouse. Macrophages are also associ-
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ated with the normal regulation of reproductive function, neuron survival, blood pres-
sure, the development of mammary ducts during pregnancy, myocyte growth macrophages,
metabolism, and the growth and regeneration of bone by osteoclasts. Macrophage
depletion impairs all of these processes, illustrating the importance of macrophages
in tissue development and homeostasis outside of their characteristic immune system
roles [206, 248, 282].
Wound healing Fetal wound healing occurs in the absence of an inflammatory re-
sponse; it is sterile, fast and scarless. By comparison adult wounds are reliant on the in-
flammatory response and growth factors to promote rapid healing, resulting in fibrosis
and scarring (reviewed in [236]). Adult wound healing consists of three overlapping
stages: 1) inflammation 2) tissue formation and wound closure, and 3) remodelling.
Ablation of macrophages at these different stages causes distinct effects on the pro-
cess. Ablation pre-inflammation causes prolonged expression of the pro-inflammatory
response. Ablation during the early inflammatory response is associated with reduced
tissue formation and disrupted wound healing, while ablation during remodelling has
no discernible effect [236, 248].
1.2.3 Macrophage activation
Macrophage activation is the process by which macrophages recognise and respond
to foreign antigens or physical assaults. Macrophage activation causes dramatic struc-
tural and transcriptional changes within the macrophage which act to neutralise the
foreign ‘threat’ and to initiate a full immune response. Resolution of the inflammatory
response is required for wound healing and the prevention of chronic inflammation.
There are considered to be two types of macrophage activation. Alternatively acti-
vated macrophages (AMM or M2) are characterised as anti-inflammatory. Associated
with tissue remodelling, these cells have roles in tissue homeostasis and metabolism
[25, 182]. The alternative macrophage activation pathway is mediated by the Th2 cy-
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tokines IL-4 and IL-13 [84].
Classically activated macrophages (CAM or M1) are considered to be pro-inflam-
matory cells and are associated with the immune response to cellular pathogens such
as bacteria and viruses (e.g. Mycobacterium tuberculosis and HIV), through the ex-
pression of pro-inflammatory cytokines and chemokines (e.g. TNF-a, IL-1b, IL-12,
CXCL10 and CCL2). These cells also show tumouricidal activity [25, 182]. The
M1 phenotype is most commonly associated with IFN-g signalling and the Th1 re-
sponse. The production of IL-12 by M1 macrophages induces Th1 cell differentiation
and subsequent production of IFN-g, thereby activating macrophages and perpetuating
the immune response. However, it can be induced by microbial stimuli via Toll-like
receptors (TLRs), e.g. LPS/TLR-4 [25, 81, 84, 225].
1.2.3.1 Detection of foreign organisms
Pathogen associated molecular patterns Pathogens contain specific chemical mo-
tifs that are not present in host cells. These motifs are usually key structural com-
ponents that the pathogenic species cannot change or substitute, such as flagellin and
Gram-negative cell wall components. The enforced conservation of these molecules
makes them reliable and characteristic markers of pathogenicity which are recognised
by the innate immune system and stimulate an immunological response. These molec-
ular markers are known as pathogen associated molecular patterns (PAMPs). Although
not directly produced by pathogens, endogenous damage associated molecular patterns
(DAMPs) such as heat-shock proteins, HMGB1 and extracellular matrix (ECM) com-
ponents are released as a result of pathogen-associated host cell damage, and are also
capable of activating the innate immune response (reviewed in [3, 36, 129, 255]).
Pathogen Recognition Receptors PAMPs are recognised by specific germline en-
coded receptors called pathogen recognition receptors (PRRs). The four PRR families
currently identified are: C-type lectin receptors (CLRs), NOD-like receptors (NLRs),
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Table 1.1: Pathogen Recognition Receptors (PRRs) and Their Associated Ligands.
PRRs vary in cellular localization and in ligand specificity. This ligand specificity
between receptors enables accurate detection of, and distinction between, different
types of pathogen (bacteria, fungi, virus etc). The ability to determine the type of
pathogenic assault enables the host to initiate the appropriate immune response for the
situation detected, resulting in a more effective clearance of the pathogen. Table from
[129].
Retinoic acid-inducible gene (RIG)-I-like receptors (RLRs) and Toll-like receptors.
Different PRRs specifically recognise different PAMPs; a complete list of these inter-
actions can be found in Table1.1. PRRs are expressed on the surface of macrophages
and in specific cytoplasmic compartments. The signalling cascades generated by spe-
cific PRR/ligand interactions vary, and the genes subsequently induced drive the ap-
propriate immune response for the pathogen detected [36, 129, 255].
Toll-like Receptors Toll was initially identified in Drosophila, where it was found
to play a role in defence against fungal infections. Homologs of Toll were subse-
quently discovered in mammals and were named Toll-like receptors (TLRs). Struc-
turally, TLRs are single-membrane-spanning proteins that possess N-terminal leucine-
rich repeats (LRRs), a transmembrane domain and a cytoplasmic Toll/IL-1 homology
(TIR) domain. The LRRs determine ligand-binding specificity; to date 10 TLRs have
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been identified in humans and 12 in mice. Both species contain TLRs 1-9, but TLR-
10 is non-functional in mice and TLRs 11-13 are not found in the human genome.
TLRs -1, -2, -4, -5 and -6 are located on the cell surface while TLRs -3, -7, -8, and -9
are expressed in the cytoplasm (Fig 1.4). The interactions of TLRs as homodimers or
heterodimers (e.g. TLR-1/TLR-2 and TLR-2/TLR-6) enable the detection of a range
of microbial products and the initiation of a targeted immune response. Ablation of
individual TLRs causes specific PAMP detection failure.
TLR/ligand binding interactions induce signalling cascades via the TIR domain
that cause up-regulation of distinct gene sets. Broadly speaking, there are two main
TLR signalling pathways: MyD88-dependent and TRIF-dependent. Most TLRs utilise
only one of these pathways but TLR-4/LPS binding stimulates both pathways [36, 129,
255].
1.2.3.2 Stimulation of TLR-4 by LPS
Lipopolysaccharide (LPS) is a component of the outer membrane of Gram-negative
bacteria. LPS is recognised by the macrophage via TLR-4, and activates the immune
response. Chronic stimulation of the immune response by LPS causes septic shock.
TLR-4 is expressed on the surface of macrophages where it binds with myeloid
differentiation factor 2 (MD2) to form the LPS-binding component. LPS binds to the
TLR-4/MD2 component via lipid chains, with the assistance of CD14 and the LPS-
binding protein (LBP). The TLR-4/MD2/LPS complex then forms a homodimer with
another copy of the complex. Formation of the TLR-4/MD2/LPS homodimer in the
plasma membrane triggers macrophage activation through early stage NFkB induc-
tion via the MyD88 signalling pathway. The homodimer complex is then internalised,
where it triggers late-stage NFkB induction via the TRIF/TRAM pathway before the
endosome is marked for destruction (Fig 1.5) [36, 129, 255].
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Figure 1.4: TLR Specificity for Microbial Products. The mammalian immune system
possesses several different TLRs which demonstrate specificity for different PAMPs.
The extracellular TLRs (-1, -2, -4, -5, -6, -10 and -11) detect pathogenic structural
components while the intracellular TLRs (-3, -7, -8 and -9) detect alien nucleic acid
motifs. Both the cellular location and the ligand specificity of the TLR ensure that
PAMP/TLR binding generates the appropriate immune response for the recognised
threat. The majority of TLRs signal through the MyD88-dependent pathway; TLR-
3 and TLR-4 are exceptions. TLR-3 exclusively uses the TRIF-dependent pathway,
while TLR-4 is able to stimulate both signalling cascades. Image from [221].
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MyD88-dependent signalling MyD88 is the major TLR signalling molecule. It
is required by all TLRs except TLR-3. TLR-4/LPS binding on the surface of the
macrophage triggers the MyD88-dependent signalling pathway. This causes early-
stage activation of NFkB via IRAK and MAPK signalling, which in turn induces the
production of pro-inflammatory cytokines such as TNF-a and IL-6 [36, 129, 255].
TRIF-dependent signalling Also known as MyD88-independent signalling the TRIF-
dependent signalling pathway does not utilise MyD88. Instead the adaptor molecules
TRIF and TRAM bind to the internalised TLR-4 complex in the endosome. The TLR-
4/TRIF/TRAM interaction causes late-stage activation of NFkB and the associated
second wave of pro-inflammatory gene expression. The TRIF-dependent pathway also
initiates the type I interferon response via the activity of IRF3 [36, 129, 255].
It is the utilisation of these two signalling pathways (MyD88 and TRIF/TRAM)
that generates the two ‘waves’ of transcriptional response (early- and late-stage NFkB
induction) that are characteristic of LPS stimulation in macrophages (Fig 1.5). The
expression of hundreds of genes has been shown to change in macrophages upon LPS
signalling [189, 275]. Some of these transcriptional changes are described below.
1.2.3.3 Transcriptional changes
Activation of mature macrophages with LPS is known to cause dramatic transcriptional
changes in hundreds of genes [105, 189, 275]. A selection of genes well-characterised
within the macrophage response to LPS were chosen as experimental outputs during
this work and are described here.
TNF-a Tumour necrosis factor-a (TNF-a) is a potent pro-inflammatory cytokine that
is rapidly and strongly induced in macrophages that are stimulated with LPS ([170],
reviewed in [200]). Transcription of TNF-a is mediated via NFkB signalling and goes
on to produce a 27kDa membrane-bound product and a 17kDa soluble isoform, en-
abling TNF-a to act in either an autocrine or a paracrine fashion to affect the prolifer-
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Figure 1.5: TLR-4 Signalling Pathways. TLR-4 can stimulate both the MyD88-
dependent and the TRIF-dependent signalling pathways upon activation with LPS.
MyD88 pathway stimulation occurs at the plasma membrane and causes the early
NFkB signalling response. The TLR-4/MD2/LPS homodimer is then internalised,
triggering TRIF-dependent signalling within the endosome, in turn causing late phase
NFkB signalling and IFN production via IRF3. Activation of both of these pathways
by the TLR-4/LPS binding complex results in two distinctive waves of NFkB mediated
pro-inflammatory cytokine production. Image adapted from [129].
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ation, differentiation, activation and apoptosis of macrophages. In addition to acting
as a ‘master-regulator’ of the inflammatory cytokine signalling cascade, TNF-a also
induces lipid transduction mediators e.g. prostaglandins. TNF-a signals via two trans-
membrane receptors, TNF receptors (TNFR)-1 and -2. TNFR1 is expressed on most
cell types while expression of TNFR2 is mostly limited to immune cells. TNF-a binds
both receptors with high affinity, and both receptors induce NFkB activation via acti-
vation of IKK and subsequent IkB degradation [200].
Prolonged or over-expression of TNF-a is associated with several chronic inflam-
matory conditions such as inflammatory bowel disease, atherosclerosis, sepsis, and
arthritis (rheumatoid, juvenile and psoriatic). While most responses to TNF-a are con-
sidered ‘fast-acting,’ prolonged expression studies have found that TNF-a sustains the
inflammatory response for several days after the initial assault by keeping macrophages
primed through an autocrine loop. Furthermore, TNF-a expression is associated with
long-term macrophage survival. The combined effect of these TNF-a actions (priming
and survival) suggest that TNF-a plays an active role in chronic inflammation rather
than just being a by-product. Therefore the down-regulation of TNF-a is as important
for the resolution of inflammation as its up-regulation is for the initiation of inflamma-
tion [200].
COX2 Prostaglandin expression is associated with acute phase inflammation. Prost-
aglandins act as chemokines, aiding recruitment of other immune cells to the site of
infection. Other functions include increasing vascular permeability and vasodilation
(contributing to fever and swelling), along with promoting the production and re-
lease of pro-inflammatory cytokines such as IL-6 [269, 280]. Prostaglandin synthesis
is facilitated by the enzymes cyclooxygenase (COX) -1 and -2. COX1 is constitu-
tively expressed on most cell types while COX2 is rapidly induced in LPS stimulated
macrophages and is responsible for the synthesis of prostaglandins during inflamma-
tion [269, 280]. Inhibition of COX2 prevents prostaglandin-mediated IL-6 expression
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in response to LPS [280].
CXCL2 CXCL2, also known as macrophage inflammatory protein-2 (MIP-2) is a
major chemokine for neutrophils. LPS induces CXCL2 expression in macrophages in
a NFkB-dependent manner [53]. Inhibition of CXCL2 impairs neutrophil recruitment
to the site of infection, causing a defective immune response and contributing to the
development of sepsis [8].
IL-6 IL-6 is a pro-inflammatory cytokine that is induced in macrophages in response
to LPS and other pro-inflammatory cytokines [170]. A polypeptide cytokine that is
secreted into the extracellular fluid, IL-6 acts to amplify the inflammatory response
through increased proliferation and differentiation of macrophages. Despite its role
as a pro-inflammatory cytokine, IL-6 does not stimulate TNF-a or IL-1b production.
Instead it appears to suppress TNF-a and IL-1b at the transcriptional level [222]. The
acute phase response is compromised in IL-6-deficient mice which develop normally
but fail to efficiently control viral or intracellular bacterial infections [139].
IL-10 IL-10 is an anti-inflammatory cytokine that is released at the later stages of the
immune response. Expression of the Il-10 gene is induced by TLR/NFkB signalling.
IL-10 functions to down-regulate co-stimulatory molecules on the surface of activated
macrophages as well as the production of pro-inflammatory molecules (e.g. COX2).
The actions of IL-10 and other inflammation suppressor genes are important for the
resolution of inflammation [276].
SAA3 Serum amyloid A (SAA) proteins are acute phase proteins that were originally
discovered in the liver and are associated with high density lipoproteins (HDLs). Most
SAA proteins are expressed in the liver, then enter the circulation to produce a systemic
response. By comparison, SAA3 is expressed in macrophages in a dose-dependent
manner in LPS stimulation [169, 170]. SAA protein expression is mediated by pro-
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inflammatory cytokines such as TNF-a and IL-6 through the transcription factor SAF
(SAS-associated factor), increasing up to 1000-fold upon infection [210].
1.2.3.4 Effector functions
The extensive transcriptional changes that occur in macrophages are not the end point
of activation but contribute to the amplification of the inflammatory response as a
whole. The objective of macrophage activation is the clearance of the pathogen from
the host. This is achieved through a range of effector functions which are mediated by
the activation driven transcriptional changes (Fig 1.6).
Inflammatory mediators Activated macrophages produce and secrete many dif-
ferent molecules that act to enhance the inflammatory response. Pro-inflammatory
cytokines (e.g. TNF-a, IFN-g, IL-1 and IL-6) amplify the activation response in the
surrounding tissue through autocrine and paracrine effects, heightening the activation
state and sensitivity of immune cells at the site of infection. The release of chemo-
attractants (e.g. CXCL2 and MIP1a) by activated macrophages recruits other cells
of the immune system (neutrophils, T-cells, B-cells, NK cells) to the site of infec-
tion, leading to their activation and the perpetuation of the immune response. The
expression of cytokines such as IL-12, IL-18 and IL-23 further shapes the inflamma-
tory response by mediating the polarisation of Th1 and Th17 cells. IFN-g and other
secreted molecules, such as complement receptors and Fc receptors, promote phago-
cytosis and subsequent microbial killing by binding opsonin molecules on the surface
of the pathogen and activating the complement cascade [182, 224, 225].
Phagocytosis and microbial killing Microbes are recognised by specific recep-
tors on the plasma membrane of phagocytic cells, triggering the internalisation of the
microbe into an intracellular compartment called a phagosome. These receptors are
either PRRs (e.g. mannose receptor, Dectin-1, CD14, CD63 and scavenger receptor
A) which recognise PAMPs directly, or are opsonin receptors (e.g. FcR) which recog-
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nise host molecules (e.g. antibodies, complement) bound to the surface of the microbe.
The phagosome then binds with another intracellular compartment called the lysosome
which contains a strongly acidic cargo including several enzymes (e.g. nucleases, li-
pases, glycosidases, proteases and cathepsins) and toxic molecules such as reactive
oxygen species (ROS) and nitric oxide (iNOS), creating a phagolysosome. Upon for-
mation of the phagolysosome the microbe is destroyed by these abrasive molecules in
a process called reactive-oxygen-mediated-killing.
Some microbes have developed mechanisms to escape phagocytosis and microbial
killing. The archetypal example of this is Mycobacterium tuberculosis which survives
by blocking phagosome maturation thereby preventing lysosome binding and subse-
quent microbial clearance, causing a long-term infection.
Following successful microbial killing, the phagolysosome fuses with the Golgi
vesicles, transferring the peptides from the destroyed microbe which are then loaded
onto major histocompatibility complex class II (MHCII) molecules for antigen presen-
tation [182, 239].
Antigen presentation Antigen presentation is the process by which the intercel-
lular environment is sampled and exposed to cells of the immune system. All cells
express major histocompatibility complex class I (MHCI) molecules, but professional
antigen presenting cells such as macrophages express MHCI and MHCII molecules.
The microbial peptides (antigens) that remain in the phagolysosome after microbial
killing are transferred to the Golgi vesicles and loaded onto MHCII molecules. The
MHCII/antigen complex is then expressed on the plasma membrane where it is recog-
nised by the CD4+ T-cell receptor causing T-cell activation, thereby initiating the adap-
tive immune response.
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Figure 1.6: Macrophage Effector Functions. As a consequence of activation
macrophages carry out several functions which aid the development of the immune
response and help to clear the pathogenic assault. The secretion of cytokines,
chemokines and prostaglandins drives the recruitment of other immune cells to the
site of infection; the subsequent activation of these newly arrived cells perpetuates the
immune response. Antigen presentation on MHC molecules provides the link between
the innate and adaptive immune system, as B- and T-cells become activated through
this interaction. Where possible the macrophage phagocytoses the microbe and de-
stroys it through the release of noxious components such as nitric oxide (iNOS) and
reactive oxygen species (ROS) into the phagolysosome.
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1.2.3.5 Resolution of inflammation
The process of inflammation is necessary to fight infection, but unchecked it is ul-
timately damaging to the host and is responsible for conditions such as tissue scar-
ring, sepsis and inflammatory arthritis. Therefore it is important that inflammation is
resolved after the clearance of the pathogen and that tissue homeostasis is restored.
Many of the late-phase genes induced during macrophage activation are actually anti-
inflammatory molecules (cytokines such as IL-10, TGF-b, and inhibitors such as IkB
and IL-1RA) which act to turn off inflammation, induce tolerance and initiate tissue re-
modelling. The requirement of these genes for the normal resolution of inflammation is
seen in their absence, which results in spontaneous inflammation and hypersensitivity
to inflammatory stimuli [276].
The initiation and resolution of the inflammatory response is often described as a
see-saw between the pro- and anti-inflammatory aspects, which can act in a cross- or
self-regulatory manner to drive continued inflammation or its resolution. For example,
once IL-10 expression reaches a tipping point the anti-inflammatory response gains
the upper hand in driving transcription. This results in increased expression of anti-
inflammatory molecules which act to down-regulate the pro-inflammatory response
but also stimulates effector functions of its own (wound healing, tissue remodelling,
tolerisation). Other examples of anti-inflammatory molecules and interactions are de-
scribed below.
The resolution of inflammation is principally achieved through feedback loops in
the immune response. A major target during the resolution of inflammation is the pro-
inflammatory signalling molecule NFkB which up-regulates its own inhibitor (IkB),
and is also targeted by other molecules such as LPS-inducible isoforms of IRAK
(IRAK-M and IRAK-2) and the LPS-inducible proteins such as cryopyrin and Nod2
[276]. TLR signalling can be down-regulated by the action of TIPE2 (tumor necro-
sis factor-alpha-induced protein 8-like 2 (TNFAIP8L2)) which negatively regulates
activator protein-1 (AP-1) and NFkB activation; by the expression of suppressor of
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cytokine signalling (SOCS) proteins which are members of the E3 ubiquitin ligase
family that promote the degradation of TIRAP/MyD88-adaptor-like (MAL) or TRAF
proteins [136]; and by the expression of a LPS-induced MyD88 splice variant which
fails to bind IRAK4 [276]. MicroRNAs have also been shown to regulate macrophage
activation, including miR-155, miR-146a and miR-21 [136], and are described in more
detail in section 1.4.2.2.
Tolerisation The tolerisation of activated cells is a regulatory mechanism that acts
to prevent inappropriate immune responses such as sepsis and chronic inflammation.
Once macrophages have responded to a stimulus, a second stimulus does not result in
prolonged or re-activation. This prevents the chronic activation of macrophages which
could potentially occur in response to the presence of pro-inflammatory cytokines,
even after the pathogen has been successfully cleared from a site. Failure to tolerise
leads to chronic activation and the associated host tissue damage.
Chronic activation Chronic activation is the continued inflammatory response in the
absence of a pathogen. It is detrimental to the health of the host, creating a vicious cy-
cle of tissue damage which in turn amplifies the inflammatory response, exacerbating
the condition. Chronic inflammation can lead to the development of auto-immune con-
ditions and can worsen other physiological conditions (e.g. atherosclerosis, psoriatic
arthritis).
1.2.4 Macrophage summary
Macrophages are highly sensitive and specialised cells of the immune system. Ex-
pression of a range of PRRs for the specific detection of different PAMPs enables a
tailored immune response against the detected pathogen. The initiation and resolu-
tion of macrophage activation can be considered as a transcriptional balancing act. If
activation does not occur successfully the host can succumb to systemic pathogenic
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infection. If activation is not successfully resolved the host can succumb to septic
shock, or at least suffer extensive tissue damage and scarring. Therefore it is essen-
tial for the health of the host that activation and the subsequent immune response are
carefully regulated. Many of the genes induced by activation display auto-regulation
at the transcriptional level. In the last decade microRNAs have been discovered as a
post-transcriptional regulatory mechanism in macrophages.
1.3 MicroRNAs
1.3.1 Discovery of MicroRNAs
Although the term ‘microRNA’ was not coined until 2001, [144, 146, 148] microRNAs
were first discovered in 1993 by Lee, et al. in the larvae of the nematode C. elegans.
They identified a previously unknown short RNA transcript, lin-4, that did not encode
for any protein and yet was required for normal larval development. Knock-down
of lin-4 was found to cause a similar mutant phenotype to that associated with over-
expression of LIN-14. LIN-14 is an important protein in normal larval development;
LIN-14 mutants show abnormal development with repetition of earlier stages instead
of moving on to the adult steps. The fact that loss of lin-4 had a similar outcome to
increasing LIN-14 suggested that lin-4 was regulating expression of LIN-14. The ob-
servations that lin-14 mRNA levels did not change during larval development, and that
lin-4 was complementary in sequence to a repeated element in the 3’ untranslated re-
gion (3’UTR) of the lin-14 mRNA transcript suggested a possible post-transcriptional
regulatory mechanism. It was not until 1997 that a second microRNA:mRNA interac-
tion was discovered, again in C. elegans, by Moss, et al. [179] where lin-4 was also
found to regulate the expression of the cold-shock protein LIN28. In 2000 Reinhart,
et al. [211] discovered a new microRNA named let-7, which was found to regulate
expression of the transcription factor LIN-29 via suppression of lin-41 which contains
two potential let-7 binding sites [238]. These first characterised mRNA/miRNA in-
30
Figure 1.7: The First Characterised miRNA:mRNA Interactions During C. elegans
Development. a) During the early portion of L1 the lin-14 and lin-28 mRNAs are
translated into their associated proteins LIN-14 and LIN-28. b) Towards the end of
L1 the microRNA lin-4 is expressed. It binds to complementary sequences in the
3’UTR of the lin-14 and lin-28 mRNA transcripts, thereby blocking translation. This
results in decreased expression of LIN-14 and LIN-28 which enables the larvae to
transition into the next stage of development, L2. c) and d) During the later stages of
development the microRNA let-7 is expressed. Let-7 causes the repression of LIN-
41 thereby unblocking the expression of LIN-29 and enabling the progression of the
larvae into the adult stage. Image adapted from [211].
teractions are collectively depicted in Figure1.7. The first indication that microRNAs
were a conserved mechanism of gene regulation across species was the detection of
let-7, but not lin-4, across a range of species, including vertebrates, molluscs, arthro-
pods and hemichordates [201]. This was swiftly followed by the discovery of dozens
of new microRNA sequences across C. elegans, Drosophila and zebrafish. These new
microRNA sequences all formed stem and loop secondary structures and several were
evolutionarily conserved across several species [144, 146, 148].
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Figure 1.8: General MicroRNA Biogenesis. MicroRNAs are transcribed in the genome
by polymerase II as single hairpin structures or as hairpin clusters. These primary-
miRNA sequences are processed by Drosha/DCGR8 to form single hairpin structures
of uniform length which are then exported to the nucleus via Exportin-5. Once in the
cytoplasm the pre-miRNAs are processed by Dicer which cleaves the terminal-loop
from the hairpin leaving a miRNA duplex. The duplex is loaded into RISC, unwound
and used to target complementary mRNA sequences. MiRNAs suppress expression
of target mRNAs through translational inhibition, mRNA sequestration and mRNA
cleavage.
1.3.2 MicroRNA biogenesis
1.3.2.1 Transcription of microRNAs
Genes encoding microRNAs are transcribed in the nucleus by RNA polymerase II
[147]. The initial microRNA transcripts are termed primary-microRNAs (pri-miRNAs)
[151] and possess a 5’ cap and polyA tail, the classic structural characteristics of a RNA
pol II transcript. Pri-miRNAs form single or multiple hairpins from single or clustered
microRNA transcripts respectively. There are three categories of microRNA gene (Fig
1.9). Polycistronic genes produce a single pri-miRNA transcript that contains multi-
ple microRNA hairpins; these clustered microRNAs are often related by sequence or
by target mRNA. Intergenic or intronic/exonic genes produce individual pri-miRNAs
[63].
32
Figure 1.9: Genomic Locations of MicroRNA Encoding Genes. a) Polycistronic mi-
croRNA genes give rise to multiple microRNAs from a single transcript. The mi-
croprocessor cleaves the transcript into individual hairpins. b) Intergenic and c) in-
tronic/exonic microRNA genes produce single microRNA hairpins. Adapted from
[63].
1.3.2.2 Nuclear processing of microRNAs
The pri-miRNAs are processed within the nucleus by a protein complex known as the
microprocessor which contains the RNase III protein Drosha and a partner protein (Fig
1.8). Initially discovered in Drosophila and C. elegans, this partner protein was called
Pasha - partner of Drosha [54]. Further study in humans identified the partner protein
as DGCR8 (DiGeorge Critical Region 8) [86]. DGCR8 is a dsRNA binding protein
that interacts with Drosha [86]. Once the microprocessor has bound a pri-miRNA, the
RNase activity of Drosha cleaves the pri-miRNA into individual stem-loop structures
called pre-miRNA [150] (Fig 1.10). Knock-down of either Drosha or DGCR8 im-
paired miRNA processing, resulting in elevated pri-miRNA expression levels and an
associated drop in mature miRNA levels [54, 86, 150]. Complete knockout of DGCR8
exon 3 in embryonic stem cells (ESCs) prevents correct differentiation, suggesting that
miRNAs may be involved in regulating pluripotency and self-renewal markers under
normal conditions [274].
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Figure 1.10: Nuclear Processing of MicroRNAs. The microprocessor protein complex
consists of Drosha and a partner protein (Pasha or DCGR8 depending on species). The
microprocessor binds to the primary microRNA (pri-miRNA) transcript and the RNase
activity of Drosha cleaves it into a single pre-miRNA hairpin that can be loaded into the
RAN-GTP/Exportin-5 complex and exported to the cytoplasm for further processing.
Adapted from [228].
Once processed by the microprocessor, the resultant pre-miRNA is then exported
from the nucleus via Exportin-5. Exportin-5 is a member of the karyopherin family
of nuclear-cytoplasmic transport factors and requires a Ran-GTP co-factor to facilitate
transport of its cargo across the nuclear membrane [161, 295]. Unusually, Exportin-5
is also responsible for the nuclear export of the Dicer mRNA (mRNAs are normally
exported via TAP-p15). This interaction enables Exportin-5 to exert a double-feedback
loop on microRNA expression - decreased expression of Exportin-5 inhibits both the
export of pre-microRNAs to the cytoplasm and inhibits production of Dicer protein
through decreased export of the Dicer mRNA. Both of these factors inhibit miRNA
processing, subsequently reducing the number of mature microRNAs produced [21].
1.3.2.3 Cytoplasmic processing
In the cytoplasm the stem-loop is cleaved from the pre-miRNA by Dicer, leaving a
miRNA duplex which is then loaded into the RNA-induced silencing complex (RISC).
The duplex is subsequently unwound, one strand is degraded, and the remaining guide
strand is used for mRNA targeting (Fig 1.8).
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Figure 1.11: Cytoplasmic Processing of MicroRNAs. The pre-miRNA is processed in
the cytoplasm by the protein Dicer. The action of Dicer’s dual RNase domains (RIIIa
and RIIIb) cleaves the stem-loop from the pre-miRNA, producing the characteristic 2nt
overhang at the 3’ end of the resultant miRNA duplex. The lightning marks indicate
the cleavage sites in the RNA. Adapted from [10].
Dicer Dicer is a conserved bidentate ribonuclease with a helicase domain, dual RNase
III motifs and an Argonaute homology domain [22]. First described during RNAi stud-
ies, a role for Dicer in miRNA processing was indicated by the phenotypic mutations,
and germ-line defects of Dicer-1 C. elegans mutants [132, 135]. The key role of Dicer
in miRNA processing was confirmed by an abnormal accumulation of pre-let-7 during
Drosophila development when Dicer was knocked-down [110], and by the embryonic
lethality of Dicer mutants across species [23, 91, 277].
Processing of the pri-miRNA occurs via the Dicer dual RNase III motifs. The
motifs form a homodimer that is stabilised by the flanking RNA-binding domains,
creating a single RNA processing centre with two cleavage sites. The action of the
two cleavage sites causes the characteristic 2nt overhang at the 3’ end of the resultant
miRNA duplex [296] (Fig 1.11). The mature miRNA duplex is then loaded into RISC
which facilitates mRNA targeting and cleavage.
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RISC RISC was first identified in Drosophila during studies into the mechanism of
RNAi [98] after the surprising discovery that dsRNA was a more potent gene suppres-
sion mechanism than ssRNA [67]. Extracts from cells transfected with a dsRNA were
found to degrade their target mRNA in a sequence-specific manner. A ribonuclease
complex was found to co-precipitate with ~25nt RNA fragments and was subsequently
called RISC [98].
Argonaute One common feature of RISC across species is the presence of an Arg-
onaute (AGO) family protein, or one of the Argonaute orthologs. The role of the Arg-
onaute family in microRNA processing was initially discovered through RNAi studies
which revealed that Piwi domain proteins were required for successful small RNA me-
diated gene silencing [34]. The Piwi domain is a conserved region ~300aa in length
located at the C’ terminus of members of the RNA-dependent RNA polymerase fam-
ily of proteins. This protein family contains Drosophila PIWI and STING proteins,
human HIWI, mouse MIWI, Arabidopsis Argonaute-1 and C. elegans PRG-1 and -2.
The eukaryotic proteins contain another conserved region ~110aa in length named the
PAZ domain [34].
There are seven human and eight mouse Argonaute genes, all of which contain a C’
terminus PIWI domain and a N’ terminus PAZ domain [33]. Of the eight human Ago
genes, Agos-1-4 are expressed in several cell types, and can all interact with miRNAs.
However, only AGO-2 demonstrated endonuclease activity against the target mRNA.
When the miRNA:mRNA interaction is facilitated by AGOs -1, -3 and -4 it does not
result in target cleavage [171, 270].
The importance of Ago-2 was further confirmed in Drosophila studies which showed
that Ago-2 is required for miRNA processing and that Ago-2 mutant ESCs are defi-
cient in miRNA processing [196, 233]. The Ago-2 PAZ domain contains a nucleic acid
binding groove through which it binds the miRNA duplex in a sequence-independent
manner [156]. While the OH group of the 3’ overhang is important for RNA/PAZ
36
Figure 1.12: Argonaute Protein Structure and Function. The microRNA is represented
by the yellow line and the target mRNA is represented by the red line. The interaction
between the miRNA and the target mRNA occurs within the AGO component of RISC.
If the interaction occurs within AGO2 the target mRNA is cleaved, otherwise the target
is sequestered. Image adapted from [240].
binding [156], the 5’ phosphate of the guide strand interacts with the AGO MID do-
main. This interaction is also sequence-independent, but does show bias for A and U
terminal nucleotides which interact with a rigid loop structure within the domain, and
discriminates against C and G terminal nucleotides [71] (Fig 1.12).
Loading of the miRNA duplex into the Argonaute proteins is ATP-dependent. Once
loaded, the miRNA duplex is unwound in an ATP-independent manner leaving the
single stranded mature miRNA for targeting. Duplex unwinding is mediated by the
AGO N’ domain which prises open the end of the duplex [143]. Mismatches between
the seed regions of the two strands of the duplex result in more efficient processing
than duplexes with central mismatches [130, 131].
RNA-binding proteins The Argonaute proteins are not the only members of RISC.
Other proteins also form part of the complex and aid in its function. For example, the
chaperone proteins Hsc70 and Hsp90 are involved in the ATP-dependent loading of the
RNA duplex into AGO [116], while the endonuclease C3PO is required for passenger
strand degradation before mRNA targeting can occur [293].
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1.3.3 MicroRNA function
Once the mature microRNA is loaded into RISC, the complex binds to the 3’UTR of
the target mRNA causing decreased expression of the mRNA protein product. Im-
paired target protein expression is caused by a miRNA-mediated block of translation
and the cleavage [109] or sequestration of the target mRNA.
1.3.3.1 Target identification
Successful binding between miRNAs and the 3’UTR of target mRNAs is determined
by several factors (reviewed in [17, 55, 66]). The most influential factor is the binding
to the ‘seed region’ of the microRNA sequence. The seed region is usually located
between nucleotides 2-8 of the 5’ end of the microRNA. The degree of complemen-
tary binding in the seed region exerts a strong effect on outcome of the miRNA:mRNA
interaction. Complete complementarity is usually required in plants, but animals often
display imperfect base-pair binding at miRNA target sites. Following the seed region
is an area of non-complementarity which creates a bulge between the miRNA and tar-
get mRNA. It is this mismatch that prevents the AGO2 endonuclease activity. The
miRNA:mRNA interaction can be strengthened by binding at the 3’ end of the mi-
croRNA; binding here can compensate for poor binding in the seed region (Fig 1.13).
Software programs that aim to predict miRNA:mRNA interactions consider some
or all of the following parameters: 1) Sequence complementarity. The strongest em-
phasis is placed in the seed region, but 5’ and 3’ complementarity is also considered.
2) Multiple miRNA binding sites within the 3’UTR. This increases the likelihood that
a gene is targeted by microRNAs. 3) Sequence conservation. If a binding site is con-
served across multiple species it is given more weight within the predicted data. 4)
Thermodynamics. The physical stability of the miRNA:mRNA binding interaction is
assessed by some prediction programs (reviewed in [17, 55]).
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Figure 1.13: The miRNA:mRNA Binding Motif. The miRNA and mRNA usually bind
at both ends of the miRNA with a bulge in the middle section of the sequence. The
seed region (nts 2-8) is considered the most important area of the miRNA:mRNA inter-
action, but successful binding in the 3’ region (nts 13-16) also aids target suppression.
Image from [66].
1.3.3.2 Target suppression
Successful miRNA:mRNA interaction inhibits translation of the target mRNA. The
mechanism by which this inhibition occurs is dictated by the degree of complemen-
tarity between the miRNA seed region and the 3’UTR of the target mRNA. Perfect
miRNA:mRNA binding causes cleavage and degradation of the target mRNA while
some mismatches in the miRNA:mRNA binding cause translational suppression of the
mRNA target.
Perfect miRNA:mRNA interactions and subsequent cleavage is the predominant
mechanism in plants while in mammalian cells a slightly mismatched interaction is
most common, causing translational repression. This gives rise to the classic mam-
malian microRNA target profile of steady mRNA expression with decreased protein
expression. However, both mechanisms are observed in both plants and mammals and
are described in detail below ([109], reviewed in [115, 247]. Fig 1.14).
mRNA cleavage and decay In plants, exact miRNA:mRNA binding triggers cleav-
age of the mRNA by AGO1-RISC and subsequent mRNA degradation by endoribonu-
cleases (e.g. XRN4). In mammals, the GW182 protein binds to the PIWI domain
of AGO then recruits other factors to the target mRNA (e.g. deadenylase complexes
CCR4-NOT and PAN2-PAN3). GW182 can also dislodge the poly(A)-binding protein
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(PABP) which leaves the poly(A) tail exposed to the action of deadenylase complexes
which degrade the poly(A) tail, accelerating degradation of the target mRNA. Dead-
enylation also causes removal of the 5’ m7G-cap structure mediating 5’-3’ endonucle-
olytic decay by XRN1.
Translational suppression Imperfect miRNA:mRNA binding prevents endonucle-
olytic cleavage by RISC and results in translational suppression. The mechanism
behind miRNA mediated translational suppression is not yet as clearly understood
as those of target mRNA decay but there are currently three models which are not
thought to be mutually exclusive: 1) GW182 blocks translation initiation by preventing
PABP-eIF4G binding, thereby inhibiting the recruitment of ribosomes to the mRNA; 2)
GW182 recruits translational suppressors (e.g. CCR4-NOT complexes) and associated
proteins (e.g. CNOT1) which interfere with eIF4G binding and/or specifically bind to
DDX6 which acts as a decapping activator or translational suppressor; 3) Disassoci-
ation of eIF4A from the cap binding complex eIF4F. Messenger RNAs that possess
the 5’ m7G-cap structure require eIFs for translational initiation. Messenger RNAs
that possess alternative cap structures (e.g methylation of the 2´ hydroxy groups of the
first two ribose sugars) bypass this requirement and are resistant to miRNA mediated
translational suppression. This indicates an interaction between miRNAs and eIFs dur-
ing translational suppression. Decreased expression of translational initiation factors
was found to attenuate the effects of miRNA-mediated suppression and miRNAs have
been shown to displace eIF4A from target mRNAs, thereby inhibiting the initation of
translation by preventing ribosome binding.
1.3.4 Non-canonical microRNA processing
Although the vast majority of microRNAs are processed along the canonical biogenesis
pathway outlined here, some microRNAs contain unusual structural motifs that enable
steps in the pathway to be skipped (reviewed in [1, 45, 175, 290]).
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Figure 1.14: Mechanisms of MicroRNA Target Suppression. (a) In mammals, regular
mRNA translation is initiated by the binding of the eukaryotic translation initiation fac-
tor 4E (eIF4E) to the 5’ m7G-cap structure which mediates the binding of ribosomes to
the mRNA thereby initiating translation. Three mechanisms by which miRNA-RISC
complex suppresses the translation of target mRNAs have been suggested: (b) Inhi-
bition of the initiation of translation by preventing 5’ m7G-eIF4E binding. AGO also
possesses a 5’ m7G binding site; the binding of the RISC complex to the target mRNA
prevents eIF4E binding and subsequent ribosomal binding and translation. (c) Post-
initiation inhibition of translation via miRNA-RISC mediated disruption of mRNA-
ribosomal binding causing aborted translation and degradation of the resultant partial
protein product. (d) In mammals, mRNA degradation is mediated by AGO recruitment
of GW182 which in turn recruits deadenylation proteins (e.g. CCR4-NOT complexes)
and decapping proteins (e.g. DDX6 and DCP1). These proteins degrade the 3’ poly
(A) tail and cleave the 5’ m7G-cap structure; both actions accelerate degradation of
the target mRNA. In plants, the perfect complementarity of miRNA:mRNA binding
enables cleavage by the AGO1-RISC complex followed by degradation of the target
mRNA by endonucleases (reviewed in [115, 247]). Although target cleavage is most
common in plants and target suppression is most common in mammals, both processes
can occur in each system and are dictated by the degree of complementarity in the
miRNA:mRNA binding. Image from [247].
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Figure 1.15: Non-Canonical MicroRNA Processing. The majority of microRNAs are
produced via the canonical biogenesis pathway. Microprocessor-independent microR-
NAs are the most common type of non-canonical microRNA, two examples of which
are shown here (mirtrons and tRNaseZ-dependent microRNAs). These microRNAs do
not require the action of the microprocessor to produce a single hairpin. To date only
one Dicer-independent microRNA has been discovered, miR-451. The mature forms
of non-canonical microRNAs function in the same manner as those from the canonical
biogenesis pathway. Adapted from [175] and [290].
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1.3.4.1 Nuclear processing of non-canonical microRNAs
One class of non-canonical microRNA is the mirtron. Mirtrons are microRNAs that
are encoded within the introns of genes and are produced during the normal mRNA
splicing process. The mirtrons are formed when mRNA splice sites are located at both
ends of the microRNA hairpin. The resultant structure is equivalent to a pre-miRNA.
Mirtron pre-miRNAs are the correct size for immediate loading into Exportin-5; the
action of the microprocessor is not required. DCGR8 knockout studies have recorded
a loss of the majority of microRNAs but non-canonical microRNAs were still detected.
Once in the cytoplasm, the mirtron pre-miRNAs are processed by Dicer and loaded into
RISC, exerting an inhibitory effect on target mRNAs just like canonical microRNAs.
Mirtrons have been identified in both invertebrates and mammals. Mirtrons appear
to be more abundant in invertebrates. This is most likely due to the larger number
of short intron sequences present in invertebrate genomes which more readily form
pre-miRNAs. While classical mirtrons are fully formed by the action of the mRNA
splicer there is some evidence of 5’ and 3’ tailed-mirtrons in which one splice site
occurs at a hairpin terminus and the other is located up- or down-stream of the other
hairpin termini. By mechanisms not yet established, the tail of the mirtron is removed
enabling the mirtron to be exported from the nucleus again without processing by the
microprocessor (Fig 1.15).
1.3.4.2 Other groups of microprocessor-independent microRNAs
Other groups of microprocessor-independent microRNAs have also been identified.
Much like mirtrons, these classes of non-canonical microRNAs appear to be gener-
ated as a by-product of RNA processing. Small nuclear RNAs (snoRNAs) facilitate
the modification of ribosomal RNAs by acting as small nucleolar ribonucleoprotein
complexes. The secondary structures of some snoRNAs contain two hairpins that are
structurally similar to pre-miRNAs. These snoRNA-derived pre-miRNAs do not re-
quire processing by the microprocessor and can be loaded into Dicer.
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Another class of microprocessor-independent microRNAs is derived from endoge-
nous small hairpin RNAs (shRNAs) and tRNAs. MiR-1980 is generated from the
second hairpin of an endogenous shRNA; the first hairpin in the shRNA does not give
rise to a mature product. The primary transcript of the isoleucine tRNA gene can form
two different secondary structures, namely the traditional tRNA clover-leaf shape and
a 110nt hairpin structure that can be processed by Dicer.
Some viral microRNAs require the action of the tRNase Z enzyme rather than the
microprocessor to generate Dicer substrates (Fig 1.15). For example, the murine g-
herpesvirus 68 encodes 9 microRNAs which are located on one arm of a tRNA-like
structure that represents a pre-miRNA.
1.3.4.3 Cytoplasmic processing of non-canonical microRNAs
Although many microprocessor-independent microRNAs have been found, only one
Dicer-independent microRNA has been identified to date (Fig 1.15). The miR-451
hairpin is unusual because the terminal loop sequence is strongly conserved across
species, while the sequence of the 3’ arm is not [291]. Furthermore the mature miR-
451 sequence was found to start partway along the 5’ arm and to continue along the
stem loop terminating at the beginning of the 3’ arm [39]. The pre-miR-451 produced
by the microprocessor is too short to be a Dicer substrate and Dicer-/- experiments
confirm that biogenesis of mature miR-451 is Dicer-independent. However the pre-
miR-451 must be processed by an enzyme with slicer activity to generate the mature
sequence. Ago-/- studies indicate that AGO2 can provide the necessary slicer activity
to generate the mature miR-451 from the precursor [39].
The Dicer-independent nature of miR-451 processing was confirmed by elegant
studies in which several canonical microRNAs were ‘reprogrammed’ to have the same
structural characteristics as miR-451, i.e the mature microRNA sequence was located
partially along the 5’ arm extending across the stem loop. These reprogrammed mi-




MicroRNAs have emerged as an important post-transcriptional regulatory mechanism
in all eukaryotic life-forms. The biogenesis of microRNAs is carefully regulated to
prevent abnormalities in all biological systems. The role of microRNAs during early
development can perhaps be considered the most dramatic, as abnormal microRNA
expression is associated with extreme phenotype mutations. However other aspects of
eukaryotic growth and function are also regulated by microRNA activity. An expand-
ing example is the role of microRNAs in the immune system.
1.4 The role of microRNAs in health and disease
MicroRNAs are clearly important during normal development in many organisms and
aberrant expression during development can cause severe phenotypes, often resulting
in arrested development [23, 149, 211, 233, 274]. In the adult organism microRNA
expression is associated with tissue homeostasis [153, 172, 278], while abnormal ex-
pression of microRNAs in mature tissues is often associated with poor health as either
cause or symptom. Therefore understanding the role of microRNAs in health and dis-
ease has both diagnostic and therapeutic implications.
1.4.1 MicroRNAs in development
MicroRNAs as a global population are required for early development. This has been
shown by numerous studies across different species in which key molecules in the mi-
croRNA biogenesis pathway which were either depleted or ablated [23, 274, 277]. In
these studies embryonic arrest occurred as a result of microRNA ablation, preventing
the development of viable organisms.
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Table 1.2: The Roles of MicroRNAs During Development. Several microRNAs have
now been identified to play important roles during normal development. MicroRNAs
known to be associated with specific developmental functions in vertebrates and inver-
tebrates are listed here. Table from [278].
While the importance of lin-4 in C. elegans larval development has already been
discussed (section 1.3.1) other individual microRNAs have also been shown to play
pivotal roles during development (Table 1.2). Lys-6 and miR-273 are required for
the establishment of left-right neuronal asymmetry in C. elegans. In Drosophila, the
expression of bantam and miR-14 is required for the regulation of apoptosis, while
Notch-controlled patterning is regulated by a range of microRNAs. HOX-mediated
anteroposterior axis alignment is regulated by miRs-10 and -196, and expression of
the microRNAs -1, -124 and -143 is associated with the development of muscle, brain
and adipose tissues respectively (reviewed in [7, 28, 278]).
1.4.1.1 MicroRNAs in embryonic stem cells
Individual microRNAs, such as those discussed above, are known to exert strong ef-
fects during specific developmental stages. However during the very early stages of
development, when the embryo only consists of embryonic stem cells (ESCs), it is
the global microRNA population that is required for continued development rather
46
than any individual microRNA. The removal of Dicer or DCGR8 - key molecules in
the microRNA biogenesis pathway - blocks the production of all canonical microR-
NAs and results in embryonic arrest in the early developmental stages in vertebrates
[23, 274, 277]. Dicer-/- and DCGR8-/-ESCs demonstrate that microRNA-deficient
ESCs are viable in vitro and display typical ESC morphology, but proliferate more
slowly than WT ESCs [126, 181, 274]. Dicer-/-cells successfully form embryoid bod-
ies (EBs) but fail to differentiate. Dicer-/-ESCs also fail to contribute to the germline
in chimeric mice experiments and fail to form teratomas when injected subcutaneously
into mice. [126]. Similarly, DCGR8-/- ESCs successfully form EBs but fail to differ-
entiate, and most cells remained undifferentiated in teratoma formation experiments
[274]. Ago2-/- ESCs are able to differentiate into the three germ layers, but the timing
is delayed compared to WT cells. Like Dicer-/-and DCGR8-/- ESCs, the Ago2-/- ESCs
demonstrate impaired self-renewal and prolonged expression of pluripotency markers
[233].
1.4.2 MicroRNAs in the immune system
Knowledge of microRNA function in the immune system is reviewed in [160, 191,
192, 283]. It is clear that the expression levels of certain microRNAs are very impor-
tant, as both over- and under-expression can be damaging to the host (Figures 1.16 and
1.17). Aberrant microRNA expression is associated with cancers, abnormal inflamma-
tory responses and autoimmune diseases (Table 1.3). The expression of microRNAs
can also be dynamically regulated in response to a range of PAMPs, for example the
expression of miR-155 is induced by several different PAMPs [185, 191].
1.4.2.1 MicroRNAs in the innate immune system
The innate immune system contains several different cell types (macrophages, neu-
trophils, NK-cells) which detect PAMPs through cell-surface and intracellular PRRs
(section 1.2.3.1). The interactions between PRRs and PAMPs cause changes in the
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expression of microRNAs within these cells, implicating microRNAs in the regulation
of the immune response (reviewed in [160, 185, 191, 192, 283]).
1.4.2.2 Macrophage-associated microRNAs
A collective understanding of the role of microRNAs in the regulation of the macrophage
activation response is still being developed. At the time that this project was conceived,
fewer than 35 papers had been published about the role of microRNAs in all aspects
of macrophage biology, and only a fraction of those addressed the role of microR-
NAs during macrophage activation [73, 77, 178, 194, 214, 259]. Outlined here are
the major macrophage-associated microRNAs, focusing on the role of microRNAs in
macrophage stimulation via LPS/TLR-4 signalling.
miR-155 Encoded in exon 3 of the non-coding gene bic [256], miR-155 is the best
characterised of the macrophage-associated microRNAs and is generally described as
a pro-inflammatory microRNA. Expression of miR-155 in macrophages can be in-
duced by several of the TLR signalling pathways [185, 194], although it is most com-
monly associated with LPS/TLR-4 stimulation. Numerous genes have been identified
as targets of miR-155 (reviewed in [166, 185]) and some targets are prominent anti-
inflammatory genes, e.g. SHIP1 [190] and SOCS1 [42, 272]. Therefore induction of
miR-155 by pro-inflammatory stimuli helps to drive the pro-inflammatory response
through the up-regulation of pro-inflammatory cytokines (e.g. TNF-a, IL-6 and IL-
1b), positive regulation of NFkB signalling and the suppression of anti-inflammatory
molecules [15, 166].
In vivo studies show that Em-miR-155 mice, which over-express miR-155 in B-
cells, express more TNF-a in response to LPS stimulation; these mice are also more
susceptible to endotoxin shock than their WT counterparts [259]. Furthermore, over-
expression of miR-155 results in a dramatic myeloproliferative disorder [193]; this
finding concurs with studies showing that the knock-down of its targets, SOCS1 and
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SHIP1, also cause myeloproliferative disorders ([173, 190] respectively) demonstrat-
ing the importance of these molecules in maintaining appropriate inflammatory re-
sponses and myeloid cell turnover. Interestingly, miR-155-/- also facilitates the growth
of solid tumours through increased immunosuppression [271]. Knocking down miR-
155 dampens the immune response to its stimuli [213, 257] and impairs microbial
clearance [80, 265] but is associated with improved wound healing and reduced scar-
ring [263].
The expression of pro-inflammatory molecules such as miR-155 must be carefully
regulated to enable the proper resolution of inflammation in order to prevent chronic
inflammation and associated damage to the host (section 1.2.3.5, Fig 1.16). MiR-155
expression is modulated by anti-inflammatory molecules such as IL-10, which down-
regulate miR-155 expression [167], but miR-155 also forms part of its own negative
feedback loop. MiR-155 inhibits SHIP1 expression, thus preventing SHIP1 inhibition
of Akt. The subsequent increase in Akt expression helps to drive the pro-inflammatory
response but at the same time Akt also down-regulates the expression of miR-155 [11],
facilitating the resolution of inflammation.
miR-146a Another well-characterised macrophage associated microRNA is miR-
146a. MiR-146a is a constitutively expressed anti-inflammatory endotoxin responsive
gene [254] that is important for the resolution of inflammation and for the establish-
ment of endotoxin-induced tolerance [184]. In fact miR-146a over-expression is able
to induce cellular tolerance without LPS priming [219]. The expression of miR-146a is
induced by several PAMP/PRR interactions in an NFkB-dependent manner and it goes
on to form a negative feedback loop [219]. MiR-146a directly targets two members
of the MyD88-independent NFkB signalling pathway: IRAK1 and TRAF-6 [254],
causing the downstream down-regulation of several pro-inflammatory mediators in-
cluding TNF-a, IL-1b, IL-6, IL-8, CCL5, CXCL8, RANTES and type-1 interferons
(IFNs). There is some work suggesting that miR-146a may down-regulate expression
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Figure 1.16: The Importance of Normal MicroRNA Expression for the Regulation
of the Inflammatory Response. The expression of microRNAs during the immune
response must be carefully regulated as both the under- and over-expression of mi-
croRNAs can result in an inappropriate immune response. For example, in the absence
of the pro-inflammatory miR-155 the inflammatory response is suppressed, causing a
deficient immune response. Over-expression of miR-155 or under-expression of miR-
146a results in an overly aggressive immune response. Long-term dysregulation of
these microRNAs can result in chronic inflammation. Adapted from [191].
of TLR-4 [219] and impair the recruitment of monocytes to the site of infection through
suppression of CCR2 [242].
In the absence of miR-146a, NFkB signalling is incorrectly regulated, thus caus-
ing an exaggerated immune response, impaired tolerance and increased susceptibility
to endotoxin shock in response to LPS stimulation. MiR-146a-/- mice also develop
myeloproliferative disorders, tumours and autoimmune conditions, indicating a role
for miR-146a in tumour suppression and regulation of proliferation [27, 219, 298].
Aberrant expression of miR-146a has been recorded in several autoimmune and neu-
rological conditions: systemic lupus erythematosus (SLE), rheumatoid arthritis (RA),
Sjögren’s syndrome (SjS), Alzheimer’s and multiple sclerosis (MS) [219].
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Other macrophage-associated microRNAs When this work was undertaken only a
handful of microRNAs were known to be associated with macrophage activation. In
addition to miR-146a and miR-155, miR-125b and miR-132 had been found to be dif-
ferentially expressed during macrophage activation [194, 253, 254, 259]. Subsequent
work in this field, particularly the utilisation of next generation sequencing (NGS)
methods, has greatly expanded knowledge of the presence and function of microRNAs
during macrophage activation. A list of some microRNAs known to be differentially
regulated during macrophage endotoxin challenge is presented here.
• miR-9 is up-regulated during macrophage activation and acts to negatively reg-
ulate the pro-inflammatory response by directly targeting the NFKB1 transcript,
reducing expression of its product, the NFkB subunit p50, thus impairing NFkB
mediated signalling [19, 198]. MiR-9 has also been shown to inhibit the growth
of ovarian and gastric cancer cells by disruption of NFkB signalling [163].
• miR-21 is another LPS/TLR-4/NFkB-induced microRNA with anti-inflammatory
properties. It is known to target the pro-inflammatory tumour suppressor gene
PDCD4, leading to decreased NFkB signalling and a subsequent rise in the ex-
pression of IL-10 [232]. MiR-21 over-expression has been detected in all human
carcinomas [163].
• miR-125b targets TNF-a and is down-regulated upon LPS stimulation to enable
a full immune response [11, 259]. The over-expression of miR-125b causes
heightened macrophage sensitivity to to IFN-g [38] and increases macrophage
activation of T-cell responses [242].
• miR-132 expression is induced by LPS [194, 254]. It has been shown to target
acetylcholinesterase (AChE) [158, 229] and the IFN-g signalling cascade tran-
scriptional co-activator p300 [187], both pro-inflammatory mediators. Therefore
miR-132 acts in an anti-inflammatory manner.
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• miR-145 is up-regulated during LPS stimulation and targets MAL (MyD88-
adaptor like protein), a component of the MyD88-dependent signalling pathway,
indicating an anti-inflammatory role for this microRNA [191].
• Up-regulated in activated macrophages, miR-147 is thought to target NFkB,
thereby negatively regulating the pro-inflammatory response. The over-expression
of miR-147 was found to attenuate the regulation of TNF-a, IL-6 and miR-147
itself [159, 198].
• miR-223 may act to limit inflammatory activation of macrophages. Usually up-
regulated during activation with LPS, miR-223-deficient macrophages express
higher levels of LPS induced cytokines IL-1b, IL-6 and TNF-a than WT cells
[242]. Pknox1 has been identified as a direct target of miR-223 and its inhibition
dampens the pro-inflammatory response [242].
• Let-7 microRNAs. Let-7e is up-regulated and let-7i is down-regulated during
macrophage activation. Both variants target TLR-4 and let-7i also suppresses
the pro-inflammatory cytokine IL-6. Through these interactions let-7e and let-7i
negatively regulate the pro-inflammatory response [191, 198, 219].
The above microRNAs are associated with TLR-4/endotoxin-mediated activation
of macrophages, but microRNAs are also involved in other facets of macrophage biol-
ogy. MicroRNAs known to be differentially regulated during alternative macrophage
activation include: miR-125b, -187, -378-3p and -511-3p. Meanwhile, microRNAs
expressed during hypoxia may have roles in the tumour environment: miR-23, -24,
-26, -27, -103, -107, -181, -210 and -213 [242].
In addition to activation, several microRNAs are associated with macrophage de-
velopment and differentiation. The microRNAs-146a, -155, -342 and -338 are all
up-regulated by PU.1 and the expression of miR-146a can drive HSCs towards the
myeloid lineage [242]. The microRNAs-17-5p, -20a and 106a act as negative regula-
tors of myelopoiesis by targeting RUNX1 expression, causing a subsequent decrease
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Figure 1.17: The Role of MicroRNAs During the Resolution of Inflammation.
Macrophage activation via TLR signalling initiates a cascade of microRNA produc-
tion that interacts with other mediators of inflammation to control the inflammatory re-
sponse. Initially pro-inflammatory microRNAs such as miR-155 are up-regulated and
help to drive the pro-inflammatory response by targeting anti-inflammatory molecules.
During this time anti-inflammatory microRNAs (e.g. let-7i and miR-125b) are down-
regulated to enable the initiation of the pro-inflammatory response. Subsequently the
expression of anti-inflammatory microRNAs (miR-9, -132 and -146a) increases. These
molecules act as negative regulators of the pro-inflammatory response and their action
facilitates the anti-inflammatory response. During the resolution of inflammation, mi-
croRNAs such as miR-147 and miR-21 continue to promote the anti-inflammatory re-
sponse through the suppression of pro-inflammatory cytokines, pro-inflammatory mi-
croRNAs and the up-regulation of anti-inflammatory cytokines (such as IL-10). Image
from [198].
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in CSF-1R expression and monocyte differentiation. RUNX1 is able to suppress miR-
17-5p/20a/106a in turn, indicating mutual regulation between these opposing factors
[49, 242]. MiR-223 is a myeloid-specific microRNA that is associated with mono-
cyte differentiation; down-regulation of miR-223 is associated with increased expres-
sion of neutrophils [123, 283]. MiR-424 stimulates myeloid cell differentiation by
up-regulating CSF-1R and down-regulating nuclear factor I/A (NFI-A) [242].
1.4.2.3 MicroRNAs in the adaptive immune system
The adaptive immune system constitutes the second wave of the inflammatory re-
sponse. It is mediated by B-cells and T-cells and results in antibody production,
cytotoxic cell killing and immunological memory. Many studies have determined
roles for microRNAs in the adaptive immune response in the development of both
B- and T-cells, and in the initiation of the adaptive immune response (reviewed in
[142, 165, 191]). Some of these interactions are described here.
T-cells The proper expression of microRNAs is required for the normal development
of T-cells in general and the development of specific T-cell populations. This was
shown in Dicer-/- mice which displayed fewer T-cells than WT mice [191]. When
specifically deleted in Treg cells, Dicer ablation resulted in impaired Treg maturation
and function and caused a lethal autoimmune inflammatory disease [208].
MiR-150 is strongly expressed in mature T-cells; the over-expression of miR-150
blocks T-cell development in the thymus causing decreased proliferation and survival
through c-Myc and NOTCH3 targeting [142]. An important stage in T-cell maturation
is the removal of self-reactive T-cell receptors (TCRs) during selection in the thymus.
MiR-181a expression is required for setting an appropriate threshold for self-reactivity.
Reduced or absent miR-181a expression resulted in the release of auto-reactive T-cells
from the thymus into the periphery [142, 191].
Once T-cells have been released into the periphery microRNAs help to shape the
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adaptive immune response by driving the differentiation of different T-cell classes.
MiR-155 is up-regulated upon normal T-cell activation. However miR-155-/- T-cells
do not readily form Th1 or Th17 type cells, resulting in a Th2 response bias which may
not be the appropriate response (Th1 cells help to clear bacterial infections) [191, 208].
MiR-301 is highly expressed by Th17 cells, and miR-301 inhibition is associated with
decreased STAT3 signalling, causing impaired Th17 differentiation [142]. MiR-326
is also required for the proper development of the Th17 cell population as it targets
the (anti-Th17) transcription factor Ets1 [191, 208]. The miR-17-92 cluster is strongly
induced during T-cell activation and facilitates the production of long-lived antibody
responses through its association with the development and function of T follicular
helper cells [142, 208].
B-cells The other cell of the adaptive immune system is the B-cell. The complete
removal of microRNAs from B-cells through the ablation of Dicer causes the arrest
of B-cell development in the bone marrow. In mature B-cells Dicer ablation causes a
skewed physical distribution of B-cells in the germinal centres along with increased
auto-reactive antibody production [165, 191, 208]. This demonstrates that microRNAs
are required for correct development and distribution of B-cells.
Specifically, miR-155 is important for regular B-cell development. It is induced
during B-cell activation in response to bacterial products (LPS) and during the sub-
sequent development of the germinal centre. Knock-down of miR-155 inhibits the
correct formation of germinal centres, resulting in defective antibody production [213,
257, 266]. Misregulation of miR-155 expression is associated with several cancers
[56].
Another well-characterised B-cell associated microRNA is miR-150 which is strongly
expressed in, and required for the normal development of mature B-cells. MiR-150 tar-
gets the lymphocyte transcription factor c-Myb, which is required for pro- to pre-B-cell
development, in a dose-dependent manner. Over-expression of miR-150 causes a block
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in B-cell differentiation at the pro-B-cell stage and a corresponding decrease in mature
B-cell numbers. While miR-150-/-mice displayed an expanded population of B1 cells,
the mature (B2) cell population in these mice was diminished [165, 208].
1.4.3 The clinical potential of MicroRNAs
Although the biological roles of many microRNAs are not yet fully understood, aber-
rant microRNA expression profiles are gaining interest as reliable biomarkers which
may provide a guide for the next appropriate step in diagnosis and treatment of many
conditions. One benefit of microRNAs as biomarkers is that expression profiles can
be generated from extracellular fluids such as blood, saliva and urine, providing a sim-
ple, quick and noninvasive method of patient sampling. However, since individual
microRNAs can be associated with several different conditions, it is highly unlikely
that individual microRNAs will become a major diagnostic agent. Rather, it is more
likely that a panel of microRNA expression will be assessed to further refine a diagno-
sis, and used as a predictive tool to provide guidance on side-effects, likely outcomes
or drug-resistance when planning a treatment (reviewed in [2, 97, 137, 165]).
There is also growing interest in developing therapies that aim to ‘correct’ the aber-
rant microRNA expression profile through the use of microRNA mimics and inhibitors
[2, 97, 204].
MicroRNAs as biomarkers in cancer Oncology currently represents the most promis-
ing area of research for the use of microRNAs as biomarkers. Abnormal microRNA
expression has been associated with many cancers (reviewed in [2, 61, 79, 118, 137,
165]). The dysregulation of some microRNAs appears to be causal (e.g. miR-155
and myeloproliferative disorder [193]), while dysregulation of others appears to be
a downstream consequence of cancer-induced transcriptional changes. Aspects of
cancer biology that can be regulated by microRNA expression include tumourigen-
esis, tumour growth, angiogenesis and metastasis (Fig 1.18). MicroRNAs that are
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Figure 1.18: MicroRNA Mode of Action in Tumourigenesis. MicroRNAs can act to
suppress or facilitate tumourigenesis; loss of function mutations in these microRNA
genes then cause the opposite effect. Image from [137].
strongly associated with cancerous phenotypes have been termed oncomiRs; examples
include miR-21 and the miR-17-92a cluster. Tumour-suppressing microRNAs include
miR-15, miR-16, miR-30 family, miR-34a family, miR-200 family and let-7 family
[61, 97, 137].
The role of individual microRNAs in cancer is often cell-type specific due to the
inherent transcriptional differences between cell types. As a result some microRNA
profiles from tissue and blood samples strongly correlate with cancer types, sub-types
and prognosis. It is feasible that in the future a blood sample for microRNA profiling
could become the first step in confirming a cancer diagnosis, rather than a tissue biopsy.
MicroRNAs as biomarkers in inflammatory conditions Given how carefully the
initiation and resolution of inflammation must be regulated, and the dynamic and mul-
tifunctional roles microRNAs play within the immune system, it is not surprising that
microRNA dysregulation has been identified in several autoimmune conditions. These
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Table 1.3: MicroRNAs Associated with Inflammatory Conditions. Specific microR-
NAs have been found to be associated with certain autoimmune conditions. Using
microRNAs as biomarkers could add another diagnostic tool when assessing these
conditions. Table from [191].
include, but are not limited to multiple sclerosis, psoriasis, asthma, rheumatoid arthri-
tis, systemic lupus erythematosus, Sjögren’s syndrome and inflammatory bowel dis-
ease (Table 1.3) [191, 202, 241]. The assessment of a panel of microRNAs has the
potential to be a valuable asset in the diagnosis of these conditions as many are hard to
diagnose by symptoms alone in the early stages.
1.4.4 Summary of microRNAs in health and disease
Although there is still much to uncover and understand, it is apparent that microRNAs
are closely associated with the health of an organism, and dysregulation of microRNAs
can be a cause or symptom of disease. Furthering understanding of the complex path-
ways, interactions and redundancies associated with the role of microRNAs in health
and disease clearly has implications for both diagnosis and treatment.
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1.5 Aims
At the time that this project was conceived there were only two accurately documented
microRNAs in the macrophage response to LPS (miR-155 and miR-146a), and no pro-
filing data of the global microRNA population during macrophage activation by LPS
had been published. It was considered highly unlikely that these two microRNAs were
the only ones to show dynamic expression and to exert discrete biological effects on
macrophage activation. Therefore the primary aims of this project were to characterise
the microRNAs expressed during the macrophage inflammatory response and then to
further assess the role of selected microRNAs during that process.
To achieve these goals, three steps were envisaged. 1) To establish in vitro sys-
tems for the differentiation and activation of macrophages, and to fully characterise
these processes using morphology and marker gene expression. The expression pro-
files and turnover of the macrophage associated microRNAs miR-155 and miR-146a
would also be recorded. 2) RNA samples from these in vitro systems would be used
in next generation sequencing to individually characterise the expression of the global
microRNA population during macrophage activation. The NGS expression profiles
for selected microRNAs would be confirmed through microRNA Northern hybridisa-
tion, and functional analysis would be carried out to determine the role of the selected
microRNAs during macrophage activation. 3) In order to characterise the role and re-
quirement of the global microRNA population during macrophage activation, systems
for the development of microRNA-free macrophages would be established within the
laboratory. These systems would subsequently be used to assess the effect of global





Stock reagents prepared on-site by the Roslin Laboratory Services were Tris/Hcl pH8,
EDTA, NaCl, 3M NaAc, agar, LB broth, TE buffer, glycerol and 20x SSC. All other
reagents were acquired from reputable laboratory supply companies and are noted in
the text.
2.1 Cell culture
All cell types were cultured at 37°C in an atmosphere of 5% CO2. All culture media
were stored at 4°C and warmed to 37°C in a water-bath before use. The following
media were used in cell culture.
• Complete media: RPMI-1640 (Sigma-Aldrich, Irvine, UK), 10% heat-inactivated
FBS (ThermoFisherScientific, Paisley, UK), 20 units/mL penicillin, 20mg/mL
streptomycin (penicillin/streptomycin #15140; Invitrogen, Paisley, UK), 1x glu-
tamax (GlutaMAX-I supplement #35050-61; Invitrogen)
• Macrophage culture media: complete media + 104unit/mL hr-CSF-1
• Serum-free media: RPMI-1640, 20 units/mL penicillin, 20mg/mL streptomycin,
1x glutamax
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• Transfection media: RPMI-1640, 10% FBS, 1x glutamax
• Differentiation media (for ESCs): complete media + 104unit/mL hr-CSF-1 +
rIL-3 + 1x beta-mercaptoethanol (Invitrogen)
Other cell culture reagents:
• Cryopreservation media: 20% DMSO, 80% FBS. Stored at -20°C
• LPS from Salmonella enterica serotype minnesota Re 595 (L9764; Sigma-Aldrich).
LPS storage stock: 2mg/mL in complete media, stored at -20°C. Working stock:
10mg/mL in complete media stored at 4°C
• rIL-3 (Invitrogen) storage stock 1mg/mL in nuclease-free water, stored at -20°C.
Used at a final concentration of 25ng/mL in culture
• 1xPBS: 50mL 10x PBS, 500mL sterile water




Wild-type cells were cultured from male c57/bl6 mice, aged 6-12 weeks. Dicer-floxed
cells were harvested from Dicer1bdh mice [99] and floxed YFP-reporter cells were
harvested from R26R-EYFP mice [243]. Dicer and YFP mice were provided courtesy
of Tomasz Nowakowski, Dr. John Mason’s Group, University of Edinburgh.
2.1.1.2 Bone marrow derived macrophages
Adult mice were euthanised and the femur bones were dissected. The bones were
cleaned in 70% ethanol and in 1x PBS to remove any remaining extraneous tissue
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from the surface of the bones. Both ends of the femurs were then removed using scis-
sors, and the bone marrow was harvested by flushing the bone cavity with complete
media using a 21-gauge (G) needle attached to a 10mL syringe into a 50mL non-skirted
centrifuge tube. The marrow from tibia bones was also collected by the same method,
using a 23G needle to flush the bone marrow from the bone. The bone marrow so-
lution was centrifuged at 500g for 5 minutes at room temperature. The supernatant
was discarded and the pellet resuspended in complete media (10mL per femur, 5mL
per tibia) using a blunt 18G needle attached to a 10mL syringe. Cells were plated in
10cm2Sterilin dishes (ThermoFisherScientific) at 5mL per plate and a further 17mL
complete media containing 104unit/mL hr-CSF-1 was added. Macrophage culture me-
dia (10mL complete media and 104unit/mL hr-CSF-1) was replaced at 5 day intervals
to replenish nutrients. Cells were harvested and plated for activation as described be-
low.
2.1.1.3 Cryopreservation of bone marrow and primary cells
Dicer1bdh and R26R-EYFP bone marrow, and bone marrow derived macrophage were
cryopreserved for long term storage. BMDMs were harvested from the surface of the
plate as described in section 2.1.3.2. Bone marrow was not resuspended in complete
media and counted after centrifugation; instead the supernatant was discarded and the
pellet resuspended in 1mL of FBS per femur. BMDMs were counted, then the BMDM
solution centrifuged at 500g for 5 minutes at room temperature. The supernatant was
discarded and the pellet resuspended in FBS at approximately 20 x106cells/mL. An
equal volume of cryopreservation media was added drop-wise. The resultant cell sus-
pension was dispensed into 1mL aliquots in labelled cryovials. These were stored at
-80°C overnight in an isopropanol freezing unit. Vials were then transferred from the
freezing unit into -150°C storage.
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2.1.1.4 Recovery of bone marrow and primary cells from cryopreservation
Cryovials of cells were thawed in a 37°C water bath. Samples were transferred into
50mL non-skirted centrifuge tubes. 10mL of complete media was added drop-wise.
The samples were then centrifuged at 500g for 5min at room temperature, the super-
natant discarded and the cells resuspended in 5mL complete media. The cells were




The macrophage cell line RAW264.7 cells [209] were obtained from ATCC. 5x106
RAW264.7 cells were plated in 10cm2Sterilin dishes in 22mL complete media. Cul-
tures were passaged every 2-3 days, the cells were harvested (section 2.1.3.2) and
replated 1 in 4.
2.1.2.2 hELAM-GFP cells
RAW264.7-hELAM-GFP cells, referred to here as hELAM-GFP cells, are a sub-clone
of RAW264.7 cells which has been stably transfected with the human ELAM promoter
(hELAM) coupled to EGFP. Expression of hELAM in these cells is induced by NFkB.
Thus when the cells are activated they express GFP [245]. 5x106hELAM-GFP cells
were plated in 10cm2Sterilin dishes in 22mL complete media. Cultures were passaged
every 2-3 days, the cells were harvested (section 2.1.3.2) and replated 1 in 4.
2.1.2.3 Cryopreservation of cell lines
RAW264.7 and hELAM-GFP cells were cryopreserved for long-term storage using the
same method as for BMDMs (section 2.1.1.3) with the following variation: Once har-
vested, the cells were resuspended in complete media (at approximately 20 x106cells/mL)
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before the addition of cryopreservation media.
2.1.2.4 Recovery of cell lines from cryopreservation
RAW264.7 and hELAM-GFP cells were cryopreserved for long term storage using
the same method as for BMDMs (section 2.1.1.4) with the following variation: After
recovery from cryopreservation, the cell lines were plated at approximately 5x106cells
in 10cm2Sterilin dishes with a further 17mL complete media.
2.1.3 General cell culture methods
2.1.3.1 Splitting cell cultures
Cells were gently detached from the surface of the culture dish using an 18G needle
attached to a 10mL syringe to flush the media over the surface of the plate. Duplicate
cultures were plated in 22mL of complete media at x106 cell/mL.
2.1.3.2 Harvesting cells
The media was removed from the culture dish and transferred into a 50mL non-skirted
centrifuge tube. 10mL sterile 1x PBS was added to each plate and left for approx-
imately 2min. Cells were then gently washed off the surface of the culture dish by
flushing using a blunt 18G needle attached to a 10mL syringe. The cells were then
collected, added to the previously collected media and pelleted by centrifugation at
500g for 5min at room temperature. Cells were resuspended in 10mL complete media,
counted by haemocytometer and diluted to the desired concentration.
2.1.3.3 Plating cells
Cells were harvested as previously described (section 2.1.3.2) and plated into 6-well
tissue culture plates at an appropriate density (usually 1 x106cells per well) in a total
volume of 5mL complete media for cell lines or 5mL macrophage culture media for
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BMDMs. Cells were incubated overnight to allow for attachment to the culture dishes
prior to treatment.
2.1.3.4 Activation of cells with LPS
Cells were plated as previously described (section 2.1.3.3) and incubated overnight.
LPS (10µg/mL working stock) was added to a final concentration of either 10ng/mL
or 100ng/mL as desired. RNA, DNA and protein were harvested post-activation as
described below at appropriate time-points.
2.1.4 Transfection with locked nucleic acids (LNAs) and microRNA
precursor molecules
RAW264.7 and hELAM-GFP cells were used in microRNA knock-down and over-
expression experiments. Cells were harvested as previously described (section 2.1.3.2)
and plated into 6-well tissue culture plates at a density of 0.5 x106cells per well in
a total volume of 5mL complete media. Cells were incubated overnight to allow for
attachment to the culture dishes. The media was then changed from complete media to
1mL per well of transfection media (without antibiotics).
The LNAs used to knock-down specific microRNA sequences are listed in Table
2.1. The microRNA precursor molecules used to over-express specific microRNA se-
quences are listed in Table 2.2. A LNA mix was made by the addition of 1mg of LNA
to 62.5mL of Opti-MEM (ThermoFisherScientific). A pre-miRNA mix was made by
the addition of 3.4mL Pre-miRNA to 62.5mL of Opti-MEM. A lipofectamine mix was
created by addition of 2.5mL of lipofectamine2000 (ThermoFisherScientific) to 62.5mL
of Opti-MEM, which was incubated at room temperature for 5min. 62.5mL of the lipo-
fectamine mix was then added to the LNA mix. This transfection mix was incubated at
room temperature for ≥30min. 125mL of the transfection mix was added to each des-
ignated well. The cells were incubated at 37°C overnight, after which the transfection
reaction was stopped by changing the media. Media was changed to 5mL of complete
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media; at the same time cells were activated with 10ng/mL LPS. RNA was harvested
(section 2.2.1) at 6hr post-activation.
N.B. The Ambion® Pre-miR™ miRNA Precursor molecules (Ambion, ThermoFish-
erScientific, Paisley, UK) are not small RNA hairpins, rather they are small dsRNA
molecules, similar to siRNAs, encoding specific miRNA sequences that mimic the
function of mature miRNAs.
Table 2.1: Locked Nucleic Acid (LNA) Sequences. The capital letters within the se-
quence represent the LNA bases. Manufacturers: Exiqon, Qiagen, Manchester, UK.
Proligo and Sigma-Proligo, Sigma-Aldrich, Irvine, UK.
Table 2.2: Ambion® Pre-miR™ miRNA Precursors. N.B. These molecules are not
small RNA hairpins, rather they are small dsRNA molecules, similar to siRNAs, en-
coding specific miRNA sequences that mimic the function of mature miRNAs.
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2.1.5 Embryoid bodies
Embryoid bodies made from two wild-type embryonic stem cell lines, E14s and CGR8s,
and one mutant cell line, DGCR8-/-, were acquired courtesy of Laura Bailey ([103],
[188] and [274] respectively). The cells were plated in 10mL DMEM (ThermoFish-
erScientific) + LIF (ThermoFisherScientific) at a concentration of 2 x105cells/mL and
were cultured for 3 days in 10cm round Sterilin dishes (ThermoFisherScientific) to
form embryoid bodies.
2.1.5.1 Embryoid body differentiation
Plates of EBs were gently swirled in a circular motion along the horizontal plane,
causing the EBs to gather in the centre of the plate. Approximately thirty day-3 em-
bryoid bodies were plated in 10cm2Sterilin dishes with 20mL of complete media sup-
plemented with 104units/mL hrCSF-1, 25ng/mL rIL-3 and 1x beta-mercaptoethanol.
Media was changed and replenished with hrCSF-1 and rIL-3 every 5 days. This was
achieved by swirling the plates as before, removing the EBs into a non-skirted 50mL
centrifuge tube, and changing the media in the plate. The EBs settled to the bottom of
the tube and the excess media was carefully removed from the EBs which were then
resuspended in fresh media and returned to the plate.
2.1.6 FACS analysis
FACS analysis was carried out on the Dako CyAn ADP 3 laser flow cytometer.
For FACS analysis the cells were usually plated on a Sterilin 25-cell plate (Ther-
moFisherScientific) in 1 mL of media. The media were collected from the plates using
a pipette and placed in flow-tubes. Approximately 1mL of sterile 5mM EDTA (diluted
from 0.5M EDTA, Sigma-Aldrich) was added to each well of a Sterilin 25-cell plate
for 10min at 4°C (a larger volume of EDTA was used if a larger plate was used, e.g.
2mL in a 6-well TC plate). Cells were then gently washed from the surface of the plate
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using either a P1000 Gilson pipette or a blunt 18G needle attached to a 10mL syringe,
depending on plate size. The cells were then collected and added to the flow-tubes.
Cells were pelleted by centrifugation at 410rpm for 5min at room temperature. The
supernatant was discarded and the cells were resuspended in the residual liquid in the
flow-tubes (approx. 200mL). 100 mL EDTA was added to each flow-tube, giving a total
volume of 300mL. 3mL of 100x propidium iodide was added to identify dead cells.
2.1.7 Roche xCELLigence machine
The Roche xCELLigence system (now the ACEA Biosciences xCELLigence real time
cell analyser, San Diego, CA, USA) is an instrument designed to measure the impedance
of an electrical current across each well of a specially designed 96-well culture plate
(the E-view plate, ACEA Biosciences), generating a measurement known as a cell in-
dex (CI) value. The presence of cells on the surface of the plate increases impedance,
resulting in a higher CI value. The impedance across culture wells can be affected by
cell number, cell morphology and degree of adherence. The system can be used within
the incubator, providing a real-time, continuous assessment of the adherent population
being studied, rather than snapshots at selected time-points.
For each experiment a ‘read schedule’ is created. This is the frequency at which
the impedance across the surface of the plate is measured. The first measurement to
be made is a background read to calibrate the machine for the experiment. To achieve
this media is added to each well of the experiment (100µL per well of a 96-well E-
view plate) and the CI measured. The cells and remaining media are added to wells
and the read schedule is started. The maximum frequency is one read per minute. A
typical read schedule is outlined in Table 2.3. Stages can be added to, or removed
from the schedule to tailor it to the individual experiment. The read schedule can
be paused, enabling the E-view plate to be removed from the xCELLigence machine
to take photographs, change the media, or carry out a treatment as desired, then the
schedule resumed once the place is returned to the xCELLigence machine.
69
In these studies, 100µL of complete media was loaded into each well of a 96-well
E-view plate for the background reading. The desired number of cells was added to
each well in a further 100µL of complete media, giving a total volume of 200µL per
well. The plate was then loaded onto the xCELLigence machine, and the read schedule
started. The CI measurements were plotted and viewed using the associated RTCA
software. Data could be viewed for the individual wells, or as the mean CI value with
±1 S.D. for replicate wells. The data could also be exported to appropriate software
packages for further statistical analysis.
Table 2.3: Example Read Schedule on the Roche xCELLigence Machine.
2.2 RNA analysis
RNA extraction steps and procedures were carried out on ice, with centrifugation
steps at 4°C unless otherwise stated. Surfaces and pipettes were decontaminated with
RNaseZap® RNase decontamination solution and wipes (Ambion, ThermoFisherSci-
entific) before RNA work was undertaken. Designated pipettes were used to avoid
gDNA contamination. Nuclease-free filter tips were used at all times. Nuclease-
free water (Ambion, ThermoFisherScientific) was used for work with RNA. Running
buffers were created with autoclaved, distilled H2O (dH2O). All tubes were double-
autoclaved (120°C for 15min x2) before use with RNA.
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2.2.1 RNA harvest and extraction
The media was removed from the cultures, cells were washed with 1x PBS to remove
any residual serum and then lysed in RNA-Bee (AMS Biotechnology, Abingdon, Ox-
fordshire, UK) (usually 1mL per well in a 6-well plate). The cells were detached from
the plate surface using a cell scraper and transferred to 2mL microcentrifuge tubes.
Samples were stored at -80°C. For RNA extraction the samples were thawed on ice,
then sonicated for 10min to shear the genomic DNA. Next 0.2 volumes of chloroform
were added to each sample, and mixed vigorously for 30 seconds. The samples were
then centrifuged at 12,000g for 30min at 4°C. The upper aqueous phase was then re-
moved to a fresh microcentrifuge tube, 0.7 volumes of isopropanol were added and
the samples were centrifuged at 13,000g for 30min at 4°C. The supernatant was re-
moved, then the pellet was washed in ice-cold 85% ethanol and centrifuged at 13,000g
for 15min at 4°C. The supernatant was removed and the pellet was air-dried at 45°C
for 2min. The pellet was resuspended in 50mL nuclease-free water by vortexing and
heating to 65°C.
At this stage the RNA was either precipitated for storage or, if being used immedi-
ately, treated with DNase to remove any residual DNA in the sample.
2.2.2 DNase treatment
Samples were resuspended in 50mL nuclease-free water. DNase treatment was carried
out using the DNA-Free kit (Ambion, ThermoFisherScientific), following the manu-
facturer’s instructions. The treated RNA was then precipitated and recovered before
use to remove any remaining reagents.
2.2.3 RNA precipitation
RNA was stored as precipitate at -20°C following the addition of 0.1 volumes 3M
NaAc (prepared by Roslin Laboratory Services) and 2.5 volumes ice-cold absolute
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ethanol.
2.2.4 Recovery of RNA from precipitate
The precipitate was pelleted by centrifugation at 13,000g for 30min at 4°C. The su-
pernatant was removed, the RNA pellet was washed in ice-cold 85% ethanol and cen-
trifuged at 13,000g for 15min at 4°C. The supernatant was removed and the pellet was
air-dried at 45°C for 2min. The pellet was then resuspended in an appropriate volume
of nuclease-free water by vortexing and heating to 65°C.
2.2.5 RNA quantity and quality
RNA was quantified using the Nanodrop ND100 Spectrophotometer (LabTech, Uck-
field, East Sussex, UK). The pedestal was wiped clean, then 1mL of nuclease-free water
was used to calibrate the machine. The RNA content of 1mL of each sample was quan-
tified, wiping the pedestal clean between each sample. Good quality, clean RNA was
confirmed by a smooth trace and 260/280 and 260/230 ratios within the appropriate
ranges, 1.8-2.0 and 2.0-2.2 respectively.
RNA quality was also assessed by Agilent Total RNA 6000 Nano Assay (#5067-
1511, Agilent Technologies, Stockport, Cheshire, UK), on the Agilent 2100 Bioana-
lyzer following the manufacturer’s instructions. 1mL of each RNA sample within the
recommended range (150-350ng/mL) was loaded onto the chip.
2.2.6 Generation of microRNA-Northern membranes
1-2.5mg of good quality DNase-treated total RNA in nuclease-free water (sections
2.2.1, 2.2.5and 2.2.2) was heated to 70°C for 3min to disrupt secondary structures
and an equal volume of 2x TBE-Urea Sample Buffer (Ambion, ThermoFisherScien-
tific) was added. The RNA samples were then loaded onto pre-cast 15%TBE-Urea
gels (Criterion, Bio-Rad Laboratories Inc., Hempstead, Hertfordshire, UK) and elec-
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trophoresis was performed at 125V for 1.5hr in a buffer of 1x TBE (diluted from 10x
TBE, Ambion, ThermoFisherScientific). Gels were removed from the plastic casings
and placed in 0.5x TBE + Sybr®Gold nucleic acid dye (at 10,000 fold dilution, Ther-
moFisherScientific) for 2 minutes. Successful RNA separation was then confirmed
by visualisation under UV. The RNA was then transferred onto Hybond-N+membrane
(GE Healthcare, Pollards Wood, Buckinghamshire, UK). The gel was placed directly
onto an equal sized piece of Hybond-N+membrane; the transfer of the RNA from the
gel to the membrane begins immediately. Therefore it was important not to realign
the gel once it touched the membrane, as this would smudge the transfer. The RNA
transfer to the Hybond-N+membrane was made permanent using the Bio-Rad semi-
dry transfer apparatus (Bio-Rad Laboratories Inc., Hempstead, Hertfordshire, UK) at
20mA for 1 hour. The RNA was fixed to the membrane by UV cross-linking (120,000
mJ in the UV Stratalinker). Dried membranes were stored at room temperature between
clean sheets of filter paper.
microRNA-Northern buffers
• 1xTBE: 100mL 10x TBE (Ambion, ThermoFisherScientific), 900mL autoclaved
dH2O
• 2x SSC, 0.1% SDS: 100mL of 20x SSC (prepared by Roslin Laboratory Ser-
vices) + 5mL 20% SDS (Ambion, ThermoFisherScientific), made up to 1L with
dH2O
• 0.1x SSC, 0.1% SDS: 5mL of 20x SSC + 5mL 20% SDS, made up to 1L with
dH2O
2.2.7 MicroRNA-Northern hybridisation
ULTRAhyb-Oligo Hybridisation Buffer (Ambion, ThermoFisherScientific) was liqui-
fied by heating to 68°C for 10min. The microRNA-Northern membranes were soaked
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in ULTRAhyb-Oligo Hybridisation Buffer at 42°C for a minimum of 1hr before incu-
bation with radio-labelled 32P LNA-oligo (Table 2.1). LNAs were labelled with 32P
using the mirVana probe and marker kit following manufacturer’s instructions (Am-
bion, ThermoFisherScientific). Following overnight hybridisation membranes were
then subjected to a series of 2x 15min washes with shaking to remove unbound probe.
Wash sequence: 42°C in 2x SSC and 0.1% SDS, followed by sequential washes at
42°C, 50°C, 55°C, 60°C in 0.1x SSC and 0.1% SDS. Overnight exposure to autora-
diographic film (Carestream® Kodak® BioMax® MS film, Sigma-Aldrich) at -80°C
after each wash was used to assess microRNA expression.
2.2.8 MicroRNA-Northern quantitation
Phosphoimaging analysis was used to quantify the signal on the microRNA-Northern
membranes. Screens were scanned, and the data analysed using the GE Healthcare
Typhoon FLA 7000 PhosphoImager.
2.2.9 MicroRNA-Northern membrane stripping
Membranes were stripped by immersion in boiling 0.1% SDS. Successful stripping of
the probe was confirmed by overnight exposure to autoradiographic film at -80°C.
2.3 cDNA synthesis
cDNA synthesis was carried out on ice, with centrifugation steps at 4°C unless oth-
erwise stated. Designated pipettes were used to avoid contamination. Nuclease-free
filter tips were used at all times. Nuclease-free water was used for work with cDNA.
All tubes were double-autoclaved (120°C for 15min x2 ) before use with cDNA.
1-5mg of DNA-free total RNA (as prepared in sections 2.2.1 and 2.2.2) was resus-
pended in 8mL of nuclease-free water. RNA was heated to 65°C for 2min to denature
any secondary structure. cDNA was then synthesised using the First Strand cDNA
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Synthesis Kit (GE Healthcare) as per manufacturer’s instructions. The total volume of
cDNA synthesis was 15mL, the cDNA was aliquoted (1mL) and stored at -20°C.
2.4 RT-QPCR
Preparation for RT-QPCR was carried out on ice, with centrifugation steps at 4°C un-
less otherwise stated. Designated pipettes were used to avoid contamination. Nuclease-
free filter tips were used at all times. Nuclease-free water was used for all work during
RT-QPCR. All tubes were double-autoclaved (120°C for 15min x2 ) before use in RT-
QPCR.
RT-QPCR was carried out using aliquots of cDNA prepared as described in sec-
tion 2.3. The cDNA was diluted 100-fold using nulcease-free water and 10mL of the
diluted cDNA solution was used in each RT-QPCR reaction. Primers were used at a
working concentration of 20mM. The housekeeping gene HPRT or b-actin was used to
normalise the data in each experiment. The Invitrogen Platinum SYBR Green qPCR
SuperMix-UDG kit was used in combination with the Stratgene Mx3000P RT-QPCR
machine, a 40 cycle the thermal profile (Table 2.6) was set according to the manufac-
turer’s instructions and data analysed using the MxPro software.
2.4.1 Primer design
Unless otherwise specified, primers were designed to span the last intron of the gene of
interest. Primers were designed against the genomic sequence on Ensembl (http://uswest.
ensembl.org/index.html) using Primer3 (Invitrogen Custom DNA Oligos, ThermoFish-
erScientific) with the following specifications: primer length 20-25nt; product length
100-150bp; GC content 40-60%; melting temperature (Tm) 60°C for both primers.
Primers were ordered to HPLC purification. Primers were diluted to 100mM in nuclease-
free water to form storage stocks which were kept at -20ºC. Primers were diluted to
20mM in nuclease-free water to form working stocks for use in RT-QPCR. The primers
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used in these studies are listed in Table 2.4
Table 2.4: RT-QPCR Primer Sequences. Unless otherwise specified, primers were
designed to span the last intron of the gene of interest, using the genomic sequence
on Ensembl (http://uswest.ensembl.org/index.html) and Primer3 (Invitrogen Custom
DNA Oligos, ThermoFisherScientific).
2.4.2 Primer optimisation
To ensure optimal performance of RT-QPCR assays across a range of input cDNAs,
RT-QPCR was performed on a set of 10-fold serial dilutions of a pooled cDNA stock.
This range represented 100-fold to 100,000-fold dilutions of the original cDNA solu-
tion. The resulting Cts were used to generate a calibration curve of Ct versus dilution,
and the parameters of this curve established the efficiency of the RT-QPCR reaction.
Primers were deemed acceptable if R2 >0.9 and with an efficiency in the range 95-
105% across a minimum range of 1,000-fold dilution.
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2.4.3 RT-QPCR set-up and analysis
RT-QPCR was carried out using the Invitrogen Platinum SYBR Green qPCR SuperMix-
UDG kit, previously optimised primers at 20mM (section 2.4.2) and cDNA which was
synthesised as previously described (section 2.3) and diluted to 1:100 in nuclease-free
water before use.
A RT-QPCR master mix was created using the ratios described in Table 2.5. Cre-
ating a master mix reduces pipetting errors across the plate. 15.5mL of the master mix
and 10mL of diluted cDNA were loaded into each well of a 96-well RT-QPCR plate.
Once loaded, the plates were centrifuged at 2,500rpm for 1min. Plates were sealed
with optical caps and run on a Stratgene MxPro3000 RT-QPCR machine with the ther-
mal profile described in Table 2.6. The fold-change in expression was calculated as
described in Table 2.7.
Table 2.5: RT-QPCR Master Mix. Ratios for the components of the master mix for
Invitrogen Platinum SYBR Green qPCR SuperMix-UDG kit. The primers used are
listed in Table 2.4.
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Table 2.6: RT-QPCR Thermal Profile. Thermal profiles used with the Invitrogen Plat-
inum SYBR Green qPCR SuperMix-UDG kit on Stratgene Mx3000P RT-QPCR ma-
chine.
Table 2.7: Methodology for RT-QPCR Data Analysis. Step for calculating fold-change
of expression from RT-QPCR data.
2.5 DNA analysis
DNA extraction was carried out at room temperature unless otherwise stated. Nuclease-
free filter tips were used at all times. Wide-bore pipette tips were used to prevent shear-
ing of the genomic DNA. Nuclease-free water was used for all work with DNA. All
tubes were autoclaved (120°C for 15min) before use with DNA.
DNA extraction buffer
400mM Tris/Hcl pH8 (prepared by Roslin Laboratory Services), 60mM EDTA (pre-
pared by Roslin Laboratory Services), 150mM NaCl (prepared by Roslin Laboratory
Services), 1% SDS, 100mg/mL Proteinase K (Sigma-Aldrich).
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2.5.1 DNA extraction
The media was removed from the cultures, the cells were washed with 1x PBS to re-
move residual serum, then lysed in an appropriate volume (500mL) of DNA extraction
buffer. The cells were detached from the surface of the plate using a cell scraper and
transferred to 2mL microcentrifuge tubes. Samples were then incubated at 55°C for
a minimum of 3hr. Samples were centrifuged at 13,000g for 10min. The supernatant
was collected and transferred into a fresh microcentrifuge tube and an equal volume of
phenol/chloroform/IAA (ThermoFisherScientific) was then added to the supernatant.
Samples were mixed by gentle inversion for 30s before being centrifuged at 13,000g
for 10min. The aqueous phase was transferred to a fresh microcentrifuge tube and
an equal volume of chloroform was added. The samples were mixed by inversion,
then centrifuged at 13,000g for 10min. The aqueous phase was removed to a fresh
microcentrifuge tube and 0.7 volumes of isopropanol were added to cause DNA pre-
cipitation. The sample was gently agitated for 5min, then centrifuged at 13,000g for
10min to pellet the DNA. The supernatant was discarded and the pellet washed by
immersion and centrifugation (13,000g for 10min) with 70% ethanol and then 100%
ethanol. The DNA pellet was air-dried, then resuspended in an appropriate volume of
TE buffer (prepared by Roslin Laboratory Services). If necessary, pellets were rocked
at 4°C overnight to dissolve. Samples were stored at 4°C.
2.5.2 DNA quantitation
DNA was quantitated using the Nanodrop ND100 Spectrophotometer (LabTech). The
pedestal was wiped clean, then 1mL of TE buffer was used to calibrate the machine.
1mL of each sample was measured, wiping the pedestal clean between each sample.
Good quality, clean DNA was confirmed by a smooth trace and 260/280 and 260/230
ratios within the appropriate values ~1.8, and 1.8-2.0 respectively.
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2.5.3 PCR
Samples and reagents were kept on ice during PCR set-up. 100ng DNA in 10mL
nuclease-free water was added to 30mL of PCR reaction mix (Table 2.9) in a micro-
centrifuge tube, creating a total volume of 40mL per sample. The samples were then
loaded onto a PCR heating block and the PCR reaction initiated using the conditions
described in Table 2.10. The amplified product was then visualised on a 1% agarose
TBE gel (section 2.5.4) under UV light. PCR amplification product was stored at 4°C.
The sequences of primers used during PCR analysis are listed in Table 2.8.
Table 2.8: PCR Primer Sequences. Ordered from Primer3 (Invitrogen Custom DNA
Oligos, ThermoFisherScientific).
Table 2.9: PCR Reaction Mix. PCR reagents ordered from Roche, Burgess Hill, UK
(10x PCR buffer and Taq) and Invitrogen (dNTP). The primers used are listed in Table
2.8
2.5.4 Agarose gel preparation and electrophoresis of PCR product
Agarose powder (Sigma-Aldrich) was dissolved in 1x TBE buffer at ratio of 1g :
100mL and was melted in a microwave, then allowed to cool until hand-hot (~60°C).
Ethidium bromide (Invitrogen) was added to a final concentration of 0.5mg/mL. The
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Table 2.10: PCR Thermal Profile.
agarose was poured into a gel tank of appropriate size and left to cool. Once cooled,
running buffer (1x TBE with 0.5mg/mL ethidium bromide) was added to the gel tank
until the gel was submerged. 10mL of sample and 2mL of running dye were mixed to-
gether in a microcentrifuge tube and then loaded in each lane. 6mL of an appropriately
sized ladder was loaded in the outside lanes of the gel (Invitrogen TrackIt Ladders,
25bp, 100bp, 1kb plus). The gel was then electrophoresed at 125V for approximately
1hr, or until the desired product size was displayed on the gel. The gel was then re-
moved from the gel tank, visualised and photographed, under UV light.
2.6 Protein analysis
Protein procedures were carried out on ice unless otherwise stated. Filter tips, dH2O
and autoclaved tubes (120°C for 15min) were used throughout protein analysis.
2.6.1 Protein extraction
The media was removed from the culture. Cell samples were rinsed with 1x PBS + pro-
tease inhibitors (ThermoFisherScientific), then lysed in 50mL T-PER protein extraction
buffer (ThermoFisherScientific) + protease inhibitors. The cells were detached from
the plates using a cell scraper and transferred to a 2mL microcentrifuge tube. The
protein extract was kept on ice for 15min, then centrifuged at 10,000g for 10min. The
supernatant was transferred to a fresh microcentrifuge tube and stored at -80ºC.
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2.6.2 Protein quantitation
Protein samples were quantitated using the Bradford method. BSA (Sigma-Aldrich)
protein standards were created to give a range of concentrations: 0.1, 0.2, 0.3, 0.4
and 0.5mg/mL adjusted to a total volume of 50mL. Protein lysate samples (2.6.1) were
diluted 1:50 in dH2O. Standards and samples were plated in triplicate (10mL per well)
in a 96-well microtitre plate. Bio-Rad Protein Assay Concentrated Dye was diluted
1:5 with dH2O. 190mL of the diluted reagent was added to each well. The plate was
incubated at RT for 5min to allow colour to develop. The plate was then agitated before
absorbance was read at 595nm. A standard curve was created using the absorbance
values for the protein standards. The concentrations of the protein samples were then
calculated using the standard curve.
2.6.3 Western analysis
Western membranes were created using the Novex Xcell SureLock™ Mini-Cell Elec-
trophoresis System (ThermoFisherScientific) and apparatus for polyacrylamide gel
electrophoresis, and the LI-COR Odyssey system (LI-COR Biosciences, Cambridge,
UK) was used for antibody hybridisation and visualisation of protein expression.
Western analysis buffers
• 1xPBS + protease inhibitors: 10mL, 1 tablet
• T-PER+ protease inhibitors: 10mL, 1 tablet
• 1x Tris-glycine running buffer: diluted from 10x tris-glycine buffer (ThermoFish-
erScientific) with dH2O
• Towbins Transfer Buffer: 2.9g Glycine (Sigma-Aldrich), 5.8g Tris-base, 1.352mL
20% SDS, 200mL methanol (methanol added just before use)
• Blocking Buffer: LI-COR Odyssey blocking buffer (LI-COR Biosciences)
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• 1x PBS/0.1% Tween: 1mL Tween 20 (Sigma-Aldrich), 1L 1x PBS
2.6.3.1 Polyacrylamide gel electrophoresis
Polyacrylamide gel electrophoresis was carried out using the Novex Xcell SureLock™
Mini-Cell Electrophoresis System apparatus. Novex 10-lane Tris-Glycine 8-16% gra-
dient mini-gels (ThermoFisherScientific) were used with 1x Tris-Glycine running buffer
for analysis of Dicer protein expression. The pre-cast gels were loaded into the X-Cell
Surelock Mini-Cell apparatus and the chamber filled with 1x Tris-Glycine running
buffer (~1L). It is important to ensure that the tops of the wells are covered other-
wise the apparatus will lose its connection and electrophoresis will cease. The wells
of the pre-cast gels were flushed twice with running buffer to remove any remaining
preservative that had accumulated prior to loading the protein sample.
Protein samples prepared for loading. Quantitated protein samples (section 2.6.2)
were diluted to yield 20-50mg/well of protein. NuPAGE LDS sample buffer (x4) (Ther-
moFisherScientific) and 2mL NuPAGE Sample Reducing Agent (ThermoFisherScien-
tific) were added to each sample. Then the samples were heated to 70°C for 10min,
subjected to a pulse spin by centrifugation and loaded onto the gel. 10µl of Bio-Rad
Precision Plus Protein Standards Dual Colour markers for identification of relative
molecular weight was added to the outer wells.
The boiled protein samples were loaded into the internal wells and the gel was
then electrophoresed according to the gel manufacturer’s recommendation. (For Novex
Tris-Glycine 8-16% gradient mini-gels, 3hrs @ 120 volts, or occasionally longer to
achieve better separation of larger molecular weight proteins). After electrophoresis,
the gel was removed from the cassette and placed in Towbins Transfer Buffer.
2.6.3.2 Transfer of electrophoresed protein samples to nitrocellulose membrane
The protein was transferred from the gel matrix onto the nitrocellulose membrane (GE
Healthcare) using the Blot Module of the Novex Xcell SureLock™ Mini-Cell Elec-
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trophoresis System apparatus. If desired the Novex Xcell SureLock™ Mini-Cell Elec-
trophoresis System apparatus can be used to transfer two membranes at the same time
(see manufacturer’s instructions).
The fresh piece of nitrocellulose membrane and filters for Novex Xcell SureLock™
Mini-Cell Electrophoresis System apparatus were soaked in transfer buffer. The filters
act to ensure a robust connection between the gel and the membrane. The transfer was
set-up following the manufacturer’s instructions.
It is important during this process to eliminate all air bubbles between the layers
as these will prevent the transfer of the protein onto the membrane. To remove air
bubbles, a 10mL pipette was gently rolled over the surface of the transfer stack. The
transfer stack was then carefully placed into the Novex Xcell SureLock™ Mini-Cell
Electrophoresis System transfer apparatus and the chamber filled with Towbins Trans-
fer Buffer (~1L). Protein transfer occurred at 25 volts for 1-2hr. After the transfer
was complete the positions of the molecular markers were noted with pencil on the
membrane surface to help orientate the blot.
The blot was either immersed in blocking buffer for immediate hybridisation, or
air-dried overnight between two clean pieces of filter paper for later use.
2.6.3.3 Antibody hybridisation and visualisation
It is important not to treat nitrocellulose membranes with methanol, as they will dis-
solve (however methanol is a suitable rewetting agent for PVDF membranes).
The LI-COR Odyssey system was used for antibody hybridisation and visualisa-
tion. Antibody details and concentrations used are listed in Table 2.11. It is important
to avoid any contact of the membrane with fluorescent materials, e.g. Coomassie. The
blot must remain wet for it to be subsequently stripped.
Dried nitrocellulose membranes were rewetted in 1x PBS for 10 seconds prior to
use. Membranes were incubated with the Odyssey Blocking Buffer for 1hr at RT
with gentle shaking. The primary antibody was prepared by diluting it to the desired
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concentration in sufficient Odyssey Blocking Buffer + 0.2% Tween 20 to cover the
membrane. The first application of blocking buffer was discarded and the membrane
incubated in the diluted primary antibody for 1hr at RT gentle shaking. The primary
antibody solution was poured off and the membrane washed 4x 5min in 1x PBS/0.1%
Tween 20 at RT with vigorous shaking.
The secondary antibody was prepared by diluting the fluorescently labelled IRDye®
secondary antibody (LI-COR Biosciences) to the desired concentration in sufficient
Odyssey Blocking Buffer + 0.2% Tween 20 to cover the membrane. After the addition
of the fluorescent secondary antibodies, the membranes were always wrapped in foil to
protect the membrane from light. The wash buffer was poured off and the membrane
incubated in the diluted secondary antibody, in the dark, for 45min at RT with gentle
shaking. The secondary antibody solution was poured off and the membrane washed
4x 5min in 1x PBS/0.1% Tween 20, protected from light, at RT with vigorous shaking.
The membrane was then rinsed with 1x PBS to remove residual Tween. The mem-
brane was then imaged using the LI-COR Odyssey Imager to detect the fluorescent
secondary antibody. Membranes can be stored in 1X TBS or 1X PBS for up to 48
hours in the dark at 4 °C.
The two colour detection was achieved by incubating the membrane with the two
primary antibodies simultaneously. Then the two secondary antibodies were incubated
simultaneously with the membrane. For two colour detection to be successful, the
primary antibodies had to be derived from two different species, and the wavelengths
of the fluorescent secondary antibodies must overlap to enable detection of both signals
at the same time. LI-COR recommends IRDye® 800CW secondary antibody (800
nm channel) be used to detect the lower-abundance protein target and IRDye 680RD
secondary antibody (700 nm) to detect the more abundant protein.
85
Table 2.11: Antibody Details
2.6.4 Stripping Western membranes
Membranes were washed with NewBlot IR Stripping Buffer (LI-COR Biosciences) at
RT for 20min. To confirm successful stripping, membranes were imaged using the LI-
COR Odyssey Imager. Membranes were then ready to be reprobed. Membranes were
stored short-term in saran wrap at 4°C.
2.7 Illumina next generation library preparation
2.7.1 Small RNA library creation
Small RNA profiling was carried out using the illumina sequencing platform (Illumina,
Inc., Little Chesterford, Essex, UK). BMDMs were activated with 100ng/mL LPS and
total RNA was extracted and purified at 0, 1, 2, 6, 12 and 24hr post-activation as
previously described (sections 2.1.3.4and 2.2.1-2.2.5). The RNA was used in conjunc-
tion with the illumina SmallRNA sequencing kit, as per manufacturer’s instructions
(sample preparation guide v1.5 provided by the manufacturer). Indexed 5’ adaptors,
supplied by the sequencing service Ark Genomics, The Roslin Institute, Midlothian,
UK (Table 2.12), were substituted for the uniform 5’ adaptor to enable multiplexing of
libraries on the sequencing chip.
Briefly, indexed 5’ and regular 3’ adaptors were ligated to total RNA then the sam-
ples were reverse-transcribed and amplified by PCR to generate cDNA libraries. The
product then underwent size selection via gel-purification - the library preparation was
loaded onto 6% TBE gels (ThermoFisherScientific) and electrophoresed to separate the
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sample by size. The portion of the gel containing the small RNA library preparation
(~100bp, corresponding to the total length of 5’ and 3’ adaptor ligated microRNAs.)
was cut out, and the sample extracted from the gel. Correct size selection was con-
firmed visually by electrophoresis on 6% TBE gels. Library quality and quantity were
assessed by Nanodrop and Agilent DNA 1000 assay respectively. Sequencing of the
constructed libraries was carried out by Ark Genomics.
Table 2.12: Primer Sequences used in illumina SmallRNA Sequencing. Regular adap-
tors form the illumina SmallRNA sequencing kit and the custom indexed 5’ adaptor
sequences, supplied by Ark Genomics are listed here. The 5nt index portion of the
custom indexed 5’ adaptors are highlighted in bold.
2.7.2 Bioinformatics
Initial processing of the raw sequencing data to identify the expressed microRNAs
was carried out by Ark Genomics. Once the sequencing data was received it was pro-
cessed using the software package ‘R’ (www.r-project.org) [207] and then normalised
using the normalisation script ‘EdgeR’ [212]. Fold-change in expression for individ-
ual microRNAs was calculated relative to the control (0hr time-point). The complete
expression data generated by NGS sequencing, displayed as both read counts and cor-
responding fold-change, is contained in appendix A.1.
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2.8 Target prediction software
The target prediction and gene enrichment analysis software programs used during this
work are listed below:
miRBase: http://www.mirbase.org/ [88, 89, 90, 140, 141]
miRBase dead-list (miRNA.dead) List of entries that have been removed from the
database, downloaded from: http://www.mirbase.org/ftp.shtml
miRecords: http://mirecords.biolead.org/ (no longer available)[284] Table 2.13
miRDB: http://mirdb.org/miRDB/index.html [281]
miRTarBase: http://mirtarbase.mbc.nctu.edu.tw [44]
ToppFun, part of the ToppGene Suite: https://toppgene.cchmc.org/enrichment.jsp
[40]
Table 2.13: Details of the 11 Prediction Programs Utilised in miRecords [284].
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2.9 rTAT-Cre
The pET28-TAT-Cre vector was a kind gift from the S. Dowdy Laboratory, UCSD/HHMI,
San Diego, CA, USA. The cDNA for recombinant Cre had been cloned into the multi-
ple coding region (MCS) of the pET 28b TAT v2 plasmid vector. rTAT:Cre vector map
and sequence data are shown in appendix B.
2.9.1 Generation of pET28-TAT-Cre plasmid stocks
The pET28-TAT-Cre vector was transformed into XL-1 blue subcloning grade com-
petent bacterial cells (Agilent Technologies). A single bacterial colony was used to
generate large scale cultures for bulk plasmid extraction.
2.9.1.1 Pouring agar plates
Agar stocks (prepared by Roslin Laboratory Services) were melted in a microwave,
allowed to cool until hand-hot (~60°C) and then, under sterile conditions, kanamycin
was added at a final concentration of 25mg/mL. The agar was then poured into plates
and left to set under sterile conditions.
2.9.1.2 Kanamycin antibiotic stocks
A 1000x stock (25mg/mL) was created by dissolving 125mg of kanamycin salts (Sigma-
Aldrich) in 5mL of dH2O. 1mL aliquots were stored at -20ºC.
2.9.1.3 Transformation of bacterial cells
XL-1 blue subcloning grade competent cells were transformed with 50ng of plasmid
DNA. DNA was added to the cells on ice and incubated for 20min. Cells were sub-
jected to heat-shock for 45s at 42ºC, then put on ice for 2min. Next 900mL of warmed
(42ºC) SOC media was added to the cells, followed by a 30min incubation at 37ºC
with shaking. The cells were then centrifuged at 5000g for 3min and 700mL of media
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was removed. The remaining 200mL of concentrated cell suspension was spread over
an agar plate supplemented with 25mg/mL kanamycin and the plate was incubated at
37ºC overnight. Single colonies were picked, grown in 3mL of LB broth (prepared by
Roslin Laboratory Services) + 25mg/mL kanamycin for 8hr, then expanded overnight
in 100mL of LB broth + 25mg/mL kanamycin. Both rounds of culture growth occurred
at 37ºC with shaking. Glycerol stocks were made as described below. The remaining
culture was used for the plasmid preparation.
SOC media SOB media (prepared by Roslin Laboratory Services) + 20mM glucose
2.9.1.4 Glycerol stocks
500mL of overnight bacterial culture was added to 400mL of glycerol (prepared by
Roslin Laboratory Services). The stock was then snap-frozen in a dry-ice and ethanol
bath. Glycerol stocks were stored at -80ºC.
2.9.1.5 Plasmid preparation
The overnight bacterial culture was used in conjunction with the Invitrogen midi-prep
kit as per manufacturer’s instructions. The quality and quantity of plasmid DNA gen-
erated were assessed by Nanodrop, as previously described. TE buffer was used as to
calibrate the Nanodrop device. Plasmid preparations were stored at -20ºC.
2.9.2 Recombinant TAT:Cre protein production and purification
The purified pTAT-Cre plasmid DNA (section 2.9.1.3) was send to Dundee Cell Prod-
ucts Ltd., Dundee, UK. Dundee Cell Products Ltd. then followed the Dowdy Labora-
tory protocol (section 2.9.2.1) to transform BL21-RIPL (codon plus) competent bac-
terial cells with the purified pTAT-Cre plasmid DNA, subsequently culture the cells,
induce protein expression and purify the TAT:Cre recombinant protein.
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The purified recombinant TAT:Cre protein was then delivered for use in the exper-
iments described here (section 2.9.3, chapter 5).
2.9.2.1 Protocol for the production and purification of the recombinant TAT:Cre
The established protocol for the production and purification of the recombinant TAT:Cre
(rTAT:Cre) provided by the Dowdy Laboratory is reproduced below:
Make protein (2 days+O/N transformation)
1. Transform BL21-RIPL (codon plus) with pET28-TAT-Cre. Pick 6 colonies to inoc-
ulate 5mL culture in LB Kanamycin/Chloramphenicol.
2. Pick the most turbid culture and use 1mL to inoculate each of 4x500mL overnight
(in LB/Kan/Chlor) at 37˚C.
3. Induce with 500uM IPTG and grow 3hr at 37°C.
Harvest protein
4. Centrifuge @ 6000g for 5min @ 4°C; pour off supernatant and resuspend each
pellet in 20mL PBS.
5. Transfer to 2x50mL conical tube and centrifuge @ 6000g for 10min; pour off
supernatant and freeze pellet O/N @ -80°C.
6. Resuspend each pellet in 35mL Lysis Buffer by rotating at 4°C.
7. Lyse pellet by sonication (#7, 90%, 20-30 pulses x 4 with 1min between) on ice;
save 100mL sample for analysis.
8. Clear lysate via centrifugation @ 50,000g for 20min @ 4°C; collect supernatant;
save 100mL sample.
Ni column purification
9. Add cleared lysate to Ni-NTA column pre-equilibrated with 50mL Buffer A; save
flow-through for analysis.
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10. Wash with 100mL Buffer A, save flow-through for analytical gel.
11. Elute with 20mL Buffer B - collect 1mL fractions and check for protein by Brad-
ford; pool protein-containing fractions; save 100mL sample for gel.
12. Buffer Exchange pooled fractions on PD10 columns into Buffer C – collect frac-
tions and pool.
S column purification
13. Equilibrate 30S IEX column with 50mL of Buffer D.
14. Check for precipitation (each batch must be checked): Dilute 0.75mL Ni eluate
1:1 with 0.75mL H2O (if this solution turns cloudy within 10 minutes, then first dilute
1:1 with Buffer C followed by 1:1 with H2O) and add immediately to column. Repeat
until ½ of Ni eluate is on column. Save flow-through for analysis.
15. Wash column with 50mL Buffer D; save 100mL of flow-through for analysis.
16. Elute with 10mL Buffer E; collect 0.5mL fractions and check for protein by Brad-
ford; pool TAT-Cre containing fractions, save 100mL for analysis
17. Repeat with other ½ of Ni eluate
18. Quantitate concentration via Bradford; if the concentration is less than 4mg/mL
then do buffer exchange / concentration up to at least 2mg/mL.
Buffer exchange/concentration (optional)
19. Buffer Exchange on PD10 columns into Buffer F.
20. Use a 10,000 MW centricon column to concentrate: Add PD10 eluate to column,
spin column at 3750rpm in swinging bucket centrifuge in ~5 min increments until vol-
ume is about 2mL. Elute protein by turning the column over and spinning at 2000rpm.
Analysis
21. Run 10% coomassie gel with BSA controls to check final concentration and purity.
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rTAT:Cre protocol buffers
All buffers must be sterile-filtered, kept on ice, and used cold.
Lysis: Buffer A with .5% Tween-20; RNAse 10ug/mL & DNAse 200U (and 150U
benzonase); Lysozyme .5mg/mL; protease inhibitors (PMSF, leupeptin, aprotinin) 50mL
A - Ni Wash: 20mM PO4 pH 7.5; 600mM NaCl; 20mM imidazole 500mL
B - Ni Elution: 20mM PO4 pH 7.5; 1M NaCl; 250mM imidazole; 5% glycerol
50mL
C - Ni Exchange: 20mM PO4 pH 7.5; 600mM NaCl; 5% glycerol 500mL
D - S Wash: 10mM PO4 pH 7.5; 300mM NaCl; 2.5% glycerol 500mL 500mL
E - S Elution: 10mM PO4 pH 7.5; 1M NaCl; 5% glycerol 50mL
F - S Exchange: 20mM PO4 pH 7.5; .5M NaCl; 5% glycerol 500mL
2.9.3 In Vitro Work
The recombined TAT-Cre protein was used at a final concentration of 1.5mM in serum-
free media with BMDMs (8hr incubation) or on bone marrow (2hr incubation). After
incubation the serum-free media was replaced with complete media. Samples were
harvested at designated time-points for RNA, DNA and protein as previously described





maturation and activation of
macrophages
3.1 Introduction
To study the expression and function of microRNAs in macrophage biology, we utilised
the culture of both primary and established in vitro systems for macrophage differenti-
ation and activation [106, 261], as each has specific advantages.
When this work was undertaken, the literature on the role of microRNAs during
macrophage activation was sparse (section 1.4.2.2), and the global expression profile
of microRNAs during these processes had not yet been published. In order to take
advantage of the next generation sequencing (NGS) technologies that were becoming
available to characterise the global expression profile of microRNAs, it was decided
to generate samples for sequencing from primary cells, as these cells are more reflec-
tive of in vivo macrophage behavior than are immortalised cells. However, immor-
talised macrophage cells would be required for the functional analysis of microRNAs,
as established cell lines are more resistant to transfection procedures than are primary
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macrophages; typically primary macrophages respond to transfected genetic material
as an intracellular infection, and undergo apoptosis [244]. Therefore, in addition to
primary BMDMs, the macrophage-like cell line RAW264.7 and a sub-clone, hELAM-
GFP, were chosen for activation studies. The RAW264.7 cell line was derived from
murine tumour cells harvested from mice infected with the Abelson leukemia virus
[209]. The hELAM-GFP cell line is a stable sub-clone derived from the RAW264.7
cell line, where a DNA fragment comprising the protein coding region of the GFP tran-
script under the regulation of the human ELAM promoter has been inserted into the
genome. The hELAM promoter is responsive to NFkB. As a consequence, the hELAM
cells exhibit green fluorescence when stimulated via the NFkB pathway [245].
Murine macrophage models were chosen over human, bovine or porcine models
for several reasons. Firstly mice provide a consistent genetic background and a readily
accessible source of bone marrow to generate BMDM cultures. In addition, well-
established immortalised murine macrophage cell lines (including the RAW264.7 cell
line and its GFP expressing reporter sub-clone hELAM-GFP) are readily available.
These cell systems generate sufficient RNA for NGS analysis from populations en-
riched for macrophages at carefully defined stages of differentiation and activation.
Once the cell types for study had been selected, the methods for macrophage dif-
ferentiation and activation for this project were optimised. Successful differentiation
and activation of the in vitro systems were confirmed by monitoring changes in cellular
morphology and the expression of known molecular markers. A reproducible profile
of marker gene expression for these systems was characterised and used as a compar-
ison point to confirm the successful differentiation and activation of macrophages in
subsequent experiments.
3.1.1 Aims
The objective of the experiments described in this chapter was to establish reproducible
in vitro systems for the differentiation and activation of primary and immortalised
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macrophages that could then be used in subsequent work to generate NGS libraries
and for the functional analysis of differentially expressed microRNAs in macrophages.
The systems chosen were characterised in detail via analysis of mRNA and miRNA
marker gene expression. The practicality of using these systems for microRNA ex-
pression analysis was also assessed.
3.2 Results
3.2.1 Characterisation of bone marrow derived macrophage dif-
ferentiation
The objective of this section was to successfully, and reliably cultivate bone marrow
derived macrophages from murine bone marrow. An in vitro system for manipu-
lation of primary macrophage cells can be established by culturing extracted bone
marrow in the presence of CSF-1, the critical myeloid growth factor that mediates
macrophage differentiation (section 1.2.1.5). A relatively pure population (~98%) of
mature macrophages can be established by cultivation of murine bone marrow in com-
plete media + 104 units/mL CSF-1 on bacteriological plastic plates. Unlike tissue cul-
ture plastic, bacteriological plastic does not have a coating designed to promote cellular
adhesion. Therefore only naturally adherent cells can attach to the surface of the plate;
cells that are not naturally adherent remain suspended in the culture media. Mature
macrophage cells are naturally adherent, while progenitors, other haematopoietic cell
types recovered from the bone marrow (BM), and dead cells cannot adhere to the bac-
teriological plastic and therefore do not contribute to the adherent population. Thus
culturing the cells on bacteriological plastic provides an additional selection mecha-
nism when culturing BMDMs. Successful differentiation of BMDMs was assessed by
examination of morphology and by monitoring known macrophage/progenitor marker
gene expression: Runx.1, Pu.1, Csf-1r, Myb, Bclx and Upa (sections 1.2.1.3-1.2.1.5).
To generate bone marrow derived macrophages in vitro, bone marrow from a mini-
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mum of two c57/bl6 mice was extracted and pooled. A sample of the bone marrow pool
was harvested for RNA, to represent the initial, undifferentiated bone marrow popula-
tion. The remaining bone marrow was then plated on bacteriological plastic plates in
macrophage differentiation culture conditions (complete media + 104 units/mL hrCSF-
1). Seven replicate plates were created and one plate was harvested each day to study
the generation of BMDMs over a seven day period. Each day the cultures were pho-
tographed under light microscopy to study cellular morphology. The adherent and
non-adherent cellular samples from one plate were then collected separately to study
the changes in the mixed cell, non-adherent population vs. the defined, adherent,
macrophage population. On day 5 of culture the remaining plates were replenished
with 10mL fresh complete media and CSF-1 to maintain differentiation conditions.
Extracted RNA was used for both microRNA-Northern analysis and to generate cDNA
for RT-QPCR.
The gross morphological changes that occurred in the culture during the differen-
tiation period (BM - day 7) were observed via light microscopy (Fig 3.1). Immedi-
ately after collection, the bone marrow cell population was a mixture of non-adherent
lineages and progenitor stages. During the first four days of culture there was little
change in the overall morphology within the population. The majority of cells were
non-adherent, appearing as small, rounded, bright points in suspension. Only a small
number of adherent cells were observed during these early time-points. These cells
most commonly displayed a polar morphology with cellular projections pointing in
opposite directions, although some of the adherent cells displayed three projections
(Fig 3.1, day 1 and day 3). By day 5 of culture, the majority of the population had
become adherent and the surface of the culture plate was densely populated with cells
(Fig 3.1, day 5). Visual assessment showed that the number of adherent cells within
the population had continued to increase over days 6 and 7 (Fig 3.1, day 7).
These observations concurred with the expected morphological changes during this
differentiation process. The non-adherent cells represented the mixed, non-macrophage
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cells. Non-adherent cells of the myeloid lineage responded to the presence of CSF-1 in
the culture conditions and differentiated into macrophages, becoming adherent. Cells
which were of other haematopoietic lineages were unable to respond to the presence
of CSF-1 and died off during the culture period. Both of these factors resulted in a
decreased number of non-adherent cells observed over time. The CSF-1-driven differ-
entiation of macrophages was most easily observed as the increasing number of ad-
herent cells in the population over time, because macrophages can adhere to the plate
surface. It is also worth noting that there was little debris from dead cells observed
in the final stage of culture (Fig 3.1, day 7) despite the large number of non-myeloid
cells that died off. This is because the macrophages have phagocytosed the cell debris,
thereby fulfilling one of their primary functions (phagocytosis of apoptotic cells and
cell debris/tissue remodelling).
Repeating the bone marrow differentiation in the absence of CSF-1 further con-
firmed the successful in vitro differentiation of BMDMs by this method. In the ab-
sence of CSF-1, the adherent (macrophage) population did not appear. Instead, in the
absence of growth or survival stimuli, the cell population remained non-adherent and
died off during the culture period (Fig 3.1, -CSF-1).
To monitor morphological changes within macrophage cultures more specifically,
bone marrow differentiation cultures were assessed using the Roche xCELLigence sys-
tem. This is an instrument designed to measure the impedance of an electrical current
across each well of a specially designed 96-well culture plate, generating a measure-
ment known as a cell index (CI) value. The presence of cells on the surface of the
plate increases impedance, resulting in a higher CI value. The impedance across cul-
ture wells can be affected by cell number, cell morphology and degree of adherence.
This system provided a real-time, continuous assessment of the adherent population
rather than snapshots at 24hr time-points. By extension, the xCELLigence system can
be used to assess differentiation of bone marrow into macrophages. Because only the
mature BMDMs can adhere to the surface of the plate, it was expected that the CI
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Figure 3.1: Morphological Changes during In Vitro Differentiation of Bone Marrow
into Mature Macrophages. Bone marrow was extracted from c57/bl6 mice and cultured
in the presence or absence of the macrophage growth factor CSF-1. In the presence
of CSF-1 the cells differentiated and became adherent (+CSF-1, days 5 and 7). The
adherent cells displayed a polar morphology where there was space on the surface of
the culture dish; in the more crowded areas of the plate the cells maintained a rounded
morphology. When CSF-1 was absent from the culture, the cells did not receive any
growth or survival stimuli; they did not differentiate nor become adherent, and died off
during the culture period. n=5
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value would increase during differentiation as the number of adherent cells increased,
causing a corresponding increase in impedance across the surface of the plate.
Bone marrow was extracted and placed in culture at three different cell densities
(10,000, 20,000 and 40,000 cells per well) with 6 replicates at each density. The cells
were grown for 7 days and the CI value across each well was collected at hourly inter-
vals. The CI values during differentiation were plotted against time in Figure 3.2. The
plating density of the bone marrow was not found to affect the initial rate of differentia-
tion as there was no increase in CI values above the background level during the initial
3 days of culture. Because the CI value correlates with the physical attachment of the
cells on the surface of the plate, this finding indicated negligible numbers of adherent
cells within the population at these initial stages, which concurs with the population
morphology observed in Figure 3.1. Between days 3 and 4 in culture, the CI value be-
gan to increase, and continued to increase for the remainder of the experiment during
which time the plots become more divergent, with higher CI values being generated by
the higher plating density (40,000 cells per well). The increase in CI value during this
time was most likely due to the increased number of cellular attachments to the surface
of the culture dish, as the cells differentiated into macrophages and became adherent.
Visual assessment of population morphology in the plated wells concurred with
the CI data. While the difference in cell numbers was apparent visually in the non-
adherent population at the beginning of the experiment (Fig 3.2, day 1 photomicro-
graphs), the difference in plating densities became more pronounced once the cells
became adherent (Fig 3.2, day 5 photomicrographs); the quantity of adherent cells
present increased in accordance with plating density. There were more adherent cells
visible in the wells seeded with 40,000 cells than with 20,000 cells. The CI data, and
accompanying visual assessment of bone marrow differentiation on the xCELLigence
machine concurred with the pattern of adherent cell emergence observed in the initial
differentiation experiments (Fig 3.1).
An additional measure of the successful generation of BMDMs was the analysis
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Figure 3.2: Measurement of Cellular Impedance during Bone Marrow Differentiation.
The Roche xCELLigence system was used to measure the electrical impedance (CI
value) across the surface of each well, as caused by adherent cells. Bone marrow was
plated in differentiation culture at two plating densities: 20,000 and 40,000 cells per
well. The cells were grown for 7 days and the CI value across each well was measured
at hourly intervals. Top image: CI data for BMDM differentiation plotted against time.
Each individual data point represents the mean CI value at that time-point ± 1 S.D. of
6 experimental replicates (n=1). Lower image: Photomicrographs of sample wells at
day 1 and at day 5. As the cells differentiate and become BMDMs they adhere to the
surface of the plate, increasing the impedance and CI value. The greater the plating
density, the greater the CI value once the cells adhere.102
of known macrophage/progenitor associated genes by RT-QPCR. To achieve this, the
RNA harvested from the BM - day 7 samples was used to generate cDNA for RT-QPCR
analysis in order to measure macrophage and progenitor marker gene expression. Ini-
tially the expression of Csf-1r, the archetypal macrophage marker, and Runx1 and
Pu.1, two myeloid-associated transcription factors (sections 1.2.1.4 and 1.2.1.5), was
measured in the adherent cells. As the archetypal macrophage marker, the expression
of CSF-1R was expected to increase in the progenitor population and be most highly
expressed in the differentiated macrophages. The transcription factor RUNX1 is asso-
ciated with haematopoiesis and is strongly expressed in the bone marrow. The deletion
of Runx1 in adults increases haematopoietic proliferation, therefore it was expected
that the expression of Runx1 would decrease over the seven days of culture as the pop-
ulation differentiated and became more defined. PU.1 is a major myeloid transcription
factor: its up-regulation is required for macrophage differentiation and its expression
has been reported in mature macrophages.
There were very few adherent cells at day 1 and therefore no measurements were
carried out at this time-point. Gene expression for days 2-7 was calculated as fold
change (2-ddCt) relative to day 2 (the earliest differentiation time-point from which
RNA could be consistently recovered) and is displayed in Figure 3.3a-c.
In the adherent population, Runx1 expression in the BM was double that observed
in the adherent cells. Although decreased compared to BM, the adherent cell pop-
ulation does display constitutive expression of Runx1; the adherent cells (days 2-7)
showed some variation, but no definitive trend, suggesting a fairly stable level of
Runx1 expression in adherent cells. This data concurs with the role of Runx1 in
haematopoiesis and myeloid cell proliferation/maturation. The adherent cells have
already differentiated into macrophages and therefore down-regulated the expression
of genes associated with the earlier stages of haematopoiesis.
The BM is a heterogeneous population of cells of different lineages, many of which
do not express CSF-1R, while the adherent cells are an almost pure population of
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macrophages in which CSF-1R expression is not being diluted by other cell types. As
expected, this difference was reflected in the RT-QPCR data; the expression of Csf-
1r was approximately 5-fold higher in the adherent cell population than in the BM
population. There was little variation in the level of Csf-1r expression in the adherent
cell population indicating that Csf-1r is stably expressed in these cells. The expression
of Pu.1 appeared higher in the BM than in the adherent cells. This is incompatible
with published microarray data (www.biogps.org) where PU.1 is strongly induced in
BMDMs relative to precursor cells. Previous studies also showed that PU.1 protein is
very high in the nucleus of BMDMs [216]. PU.1 mRNA remained relatively stable in
the adherent cells through the time-course. The reason for the anomaly on day 0 was
not explored further.
Additional markers shown previously to be associated with CSF-1 action were ex-
amined in (Bclx, Myb and Upa, Fig 3.3d-f).
Bclx is an anti-apoptotic factor that promotes cell survival and its expression is
maintained by CSF-1. Therefore the adherent cells were expected to express Bclx.
Myb acts as a negative regulator of haematopoiesis; its over-expression blocks differ-
entiation and must be carefully regulated. It was expected that Myb would be turned
off in the adherent cells. Upa is regulated by RUNX and its expression is associated
with differentiation. It also plays a role in extra-cellular matrix remodelling and was
expected to be expressed in the adherent cells.
The expression of Bclx was highest in the BM but was also expressed in the ad-
herent cells, and expression increased over the culture period. Myb was expressed at
very low levels in the adherent population compared to expression in the BM. Upa was
not expressed in the BM but was clearly expressed throughout the culture period in the
adherent cells. The data here matched the expected expression patterns for these genes
(Bclx and uPA expressed more strongly in adherent cells than in the BM; Myb turned
off in the adherent cells compared to the bone marrow).
The mostly consistent nature of the marker gene expression observed in the ad-
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Figure 3.3: Expression of Runx1, Csf-1r, Pu.1, Bclx, Myb and uPA in Adherent Cells
during the Differentiation of Mature Macrophages from Bone Marrow, measured by
RT-QPCR. Murine bone marrow was cultured in macrophage differentiation conditions
for 7 days. cDNA generated from RNA collected each day was used in RT-QPCR to
measure the expression of the macrophage associated genes a) Runx1, b) Csf-1r, c)
Pu.1, d) Bclx, e) Myb and f) uPA. The variation in gene expression during differentia-
tion culture is displayed as mean fold-change (2-ddCt) ±1S.D. relative to day 2 (for a-c
n=2, for d-f n=1 with three technical replicates). The data was normalised against the
housekeeping gene HPRT. There was no data for gene expression on day 1 as there
were not enough adherent cells at this time-point to generate RNA for analysis.
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herent cell population strongly indicates that, as hypothesised, it represented mature
macrophages. It was decided to take a primary look at the gene expression in the
non-adherent population to determine if any progenitor cell characteristics could be
identified in this more mixed population. As the cells differentiated and became adher-
ent, or cells from other lineages died off, the non-adherent cell population decreased.
This meant that it was only possible to collect sufficient material for the full culture pe-
riod by combining cells from different experiments. Figure 3.4 displays Runx1, Csf-1
and Pu.1 expression data from one biological pool. For consistency with the adherent
cell data, the samples were normalised against day 2. The expression of Bclx, Myb and
uPA in the non-adherent cells was not assessed.
In the non-adherent population, Runx1 was expressed at a similar level to the orig-
inal BM sample and was maintained throughout the culture period. Pu.1 expression
was elevated in the BM and the non-adherent population, then decreased dramatically
and was not detected in the samples from day 4 onwards. Csf-1r expression increased
steadily for the duration of the culture period.
The changes in marker expression observed here indicated that cells in the non-
adherent population were undergoing differentiation along the macrophage lineage.
Runx1 is expressed in the non-adherent cell population which contains progenitor cells
that are still undergoing differentiation. This fits with the active role RUNX1 plays in
haematopoiesis. CSF-1/CSF-1R interactions on non-adherent cells stimulated survival
and differentiation of macrophage progenitors. Non-CSF-1R expressing cells died off.
Csf-1r expression in the non-adherent cells increased throughout the culture period.
This concurs with the biological expectation that culture moves towards a more pure
macrophage population over the seven days.
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Figure 3.4: Expression of Runx1, Pu.1 and Csf-1r in Non-adherent Cells during the
Differentiation of Mature Macrophages from Bone Marrow, measured by RT-QPCR.
Murine bone marrow was cultured in macrophage differentiation conditions for 7 days.
cDNA generated from RNA collected each day was used in RT-QPCR to measure the
expression of the macrophage associated genes a) Runx1, b) Csf-1r and c) Pu.1. The
variation in gene expression during differentiation culture is displayed as mean fold-
change (2-ddCt) ±1S.D. for three technical replicates relative to day 2 (n=1). The data
was normalised against the housekeeping gene HPRT.
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3.2.2 Characterisation of the activation response in primary macro-
phages and in immortalised macrophage cell lines
3.2.2.1 Primary cell characterisation
After seven days in culture, the BMDMs were activated with the Gram-negative bacte-
rial cell wall component lipopolysaccharide (LPS), which is a potent stimulator of the
immune response. This was to confirm that the cells were functionally active and to
characterise the activation response. To achieve this, cellular changes in morphology,
marker gene expression and microRNA expression were assessed during the response
period.
BMDMs were differentiated as described above. On day 6 of culture the cells
were harvested, counted and plated for activation onto tissue culture (TC) plastic. The
cells were incubated overnight to allow time for them to adhere to the surface of the
plate. The cells were then activated with LPS on day 7 of culture. Two doses of LPS
were assessed, 10ng/mL and 100ng/mL. The cells were photographed on the plate
under bright-field microscopy, and then harvested for RNA at multiple time-points
post-activation (usually 0, 1, 6 and 21hrs, and other times as specified). The 0hr time-
point represented the control, or unactivated sample which was not exposed to LPS.
RNA was used to generate both microRNA-Northern membranes for assessment of
microRNA expression and cDNA for use in RT-QPCR to measure marker gene ex-
pression. This data was then used collectively to characterise the activation response
of BMDMs to LPS.
A visual assessment of BMDM cellular morphology following activation was car-
ried out under light microscopy (Fig 3.5). Macrophages are motile cells and this is
reflected in their response to activation: in vivo (and during in vitro migration assays)
macrophages migrate in a directional manner towards the site of infection, demonstrat-
ing a ‘leading edge’. In the in vitro system used here, the cells were surrounded by the
stimuli and therefore it was expected that the cells would spread in all directions. The
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process of activation causes changes within the macrophage cytoplasm, as the cell pro-
duces phagosomes and lysosomes which scatter the light of the microscope, producing
the illusion of darker and more granular cells.
Dramatic changes to cellular morphology within the population were observed
during the activation time-course. The majority of unactivated BMDMs (0hr) demon-
strated a polar morphology, with two projections pointing in opposite directions. Some
cells displayed a greater number of projections, giving rise to a star-like morphology,
while others displayed a rounded morphology, most likely indicating cells undergoing
mitosis. A small number of cells demonstrated a fully flattened ‘fried-egg’ like mor-
phology. When viewed under light microscopy, the cellular membrane could be clearly
observed as a finite edge defining the cytoplasm (Fig 3.5, untreated BMDMs), and the
nucleus constituted at least half of the area of the cell. In the fully flattened cells,
the cell membrane was less clearly defined under light microscopy and the nucleus
contributed less than half of the cellular volume.
Gross morphological changes were not readily apparent in the population immedi-
ately after activation. This changed over time with a greater proportion of the activated
cells demonstrating an activated morphology at each subsequent time-point. By 12hr
post-activation, the majority of the population demonstrated morphological changes
consistent with activation. This activated population morphology was maintained at
24hr post-activation (Fig 3.5, 24hr). Where there was space on the surface of the plate,
the activated BMDMs developed a large, circular morphology in which the nuclear
membrane was visually distinct under bright-field microscopy, but the edges of the cel-
lular membrane were not. The diameter of a fully spread BMDM was approximately
3x the diameter of the nucleus. The cells appeared darker after activation, a down-
stream effect of changes within the cytoplasm. This data is in line with morphological
changes reported for activated macrophages.
The Roche xCELLigence machine was used to monitor changes in adhesion and/or
proliferation in the culture population upon activation. This machine measures the
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Figure 3.5: Morphology of Primary Macrophages Activated with LPS. BMDMs
were plated in macrophage culture conditions and activated with two doses of LPS
(10ng/mL and 100ng/mL). Morphological changes in the cell cultures after activation
were assessed at multiple time-points post-activation. Presented here are representa-
tive photographs of unactivated BMDMs and BMDMs at 24hr post-activation. Light
microscopy at x40 magnification. n=6
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impedance of an electrical current across the surface of the culture plate (CI value).
Because the attachment of cells on the plate increases impedance, it was expected that
the CI value would increase after activation as the cellular morphology of the BMDMs
changed to cover a greater surface area, thereby creating more attachment points with
the surface of the plate. BMDMs were plated at 20,000 cells per well in complete
media, incubated overnight to facilitate attachment, then activated by treatment with
10ng/mL or 100ng/mL LPS. The CI value was measured at regular intervals for 24hrs
after activation (Fig 3.6). The data plots show an initial (pre-activation) increase in
CI values congruent with cell attachment to the plate surface (from 0 to 1.5-2). Acti-
vation of the cells with LPS caused a dramatic increase in CI value compared to the
unactivated cells (at 4hr post-activation the mean CI values for unactivated, 10ng/mL
and 100ng/mL samples were ~2, 2.75 and 3.25 respectively). This elevated CI value
in the activated cells, compared to the control cells, remained for approximately 12hr
following activation after which point the activated CI value began to decrease, and by
20hr post-activation the CI value of the activated samples were similar to those of the
unactivated cells (Fig 3.6).
RNA that had been harvested from the activated macrophages at multiple time-
points post-activation with LPS was used to create cDNA for RT-QPCR analysis to
measure the expression of a number of well-characterised gene markers of activation.
Five markers known to display dynamic expression in activated macrophages were
used in RT-QPCR analysis: TNF-a, Cox2, Cxcl2, Il-6 and Saa3 (section 1.2.3.3).
TNF-a is a potent pro-inflammatory cytokine that is rapidly and strongly induced
in macrophages that are stimulated with LPS. It acts as a master regulator to stimulate
expression of other inflammatory genes and therefore it was expected to see induc-
tion of Tnf-a within the first few hours of activation. COX2 expression is known to
be rapidly induced by LPS stimulation in macrophages. Its main role is the synthe-
sis of prostaglandins during inflammation, which in turn mediate expression of IL-6.
Therefore it was expected that the expression of Cox2 would become apparent before
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Figure 3.6: Measurement of Cellular Impedance during Activation of Primary
Macrophages. The Roche xCELLigence system was used to measure changes in the
electrical impedance (CI value) across the surface of each well caused by macrophage
activation. BMDMs were plated at 20,000 cells per well. The cells were then activated
with 10ng/mL or 100ng/mL LPS. The CI value across each well was measured for
24hr post-activation at 2min intervals for 1hr, then 15min intervals for 8hr and 30min
intervals for 15hr. Each individual data point represents the mean CI value at that
time-point ± 1 S.D. of 6 experimental replicates (n=1).
the expression of Il-6 was detected. Cxcl2 expression is known to be induced by LPS
stimulation in a NFkB dependent manner. IL-6 is a pro-inflammatory cytokine that
is induced in macrophages in response to LPS and other pro-inflammatory molecules.
Despite its role as a pro-inflammatory cytokine, IL-6 is able to suppress expression of
TNF-a at the transcriptional level; therefore it was expected to see a decrease in Tnf-a
expression as Il-6 expression increases. The expression of SAA3 in LPS-stimulated
macrophages is mediated by pro-inflammatory cytokines such as TNF-a and IL-6.
Therefore Saa3 expression occurs at the later time-points, once Tnf-a and Il-6 have
had time to be expressed and take effect. The expression of these genes in the acti-
vated BMDMs is characterised here (Fig 3.7).
Levels of expression of all five transcripts increased substantially as a result of
activation. Tnf-a and Cxcl2 showed maximal levels of expression over the 1-6hr period,
Cox2 showed maximal expression at 6hr while Il-6 and Saa3 showed highest levels of
expression over the later stages of culture (6-21hr).
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Figure 3.7: Expression of Known Macrophage Activation Marker Genes during the
Activation Response in Primary Macrophages, measured by RT-QPCR. BMDMs were
activated with 100ng/mL LPS. cDNA generated from RNA collected at multiple time-
points post-activation was used in RT-QPCR to measure the expression of the activa-
tion associated genes a) Tnf-a, b) Cox2, c) Cxcl2, d) Il-6 and e) Saa3. The variation
in gene expression during macrophage activation is displayed as mean fold-change
(2-ddCt) ±1S.D. relative to the unactivated (0hr) sample (n=3). The data was normalised
against the housekeeping gene HPRT. P-values were calculated by paired student’s t-
tests against the 0hr time-point, * = P-value < 0.05, ** = P-value < 0.01
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3.2.2.2 Immortalised cell characterisation
The RAW264.7 macrophage cell line As primary macrophages cannot be routinely
transfected, the suitability of immortalised macrophage cell lines was assessed for
functional analyses of miRNAs. To determine if the RAW264.7 immortalised macro-
phage cell line was a suitable model, the activation response of this cell line was charac-
terised and compared to that of BMDMs. RAW264.7 cells were plated onto TC plastic
and incubated overnight to allow the cells to adhere, and the cells were then activated
with either 10ng/mL or 100ng/mL LPS. The RAW264.7 cells were photographed and
then harvested for RNA at multiple time-points post-activation. The 0hr time-point
represented the unactivated sample which was not exposed to LPS. The RNA was used
for both microRNA-Northern analysis and cDNA in RT-QPCR. This data was then
used collectively to characterise the activation response of RAW264.7 cells to LPS,
and to compare it against the response generated by BMDMs.
Morphological changes in the RAW264.7 population post-activation were assessed
visually by light microscopy (Fig 3.8, RAW264.7). While the RAW264.7 cells did
exhibit morphological changes upon activation, these changes were not as dramatic as
those seen in the BMDM population (Fig 3.5). The majority of unactivated RAW264.7
cells displayed a rounded morphology; a minority of cells showed small projections
that were not long enough to create a polar morphology, but instead gave the appear-
ance of a ‘spiky’ morphology. Once activated, the RAW264.7 cells displayed a polar
morphology and increased granularity. The fully flattened morphology observed in the
activated BMDM cultures was not often observed in the RAW264.7 populations, even
when there was room on the surface of the culture plate for the cells to spread out.
The morphological changes in the activated RAW264.7 population was then as-
sessed using the Roche xCELLigence machine. The cells were incubated overnight to
facilitate attachment and then activated by treatment with either 10ng/mL or 100ng/mL
LPS. The CI value was measured at regular intervals for 24hr after activation (Fig 3.9).
The data plots show a slight increase in CI values between plating and activation (from
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Figure 3.8: Morphology of Immortalised Macrophages Activated with LPS. The
immortalised macrophage cell lines RAW264.7 and hELAM-GFP were plated in
macrophage culture conditions and activated with two doses of LPS (10ng/mL and
100ng/mL). Morphological changes in the cell cultures after activation were assessed
at multiple time-points post-activation. Presented here are representative photographs
of the different cell types when unactivated and at 24hr post-activation. Light mi-
croscopy at x40 magnification. n=3
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Figure 3.9: Measurement of Cellular Impedance during Activation of Immortalised
Macrophages. The Roche xCELLigence system was used to measure changes in the
electrical impedance (CI value) across the surface of each well caused by macrophage
activation. The immortalised macrophage cell lines RAW264.7 and hELAM-GFP
were both plated at 10,000 cells per well. The cells were then activated with 10ng/mL
or 100ng/mL LPS. The CI value across each well was measured for 24hr post-
activation at 2min intervals for 1hr, then 15min intervals for 8hr and 30min intervals
for 15hr. Each individual data point represents the mean CI value at that time-point ±
1 S.D. of 6 experimental replicates (n=1).
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0 - 0.5) as the cells attached to the surface of the plate overnight.
As with BMDM, activation of the RAW264.7 cells with LPS caused an increase
in CI value. However, unlike the BMDMs where CI values returned to those of un-
activated cells, in this instance the elevated CI values were maintained throughout the
culture period. Maintenance of the high CI value in the activated RAW264.7 cells
(still increasing at 24hr post-activation) could indicate that the RAW264.7 cells do not
resolve the inflammatory response as quickly as do the BMDMs.
The RNA harvested from activated macrophages at multiple time-points post-act-
ivation with LPS was used to synthesise cDNA for RT-QPCR analysis. The panel of
marker genes used for assessing BMDM activation was also used for the RAW264.7
cells (Tnf-a, Cox2, Cxcl2, Il-6 and Saa3).
In the activated RAW264.7 cells, increased expression of Tnf-a was detectable at
30min post-activation, showing the rapid induction of this pro-inflammatory gene. Ex-
pression initially peaked at 1hr followed by a second peak at 6hr post-activation, and
then decreased for the remainder of the time-course (24hr post-activation. Fig 3.10a).
The expression of these genes in RAW264.7 cells followed similar dynamics to
that seen in BMDMs. Tnf-a and Cxcl2 showed a rapid response (1hr) and reached a
maximal response around 6-8 hr; maximum levels of Cox2 were seen between 6-8 hrs;
and maximal expression of Il6 and Saa3 were found in the latter half of the culture
period. Expression profiles differed from those of BMDMs in that elevated levels of
Tnf-a, Cxcl2 and Cox2 were maintained through the later stages of incubation.
These differences between the primary and immortalised cells suggest that while
the RAW264.7 cell line does activate successfully in response to LPS, and in a sim-
ilar manner to the BMDMs, it is not as effective at turning off the inflammation as
the primary macrophages are.This is evidenced by the much higher expression of the
pro-inflammatory genes Tnf-a, Cox2, Cxcl2 and Il-6 at 24hr post-activation in the
RAW264.7 cells at 24hr than in the BMDMs at 21hr post-activation.
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Figure 3.10: Expression of Known Macrophage Activation Marker Genes during
the Activation Response in Immortalised Macrophages, measured by RT-QPCR.
RAW264.7 cells were activated with 100ng/mL LPS. cDNA generated from RNA col-
lected at multiple time-points post-activation was used in RT-QPCR to measure the
expression of the activation associated genes a) Tnf-a, b) Cox2, c) Cxcl2, d) IL-6 and
e) Saa3. The variation in gene expression during macrophage activation is displayed
as mean fold-change (2-ddCt) relative to the unactivated (0hr) sample (n=2). The data
was normalised against the housekeeping gene HPRT.
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The hELAM-GFP fluorescent macrophage cell line In the RAW264.7 sub-clone
hELAM-GFP, green fluorescence protein (GFP) expression is regulated by NFkB sig-
nalling. NFkB is one of the major signalling molecules in the macrophage activa-
tion response and consequently the hELAM-GFP cells fluoresce green when activated
[245]. It was decided to characterise the response of the hELAM-GFP cells to LPS
since it was thought that the ability to accurately measure activation via FACS analysis
of GFP expression would be a useful method of assessing the effects of microRNA
knock-down and over-expression on macrophage activation in later experiments.
The hELAM-GFP cells were plated onto TC plastic, incubated overnight to allow
the cells to adhere, and were then activated with either 10ng/mL or 100ng/mL LPS.
Like the RAW264.7 cells, the unactivated hELAM-GFP cells displayed a mixture of
rounded and polar or ‘spiky’ morphologies (Fig 3.8). Once activated, the hELAM-
GFP cells appeared more morphologically responsive than the RAW264.7 cells, with a
larger proportion of cells developing projections and appearing visibly darker and gran-
ular. The cells were also observed under UV light to express GFP (Fig 3.11). GFP was
not observed in the unactivated RAW264.7 cells, unactivated hELAM-GFP cells nor
activated RAW264.7 cells. GFP was clearly expressed in the activated hELAM-GFP
cells, confirming that GFP is selectively expressed in hELAM-GFP cells in response
to stimulation with LPS.
The Roche xCELLigence machine was used to monitor the changes in the hELAM-
GFP population during the activation response. The hELAM-GFP cells were plated at
10,000 cells per well, incubated overnight to facilitate attachment, then activated with
either 10ng/mL or 100ng/mL LPS. The CI value was measured at regular intervals
for 24hr post-activation. It was expected that the activated hELAM-GFP cells would
generate a higher CI value than the unactivated cells. The data plots showed a slight
increase in CI values between plating and activation (from 0 - 0.6) as the cells attached
to the surface of the plate overnight. Activation of the cells with LPS increased the
CI value compared to that of unactivated cells. The CI values for the hELAM-GFP
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Figure 3.11: GFP Expression in Activated hELAM-GFP Cells. RAW264.7 and
hELAM-GFP cells were cultured with and without LPS. In the presence of LPS
the hELAM-GFP cells generate GFP and fluoresce green under UV. Photographs
were taken at 6hr post-activation with 100ng/mL LPS (x40 magnification). Top row:
RAW264.7 cells. Bottom row: hELAM-GFP cells. LHS: Unactivated (control). RHS:
Treated with 100ng/mL LPS. n=3
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cells were higher than those produced by the RAW264.7 cells (2.0 vs ~1.5; Fig 3.9 b
and a respectively), presumably since the hELAM-GFP cells displayed more dramatic
morphological changes in response to LPS.
The fluorescent reporting aspect of the hELAM-GFP cells enabled FACS analysis,
where GFP expression was a read-out of activation. To characterise the sensitivity of
the hELAM-GFP cells to LPS activation, and the corresponding expression of GFP
it was decided to carry out an activation titration with a serial dilution of LPS. The
hELAM-GFP cells were plated onto bacteriological plastic, incubated overnight to
facilitate attachment, then activated by treatment with a serial dilution of LPS concen-
trations (0 - 100ng/mL) and harvested for FACS analysis at 6hr post-activation. This
time-point was selected because, while GFP was known to be expressed at this time-
point (Fig 3.11), it did not appear to have reached maximal levels (cells still undergoing
morphological and gene expression changes at 6hr). Therefore we was expected to see
titration of GFP expression in response to varying LPS dilutions. Furthermore, we ex-
pected that in later experiments in which microRNA knock-down or over-expression
altered macrophage activation, GFP induction would also be altered and it would be
possible to detect a change in mean population fluorescence at this stage. RAW264.7
cells were cultured in a similar manner and harvested for FACS analysis as a non-
fluorescent control.
The induction of GFP in hELAM-GFP cells was shown to be dose-responsive (Fig
3.12), occurring as a clear, asynchronous population shift in mean GFP expression.
The low level of auto-fluorescence exhibited by the hELAM-GFP cells was not un-
expected as low level constitutive NFkB expression would result in low level consti-
tutive GFP expression. Upon activation, RAW264.7 cells showed no change in mean
population fluorescence while the hELAM-GFP cells showed a strong induction of
GFP, resulting in a mean population fluorescence of over 200 at LPS concentrations
>10ng/mL. At concentrations between 0.01 and 10ng/mL, GFP induction was dose-
responsive. At concentrations below 0.01ng/mL, no increase in GFP expression was
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Figure 3.12: FACS Analysis of GFP Expression in hELAM-GFP Cells in Response to
LPS. hELAM-GFP cells were stimulated with a serial dilution of LPS (0 - 100ng/mL)
and harvested for FACS analysis at 6hr post-activation. The mean population flu-
orescence was plotted against LPS concentration. GFP expression in the hELAM-
GFP cells showed a dramatic and dose-dependent increase at LPS concentrations >
0.01ng/mL. The mean fluorescence of RAW264.7 cells did not increase with LPS.




When this work was undertaken, the role of microRNAs as mediators of the macrophage
inflammatory response was just beginning to be investigated but already the immune-
associated microRNAs miR-155 and miR-146a had been reported to be induced during
macrophage activation (section 1.4.2.2). Therefore it was decided to use these microR-
NAs as marker genes for macrophage activation and to characterise a reproducible
microRNA expression profile against which future experiments could be compared.
RNA harvested during BMDMs activation with LPS was used to create microRNA-
Northern membranes for microRNA expression analysis. MicroRNA-Northern mem-
branes were generated using 15% TBE-Urea gels, as these high percentage gels re-
sult in clear separation of shorter RNA molecules (<200/300nt) after electrophoresis;
longer molecules of RNA do not penetrate the gel matrix. The microRNA fraction is re-
tained within the gel matrix and successfully transferred onto the microRNA-Northern
membrane. By this method, mature miRNA and pre-miRNAs are clearly distinguish-
able. Expression of miR-155 and miR-146a in the samples was assessed by hybridis-
ation of a complementary, denatured, locked nucleic acid (LNA) oligonucleotide that
had been radiolabelled with ATP [g-32P].
Figure 3.13 shows that the expression of both miR-146a and miR-155 was detected
in activated BMDMs. MiR-155 was not expressed in unactivated cells (0hr) but was
induced upon LPS activation; expression was clearly detected by 2hr post-activation
and levels increased steadily up to maximal levels around 12hr post-activation. MiR-
146a was found to be constitutively expressed in unactivated BMDMs. At around 7hr
post-activation elevated levels of miR-146 could be detected and these levels increased
slowly to a maximum at 24hr. These findings are in agreement with the literature
which describes both microRNAs to be up-regulated during macrophage activation, but
only miR-146a has been found to be constitutively expressed. This further confirmed
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Figure 3.13: MicroRNA-Northern Analysis of MicroRNA Expression in Activated
BMDMs. BMDMs were activated with 10ng/mL LPS and RNA was harvested at
multiple time-points post-activation. MicroRNA-Northern membranes were created
and hybridised with LNA probes complementary to mmu-miR-155, mmu-miR-146a
and mmu-let-7f . MiR-155 was not constitutively expressed but was strongly induced
by LPS stimulation. MiR-146a was constitutively expressed (0hr and control samples)
and its expression was increased following macrophage activation. Let-7f acted as a
loading control. n=3
that BMDMs had been successfully cultured and activated. It also demonstrated that
microRNA expression within this in vitro system for macrophage activation could be
successfully assessed by microRNA-Northern analysis.
Previously, only the short-term expression (up to 24hr) of miR-146a and miR-155
in response to LPS stimulation in macrophaghes had been assessed. MicroRNAs are
known to be stable molecules (in the absence of active degradation): therefore it was
decided to examine the expression of miR-146a and miR-155 over an extended time-
course to determine if they were actively degraded, suggesting a pro-inflammatory
role where active degradation of the microRNA is required for the proper resolution
of the inflammatory response, or if the microRNA expression remains steady, or even
increases, suggesting an anti-inflammatory role for the microRNA.
Primary and immortalised macrophages were cultured, activated with LPS and
RNA was harvested over an extended time-course (120hr post-activation). Expression
of miR-146a and miR-155 in these cell types (BMDMs, RAW264.7 and hELAM-GFP)
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was assessed by microRNA-Northern analysis (Fig 3.14). In BMDMs expression of
miR-155 reached maximal levels and these levels were maintained until 48hrs and then
declined to relatively low levels at 120hrs. MiR-146a was constitutively expressed in
primary macrophages and, following activation, expression levels increased steadily
throughout the culture period.
In the immortalised macrophages (RAW264.7 and hELAM-GFP cells) miR-155
expression increased throughout the culture period, suggesting that these cell types
were less effective at resolving inflammation than the primary cells. Furthermore,
the expression of miR-155 in the RAW264.7 cells was much weaker than observed
in the BMDM and hELAM-GFP cells possibly suggesting that the RAW264.7 cells
were not as strongly activated by LPS. MiR-146a was constitutively expressed in both
immortalised cell lines and following activation with LPS, expression levels steadily
increased throughout the extended culture period.
Many macrophage response genes are dose-dependent; therefore it was decided to
characterise the induction of miR-155 and miR-146a in response to a range of LPS
doses (0 - 100ng/mL serial dilution). There was also interest in determining if the im-
mortalised cell lines (particularly RAW264.7) displayed the same level of sensitivity
as the primary cells, because the induction of miR-155 and miR-146a had previously
appeared weaker in these cell types (Fig 3.14). MicroRNA-Northern analysis demon-
strated that the induction of miR-155 and miR-146a in all three cell types (BMDMs,
RAW264.7 and hELAM-GFP) was dose-dependent (Fig 3.15). The BMDMs displayed
a stronger induction of both microRNAs at all doses of LPS compared to the immor-
talised cell lines, supporting the previous finding (Fig 3.14) that the immortalised cell
lines were not as strongly activated as the primary cells, rather than the hypothesis that
the immortalised macrophages were less sensitive to LPS. After all, the hELAM-GFP
cells demonstrated a faint induction of miR-155 at LPS doses ranging from 0.1ng/mL
down to 10-4ng/mL. The expression of miR-155 in the RAW264.7 cells was not de-
tectable at LPS doses <1.0ng/mL. It is possible this was due to the induction of the re-
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Figure 3.14: MicroRNA-Northern Analysis of MicroRNA Expression in Activated
Primary and Immortalised Macrophages over an Extended Time-course. Primary
(BMDM) and immortalised (RAW264.7 and hELAM-GFP) macrophages were acti-
vated with 10ng/mL or 100ng/mL LPS. RNA was harvested at regular intervals over
the next 120hrs. Membranes were hybridised with LNA probes complementary to a)
mmu-miR-155 and b) mmu-miR-146a. n=1
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sponse not being as strong as in the primary cells and so miR-155 could not be detected
by microRNA-Northern analysis at lower LPS doses although the cells are actually ac-
tivated. In BMDMs miR-155 expression was induced by LPS doses ≥0.1ng/mL.
Similarly, the primary cells showed a stronger induction of miR-146a than the
immortalised cell lines. However, all three cell types demonstrated constitutive ex-
pression of miR-146a that was dose-responsive to LPS stimualtion, showing an in-
creased expression at even very low doses (<0.01ng/mL LPS) (Fig3.15). It is possible
that this sensitivity is related to the function of miR-146a as an anti-inflammatory
molecule, preventing macrophage hyper-sensitivity to stimuli by increased expression
of miR-146a at low doses of LPS, thereby helping to maintain the unactivated cell
state. By comparison, a stonger dose of LPS (≥0.1ng/mL) was required to trigger a
pro-inflammatory response, observed here as the induction of miR-155.
3.3 Discussion
Characterisation of bone marrow derived macrophage differentia-
tion
The in vitro bone marrow differentiation culture used here is known to be a robust
method for the generation of bone marrow derived macrophages. Culturing the bone
marrow on bacteriological plastic in the presence of CSF-1 generated an adherent
population of mature macrophages (Fig 3.1). RT-QPCR analysis of the macrophage-
associated genes Runx1 and Csf-1r demonstrated the expected expression profiles. Un-
expectedly, the RT-QPCR data for Pu.1 showed higher epxression in the BM than the
BMDMs. However, all of the other marker genes (c-myb, Bclx and uPA) were ex-
pressed in the expected manner. Therefore, based on the cellular morphology, the RT-
QPCR data and the cells’ subsequent ability to be activated by LPS, it was concluded
that macrophages had been successfully differentiated from murine bone marrow.
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Figure 3.15: MicroRNA-Northern Analysis of MicroRNA Expression in Primary and
Immortalised Macrophages across a Serial Dilution of LPS. Primary (BMDM) and im-
mortalised (RAW264.7 and hELAM-GFP) macrophages were activated with a serial
dilution of LPS (0 - 100ng/mL). RNA was harvested at 24hr post-activation. Mem-
branes were hybridised with LNA probes complementary to a) mmu-miR-155 and
b) mmu-miR-146a. The induction of these two microRNAs was found to be dose-
dependent. n=2
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Characterisation of the activation response in primary macrophages
and immortalised macrophage cell lines
Following the successful differentiation of macrophages from bone marrow, the BMDMs
were then tested for LPS responsiveness and were found to be successfully activated
based on morphological observations and assessment of mRNA and miRNA marker
genes. The activation response of two immortalised macrophage cell lines (RAW264.7
and hELAM-GFP) was also characterised for future use in microRNA functional anal-
ysis. The distinct morphological changes observed in the population following acti-
vation (Fig 3.5) did not appear in a synchronous manner. Instead the proportion of
cells exhibiting an activated morphology increased over time. This delay in producing
a uniform morphological response is likely due to cells being at different stages of the
cell cycle at the time of activation. Although macrophage activation causes cell cy-
cle arrest, cells which have already entered mitosis complete their imminent division
before adopting an activated macrophage morphology.
While CI value can be affected by cell number, cell morphology and/or adhesion
strength, the changes in CI values observed during macrophage activation (Fig 3.6)
were most likely the result of activation induced changes to cellular adhesion. Firstly,
macrophages enter cell cycle arrest during activation and so cell division is halted.
Secondly, activation causes the cells to spread; this produces more contact points with
the surface of the plate, thereby increasing the impedance and subsequent CI value.
Furthermore, the changes in CI value reflected the morphological changes observed
under light microscopy: the most dramatic responses were seen in BMDMs, followed
by hELAM-GFP and RAW264.7 cells. The differences between the primary and im-
mortalised cell lines in both mRNA marker gene expression and miRNA expression
were also supported by the CI data; the immortalised cells appear to respond to LPS
to a lesser degree than the primary cells, and do not damp down the inflammatory re-
sponse within 24hr post-activation. Together this data demonstrates that measuring the
CI value using the xCELLigence system provides an excellent system for modelling
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cellular changes associated with macrophage activation and can be used to assess cel-
lular changes instigated by microRNA knock-down.
The work here extended the characterisation of mmu-miR-146a and mmu-miR-
155 expression within these systems (section 1.4.2.2). It is clear that mmu-miR-155
expression is induced by activation, while mmu-miR-146a is constitutively expressed
in macrophages and its expression is elevated in response to LPS. It is clear that the
induction of both these miRNAs is dose-dependent and that both are long-lived. In-
terestingly, the level of expression of these two microRNAs in the RAW264.7 and
hELAM-GFP cells was not as strong as observed in the BMDMs (Fig 3.14 and 3.15).
This also fits with morphological and xCELLigence data that suggests that the immor-
talised cells produce a weaker activation response.
Overall, the data indicated by the experiments undertaken here demonstrated that
a system for macrophage activation was successfully established and generated repro-
ducible results in BMDMs, RAW264.7 and hELAM-GFP cells. It was decided that, for
ongoing experimentation, in vitro LPS activation of BMDMs would be used to gener-
ate samples to characterise the microRNA response using next generation sequencing.
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Chapter 4
Characterisation of the microRNA
response during macrophage
activation by next generation
sequencing, and functional analysis of
selected microRNAs
4.1 Introduction
The macrophage transcriptome is known to undergo dynamic changes upon activa-
tion (section 1.2.3). At the time this work was undertaken the expression of some
macrophage-associated microRNAs had already been characterised (section 1.4.2.2).
However, at that time, the microRNA profile of the activated macrophage had not
been assessed by next generation sequencing (NGS), but it was expected that, like
the mRNA-transcriptome, the microRNA-transcriptome would also undergo dynamic
changes.
When this work was undertaken, the application of NGS techniques to activated
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macrophages was expected to greatly expand the existing knowledge of the total mi-
croRNA expression profile during macrophage activation. NGS technologies could
also facilitate the potential discovery of novel microRNAs, although the likelihood of
such discovery in well studied systems such as the mouse is increasingly small. It
was decided to use the in vitro systems established here (chapter 3) to generate acti-
vated BMDM samples for use in the creation of NGS microRNA libraries that would
be sequenced by the illumina Genome Analyzer system. From this profiling data, mi-
croRNAs of interest would be selected for further study, and the established in vitro
systems for immortalised macrophages (RAW264.7 and hELAM-GFP cells) would be
utilised for functional analysis of the selected microRNAs. In this way it was hoped
to expand the knowledge of microRNA expression in activated macrophages and to
perhaps determine the function of selected microRNAs that were previously uncharac-
terised in macrophage activation.
4.1.1 Aims
The aim of the studies described in this chapter was to characterise the global mi-
croRNA population expressed during macrophage activation using NGS technologies.
The expression of a small number of differentially expressed microRNAs would then
be confirmed by microRNA-Northern analysis, and the effect of these microRNAs on
macrophage activation would be assessed using immortalised macrophage cell lines
(hELAM-GFP and RAW264.7).
4.2 Results
4.2.1 Production of RNA samples for NGS
Generation of RNA samples To characterise the changing microRNA population
during macrophage activation using NGS, it was necessary to generate good quality
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RNA samples. To achieve this the BMDM activation system established within the
laboratory (chapters 2 and 3) was utilised. BMDMs were generated from a pool of
mice, plated in triplicate, and activated with LPS. RNA was then harvested at multiple
time-points post-activation. Morphological assessment of the cultures by bright-field
microscopy demonstrated that the BMDMs had been successfully generated and acti-
vated. The RNA extracted from the triplicate samples was assessed by Agilent Bio-
analyser RNA 6000 nano assay and Nanodrop ND 100 spectrophotometer analysis and
confirmed to be of good quality and quantity (Fig 4.1).
Assessment of RNA samples The activation of the BMDMs used to generate RNA
for NGS was confirmed by mRNA and miRNA analysis (Fig 4.1, Fig 4.2 and Fig 4.3).
RNA from the triplicate samples at each time-point was pooled. Agilent Bioanalyser
RNA 6000 nano assay and Nanodrop ND 100 spectrophotometer analysis was used
to confirmed the RNA pools were of good quality and quantity. The RNA was then
used to generate microRNA-Northern membranes for the assessment of microRNA
expression, and cDNA for RT-QPCR analysis of marker gene expression. Expression
of the activation marker genes (Tnf-a, Cox2, Cxcl2, Il-6 and Saa3, Fig 4.2) and the
known macrophage-associated microRNAs (miR-146a and miR-155, Fig 4.3) were
confirmed to be within the normal laboratory parameters. Taken together, these results
showed that the samples had been successfully activated and therefore could be used
with confidence to produce libraries for NGS.
4.2.2 Profiling of microRNAs in activated BMDMs by illumina next
generation sequencing
illumina small RNA library preparation The illumina next generation sequencing
platform was selected for characterising microRNA expression during macrophage ac-
tivation because it supported indexed adaptors. Indexed adaptors, or barcodes, contain
distinct nucleotide motifs that enable multiple samples to be sequenced together, as the
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Figure 4.1: Overview of the Generation of RNA Samples from Activated BMDMs
for Use in NGS Library Production. Bone marrow was pooled from six male c57/bl6
mice, aged 10-12 weeks. The bone marrow was cultivated for six days in the presence
of rhCSF-1, then the cells were harvested, counted and plated in triplicate on circu-
lar 10cm tissue culture dishes in 10mL of complete media. The cells were incubated
overnight to facilitate attachment to the surface of the plate. The cells were then ac-
tivated with 100ng/mL LPS, and RNA was harvested at 0, 0.5, 1, 2, 6, 12 and 24hr
post-activation. The RNA from the triplicates was harvested and stored separately. A
pool of RNA for analysis was created using a proportion of RNA from each tripli-
cate. The quality of the RNA pool was assessed by Nanodrop ND 100 spectropho-
tometer measurements and Agilent Bioanalyser RNA 6000 nano assay analysis, and
found to be of good quality. This pooled RNA was used to make microRNA-Northern
membranes and cDNA for RT-QPCR analysis to confirm successful activation of the
samples before being used for NGS library generation.
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Figure 4.2: Expression of Activation Markers during the Activation of BMDMs with
LPS, measured by RT-QPCR. Murine BMDMs were activated with 100ng/mL LPS
and RNA was harvested at 0, 0.5, 1, 2, 6, 12 and 24hr post-activation. cDNA gen-
erated from harvested RNA was used in RT-QPCR to measure the expression of the
macrophage activation associated genes a) Tnf-a, b) Cox2, c) Cxcl2, d) Il-6 and e)
Saa3. Expression was calculated as mean fold-change (2-ddCt) ±1 S.D. from 3 ex-
perimental replicates relative to unactivated (0hr) samples. The data was normalised
against the housekeeping gene HPRT. n=1. The data shows successful induction of
the macrophage activation marker genes in a manner similar to that observed when
establishing the activation procedure (chapter 3). Therefore it was concluded that the
samples had been successfully activated and represented an appropriate starting mate-
rial for the production of NGS profiling libraries.
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Figure 4.3: MicroRNA-Northern Analysis of Known MicroRNA Expression in Acti-
vated BMDMs. Murine BMDMs were activated with 100ng/mL LPS and RNA was
harvested at 0, 0.5, 1, 2, 4, 6, 12 and 24hr post-activation. MicroRNA-Northern mem-
branes were created and used to confirm expression of known LPS-induced microR-
NAs (miR-146a and miR-155). The microRNA-Northern membranes were hybridised
with LNA probes complementary to mmu-miR-155, mmu-miR-146a and mmu-let-7f.
The microRNAs were induced in the manner expected, confirming successful acti-
vation of the BMDM samples: mmu-miR-155 was not constitutively expressed but
was strongly induced by LPS stimulation, while mmu-miR-146a was constitutively
expressed (0hr) and its expression was increased following macrophage activation.
Mmu-let-7f acted as a loading control. n=1, material for NGS profiling libraries.
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barcodes can be used to identify the library from which the samples were generated.
Furthermore, sequencing multiple experimental samples together would be expected
to reduce run-related bias.
The quality-checked RNA pools from six time-points (0, 1, 2, 6, 12 and 24hr post-
activation) were used to create duplicate small RNA libraries for sequencing. The li-
braries were prepared following the manufacturer’s instructions (illumina Small RNA
sequencing kit, sample preparation guide v1.5 provided by the manufacturer). Briefly,
the 5’ indexed and regular 3’ adaptors were ligated to the total RNA; the product was
then reverse-transcribed and amplified by PCR to generate the cDNA library (Fig 4.4).
The libraries were then gel-purified by size to enrich for the desired adaptor-ligated
microRNA sequences (~100bp, Fig 4.4, gel-purification step). The concentration and
quality of the prepared cDNA libraries were assessed by Nanodrop ND 100 spec-
trophotometer measurements and Agilent Bioanalyser DNA 1000 assay respectively.
The Agilent Bioanalyser DNA 1000 nano assay analysis demonstrated that the gel-
purification method of size selection had been successful and that the library prepa-
rations were of the expected size. The 12 libraries were then delivered to an external
service provider (Ark Genomics) to carry out the illumina next generation sequencing.
NGS data analysis The sequencing service provider (Ark Genomics) sequenced the
libraries and performed the initial analysis on the data. Genuine sequencing reads
were identified by the presence of the adaptor sequences. Two of the three lanes on
the illumina sequencing chip (containing 8 of the 12 small RNA libraries) returned a
good yield of sequencing reads (6,132,646 and 5,945,078 reads, see appendix A.2).
However the third lane (containing the remaining four small RNA libraries) returned
a much lower yield of sequencing reads (599,194 reads). Ark Genomics were unable
to identify the reason for this anomaly. The four small RNA libraries in that lane had
passed the QA performed by both our laboratory and Ark Genomics. Furthermore, the
control lane and the other samples on the sequencing chip (both from our laboratory
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and other laboratories) returned the expected yield of sequencing reads. There was not
enough sample left to re-sequence the four small RNA libraries and to do so would
have introduced run-bias into the data set when comparing the data against the other 8
samples. Ark Genomics advised that the data was still suitable for use, as normalising
the data would compensate for the difference in yield between the samples.
The data was trimmed to remove the standard portions of the adaptor sequences,
then sorted by 5’ nucleotide indexed adaptor sequences into the specific libraries. The
generated sequences were then compared against the mouse genome (BLAST analysis)
in order to annotate them. Small RNA sequences that were removed from the analysis
at this juncture included primer-dimers, sequences which did not map to the murine
genome and sequences which did not form hairpin structures (appendix A.2). This
removed approximately 75% of the sequence reads from each lane.
The data was returned from Ark Genomics at this stage and contained the read
counts of mature microRNAs, microRNA hairpins, microRNA homologs (isomiRs),
and sequences which mapped to the mouse genome which were capable of forming
hairpin structures with their flanking RNA sequences. I then assessed the mapped reads
and removed any sequences which did not map to a mature murine miRNA. This in-
cluded the removal of miRNA hairpin fragments, ‘dead’ microRNAs (www.mirbase.org
‘download’ section, ‘deadlist’), tRNA fragments, 5s RNA fragments, predicted non-
coding RNA fragments, and RNA fragments that mapped to the mouse genome but
were not identified within any gene (Ensembl analysis, www.ensembl.org). In total
these categories represented ~10% of the mapped reads in each lane, and the different
categories represented a similar percentage of total reads in each lane (appendix A.2).
The fact that all three lanes showed similar proportions of unmapped reads (~75%)
and non-mature murine miRNA sequences (~10%), suggested that the low yield in the
third lane was a matter of read quantity and had not introduced sequencing bias into
the data set.
The remaining mature murine microRNA sequences across the 12 libraries were
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then normalised to enable meaningful comparisons between the libraries despite the
differing yields. The sequencing data was processed using the software package ‘R’
(www.r-project.org) [207]. The data in each library was ordered by microRNA name,
and multiple entries for a mature microRNA were ‘collapsed’ together, generating a
single count number for each mature microRNA. Next the data sets were combined
into a single file containing all 12 libraries (0, 1, 2, 6, 12 and 24hr post-activation, in
duplicate). To enable direct comparison between the libraries, the read counts were
normalised using the normalisation script ‘EdgeR’ [212]. This generated a normalisa-
tion factor for each library; once applied to the library data it was possible to directly
compare microRNA expression across the libraries. The mean expression of each mi-
croRNA at each time-point (0, 1, 2, 6, 12 and 24hr post-activation) was then calculated
from the duplicate libraries. This provided a final data set containing the relative ex-
pression of each microRNA across the six time-points (appendix A.1).
In total 437 distinct microRNAs were identified. Although these individual mi-
croRNAs had been identified across the six time-points, this full complement of mi-
croRNAs was not expressed at every time-point (Table 4.1) as individual microR-
NAs are turned on and off during the time-course. This showed that the microRNA
transcriptome, like the RNA transcriptome, undergoes dynamic changes during the
macrophage activation response.
Table 4.1: Number of Identified MicroRNAs in NGS Profiling that are Expressed in
BMDMs at Each Time-point Post-activation. Although 437 distinct microRNAs were
identified across all 6 time-points, this full complement of microRNAs was not ex-
pressed at every time-point. Instead each time-point expressed 300-400 individual
microRNAs.
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Table 4.2: The 20 Most Highly Expressed MicroRNA Sequences in Unactivated
BMDMs, and the Expression of these MicroRNAs during Macrophage Activation. The
data is displayed as both total read counts and corresponding fold-change of expression
at 0, 1, 2, 6, 12 and 24hr post-activation with 100ng/mL LPS. The processed data (col-
lapsed, normalised, mean of duplicates) from the NGS libraries is presented as read
counts on the left hand side of the table. The right hand side of the table contains the
fold-change expression calculated from the data counts relative to 0hr. Corresponding
data for all of the microRNAs detected in the NGS libraries is contained in appendix
A.1.
To more easily identify and compare microRNA expression trends during macrophage
activation, expression at each time-point was calculated as fold-change against the un-
activated sample (0hr) (sample of data in Table 4.2, full data in appendix A.1). To
ensure consistency when assessing microRNA expression patterns across the data, the
following fold-change parameters were used to define the identified microRNAs as up-
regulated, down-regulated or unchanged during macrophage activation: up-regulated
= >2.0; down-regulated = <0.5 and unchanged = 0.5< q <2.0 (Table 4.3).
Selection of microRNAs for further analysis It was not possible or practical,
within the scope of this project, to assess all identified 437 microRNAs in the labora-
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Table 4.3: Summary of Global MicroRNA Population Expression Dynamics during
Macrophage Activation. The fold-change data for the 437 microRNAs detected in
the NGS libraries (appendix A.1) were categorised using the following cut-offs: up-
regulated = >2.0; down-regulated = <0.5 and unchanged = 0.5<q<2.0. These param-
eters were used to generate a list of differentially regulated microRNAs from which a
short-list was selected for further analysis.
tory. Therefore a short-list of microRNAs was selected for further analysis. The short-
listed microRNAs were not selected on the basis of the NGS expression data alone. As
the expression of the microRNAs was to be confirmed by microRNA-Northern anal-
ysis and quantitation, the selected microRNAs had to be expressed at a level that was
expected to be detectable that method. Therefore microRNAs with read counts con-
sistently fewer than 500 reads were dismissed. MicroRNAs that displayed a dynamic
expression pattern during macrophage activation were considered more likely to be
playing an active role in the inflammatory response and were preferentially included
in the short-list. MicroRNAs that had been reported, but not fully characterised in the
literature to display dynamic expression during macrophage activation were preferen-
tially included in the short-list for two reasons. Firstly, the fact that dynamic expression
of the microRNA had already been reported to be associated with macrophage activa-
tion increased our confidence that the selected microRNA played an active role. Sec-
ondly, because the role of the microRNA had not yet been characterised there was still
the potential to uncover its mechanism of action. The macrophage-associated micro-
RNAs miR-146a and miR-155 were included on the short-list because their expression
within the system is well-characterised and, from the literature, could be expected to
generate positive results during further analysis.
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The final short-list consisted of 12 microRNAs; 6 up-regulated, 3 down-regulated
and 3 unchanged in the NGS profiling data (Table 4.4). The up-regulated microRNAs
were mmu-miRs -142-3p, -146a, -155, -15b, -191 and -322-5p. The down-regulated
microRNAs were mmu-miRs -7a, -16 and -30b. The unchanged microRNAs were
mmu-miR -21, -27b and -378.
Table 4.4: Expression of the 12 MicroRNA Sequences Selected from the NGS Pro-
filing Data for Further Study. The microRNAs mmu-miR-142-3p, mmu-miR-146a,
mmu-miR-155, mmu-miR-15b, mmu-miR-16, mmu-miR-191, mmu-miR-21, mmu-
miR-27b, mmu-miR-30b, mmu-miR-322, mmu-miR-378 and mmu-miR-7a were se-
lected for further study. The expression of these microRNAs is displayed as both total
read counts and the corresponding fold-change of expression at 0, 1, 2, 6, 12 and 24hr
post-activation with 100ng/mL LPS. The processed data (collapsed, normalised, mean
of duplicates) from the NGS libraries is presented as read counts on the left hand side
of the table. The right hand side of the table contains the fold-change expression cal-
culated from the data counts relative to 0hr.
The expression of the short-listed microRNAs was assessed by microRNA-Northern
analysis to determine the accuracy of the NGS data. MicroRNA-Northern membranes
were created using RNA harvested from BMDM activation experiments and hybridised
with anti-miR LNA sequences complementary to the selected microRNAs. The micro-
RNA-Northern results were quantified by phospho imaging analysis and used to cal-
culate the expression fold-change of the 12 short-listed microRNAs across the time-
points. These results were then compared against the NGS data.
This assessment showed discrepancies between the sequencing results and the
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microRNA-Northern quantitation for some of the short-listed microRNAs (Fig 4.5,
Tables 4.5 and 4.6). With the exception of mmu-miR-322-5p, the expression of the up-
regulated microRNAs was confirmed by microRNA-Northern analysis. However, there
were some large differences in the fold-induction observed between the two methods
(Table 4.5). None of the expression patterns for the down-regulated or unchanged mi-
croRNAs were confirmed by microRNA-Northern quantitation. Of the microRNAs
classified as down-regulated in the profiling data, mmu-miRs -7a and -16 were found
to be up-regulated, while the expression of mmu-miR-30b appeared unchanged. All
three of the unchanged microRNAs in the profiling data were found to be up-regulated
by microRNA-Northern analysis (Fig 4.5). For mmu-miR-21 this result was less sur-
prising, as miR-21 has been shown to be induced by macrophage activation [232].
These discrepancies between the NGS profiling data and the microRNA-Northern
results indicated that the NGS profiling data did not accurately reflect the microRNA
transcriptome during macrophage activation.
Data discrepancies and PCA A possible explanation for the discrepancies observed
between the NGS profiling data and the microRNA-Northern results was the presence
of sequencing bias in the libraries. Upon request, the sequencing service provider (Ark
Genomics) carried out a principal component analysis (PCA) of the sequencing data
(Fig 4.6) to assess this possibility.
A PCA is a statistical procedure that identifies the vectors of most variance (the
principal components) of the data. The data can then be measured in terms of its
principal components rather than on a normal x-y axis. The number of principal com-
ponents is less than or equal to the number of original variables. If there is no bias
within the data set, the data points would display random distribution; inversely a non-
random distribution of data-points would indicate the presence of bias within the data
set. Because of the similarities of the starting material in these libraries (same bio-
logical base material and dose of LPS), the main variables for this data were time and
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activation. Therefore it would be expected that the data would cluster by time-point
(duplicate libraries), or possibly by activation status (activated vs. unactivated).
Instead, the PCA analysis showed that libraries demonstrated indexed adaptor bias
rather than a biological function bias (Fig 4.6). In Figure 4.6 each data point repre-
sents a single library, while points of the same colour contain the same indexed 5’
adaptor. The data points are broadly clustered by indexed adaptor, demonstrating that
the indexed 5’ adaptors introduced sequencing bias. It transpires that the design of the
indexed adaptors supplied by the service provider was faulty, and as a direct result, the
data derived using this approach was not an accurate representation of the microRNA
distribution in the individual libraries/RNA samples. The service provider has now
discontinued the use of these adaptors.
NGS Summary Although RNA from activated macrophages was used to success-
fully generate small RNA libraries for sequencing, the sequencing bias introduced to
the data set by the indexed adaptors rendered in silico analysis inappropriate for this
data set. However as the microRNA-Northern analyses demonstrated, a number of
the selected miRNAs did show dynamic expression changes during the activation pro-
cess, therefore it was decided to continue with downstream functional analysis of these
microRNAs.
4.2.3 Functional analysis
The objective of the work described in this section was to use gain-of-function and loss-
of-function approaches to assess the effects of manipulating levels of specific miRNAs
on macrophage activation. In order to manipulate cellular levels of miRNA, we elected
to transfect cells with small chemically modified RNA molecules that functioned ei-
ther as Anti-miRs (Locked Nucleic Acid [LNA] oligonucleotides complementary to
specific miRNA sequences) or Pre-miRs (small dsRNA molecules, similar to siRNAs,
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Figure 4.4: Overview of NGS Library Production Method using the illumina Small
RNA Sequencing Kit. 5’ indexed and 3’ regular adaptors were ligated to total RNA,
reverse-transcribed and amplified by PCR to generate cDNA libraries. The product
then underwent size selection via gel-purification. The library preparation was loaded
onto 6% TBE gels and electrophorised to separate the sample by size. The portion of
the gel containing the small RNA library preparation (~100bp, corresponding to the
total length of 5’ and 3’ adaptor ligated microRNAs) was cut out, and the sample ex-
tracted from the gel. Correct size selection was confirmed visually by electrophoresis
on 6% TBE gels and by Agilent Bioanalyser DNA 100 assay. The purified library
samples were used for illumina next generation sequencing.
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Figure 4.5: MicroRNA-Northern Analysis of Selected MicroRNA Expression from
NGS Profiling Data of Activated BMDMs. BMDMs were activated with 100ng/mL
LPS and RNA was harvested at multiple time-points post-activation. MicroRNA-
Northern membranes were created and hybridised with LNA probes complementary
to mmu-miR-142-3p, mmu-miR-15b, gga-miR-16c, mmu-miR-191, mmu-miR-21,
mmu-miR-27b, mmu-miR-30b, mmu-miR-322-5p, mmu-miR-378 and mmu-miR-7a.
n=1. The NGS profiling data indicated that mmu-miRs -142-3p, -146a, -15b, -155, -
191 and -322-5p were up-regulated; mmu-miRs -7a, -16 and -30b were down-regulated
and mmu-miR -21, -27b and -378 were unchanged during macrophage activation.
Many of these expression profiles were not confirmed by microRNA-Northern anal-
ysis. Expression of mmu-miR-146a and mmu-miR-155 is shown in Figure 4.3.
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Table 4.5: Comparison of Selected MicroRNA Expression between NGS Profiling
Data and MicroRNA-Northern Quantitation. The changes in microRNA expression
at multiple time-points post-activation are displayed as fold-change values relative to
the unactivated control (0hr) in the NGS profiling data (black) and the microRNA-
Northern quantitation (blue). Time-points where the fold-changes in miRNA expres-
sion that met the cut-offs for up- and down-regulation (>2.0 and <0.5 respectively)
are highlighted. The NGS profiling data indicated that mmu-miRs -142-3p, -146a,
-15b, -155, -191 and -322-5p were up-regulated; mmu-miRs -7a, -16 and -30b were
down-regulated and mmu-miR -21, -27b and -378 were unchanged during macrophage
activation. The microRNA-Northern quantitation did not concur with several of the ex-
pression trends identified by the NGS profiling data. MicroRNA-Northern expression
of mmu-miR-146a and mmu-miR-155 is shown in Figure 4.3; all other microRNAs
are displayed in Figure 4.5.
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Table 4.6: Summary of Selected MicroRNA Expression in NGS Profiling Data,
MicroRNA-Northern Analysis and the Literature. The data in Table 4.5 is summarised
here and compared against the reported literature for the role of these microRNAs dur-
ing macrophage activation. The microRNA expression patterns in the NGS profiling
data and the microRNA-Northern analysis did not always match up. Up-regulated ex-
pression patterns in the profiling data were confirmed more often than down-regulated
or unchanged expression patterns. The up-regulated expression patterns were also
more likely to have been reported in the literature (at the time of this study).
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Figure 4.6: Principal Component Analysis of the illumina Small RNA Profiling Data.
Each point represents a single library; points of the same colour represent libraries with
the same indexed 5’ adaptor. The libraries are loosely clustered by indexed 5’ adaptor
sequence rather than biological similarity, indicating that the indexed adaptors caused
sequencing bias within the profiling data (Profiling data and PCA analysis provided by
Ark Genomics).
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encoding specific miRNA sequences that mimic the function of mature miRNAs).
Anti-miRs hybridise strongly to specific target miRNAs and effectively reduce miRNA
levels by degradation or sequestration. Pre-miRs are processed by the cellular machin-
ery to generate mature miRNA sequences and thereby increase endogenous levels of
specific miRNAs.
Prior to assessing the effects on macrophage activation, a series of experiments
were performed to establish that a) Anti-miR suppression of miRNA levels was specific
to targeted miRNAs, b) Pre-miRs generated miRNA levels within the physiological
range, and c) the transfection procedures alone did not result in macrophage activation.
4.2.3.1 Optimisation of procedures and reagents
a) RAW264.7 cells were transfected with 1mg Anti-miR against either mmu-miR-142-
3p, mmu-miR-146a, mmu-miR-155, mmu-miR-15b or mmu-miR-30b. This quantity
of Anti-miR had previously been shown to be effective in suppressing levels of the
majority of miRNAs [L.Bailey-personal communication]. Cells were incubated with
transfection reagents for 18hr and then activated by treatment with LPS. At 6hr post-
activation, cells were harvested and RNA extracted. The RNA was used to generate a
series of microRNA-Northern analyses and the resulting membranes were individually
hybridised with a LNA probe complementary to one of the targeted miRNAs. The
images generated from this series of microRNA-Northern analyses are shown in Figure
4.7.
RNA from cells cultured without LPS was included for analysis which showed that,
of these miRNAs, only mmu-miR-146a and mmu-miR-30b were expressed in unacti-
vated cells, whereas all five of these miRNAs were expressed by 6hr post-activation.
It was clear from this analysis that Anti-miR suppression of miRNA levels was both
highly specific and highly effective. Transfection of individual LNAs resulted in the
complete suppression of the targeted miRNAs. It is also very interesting to note that
knock-down of both mmu-miR-142-3p and mmu-miR-146a resulted in a marked re-
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Figure 4.7: MicroRNA-Northern Confirmation of MicroRNA Knock-down in Trans-
fected RAW264.7 Macrophages. Selected microRNAs were knocked-down in
RAW264.7 cells. RAW264.7 cells were plated at 0.5 x106cells per well in a 6-well
TC plate and transfected with 1mg of complementary LNAs (Anti-miRs) against either
mmu-miR-142-3p, mmu-miR-146a, mmu-miR-155, mmu-miR-15b or mmu-miR-30b
for 18hr. The cells were then activated with 10ng/mL LPS and harvested for RNA
at 6hr post-activation. MicroRNA-Northern membranes were created and hybridised
with LNA probes complementary to mmu-miRs -142-3p, -146a, -155, -15b and -30b.
Knock-down of the microRNA was deemed successful if it could not be detected in the
sample. Anti-mmu-miR-203, an ESC associated microRNA, was included as a control
transfection and does not affect the expression of the selected microRNAs. n=1
duction in the levels of mmu-miR-155, and that knock-down of mmu-miR-155 led to
an increase in the levels of mmu-miR-30b.
b) To assess the effectiveness of elevating miRNA levels, RAW264.7 cells were
transfected with Pre-miRs for either mmu-miR-146a or mmu-miR-155. A series of
five dilutions was prepared, generating concentrations ranging from 120nmol to 1.875
nmol. Cells were transfected with different concentrations of Pre-miR for 18hr, the
cells were harvested and RNA extracted. RNA was used for two microRNA-Northern
analyses and the resulting membranes were hybridised with either a LNA probe com-
plementary to mmu-miR-146a or to mmu-miR-155. The images from these microRNA-
Northern analyses are shown in Figure 4.8. The endogenous levels of mmu-miR-146a
and mmu-miR-155 in unactivated and activated cells are also shown (untreated and
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LPS-only samples respectively).
Figure 4.8: MicroRNA-Northern Analysis of Pre-miR Dilution Series during Trans-
fection Optimisation. Transfection of RAW264.7 cells with a range of precursor (pre-
miR) doses confirmed that the transfection protocol was successful and that miRNA
synthesis occurred in a dose-dependent manner. Precursors for mmu-miR-146a and
mmu-miR-155 were transfected in a 2-fold serial dilution from a starting concentra-
tion of 120nmol. Membranes were hybridised with LNA probes complementary to
mmu-miR-146a and mmu-miR-155. n=1
It is clear that the level of miRNA produced was dose-dependent on the Pre-miR
concentration, and that the tested range of Pre-miR concentrations encompassed the
normal physiological levels of these specific miRNAs. While the lowest concentration
of Pre-miR tested did not generate levels above those found in non-transfected cells,
there was a clear increase in both mmu-miR-146a and mmu-miR-155 levels with as
little as 7.5nmol of the particular Pre-miR.
c) A series of transfections were carried out to ensure that cells were not activated in
a non-specific manner by either the transfection reagents, Anti-miRs or Pre-miRs. To
ensure that any effects were a result of manipulating levels of specific miRNAs, rather
than a result of transfecting random nucleic acid, reagents for a miRNA not normally
expressed in macrophages were selected, and cells transfected with these reagents were
analysed. To this end mmu-miR-203 was selected as a transfection control becuase the
expression of this miRNA is reported to be restricted to embryonic stem (ES) cells.
To confirm that mmu-miR-203 was not expressed in macrophages, miRNA-Northern
anlaysis of activated cells was performed.
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hELAM-GFP cells were cultured and either activated with different concentrations
of LPS, or transfected with a range of concentrations of a Pre-miR for mmu-miR-
203. RNA was harvested from these cells and used in microRNA-Northern analysis.
MicroRNA-Northern membranes were hybridised with a LNA probe complementary
to mmu-miR-203; the resulting images are shown in Figure 4.9.
Figure 4.9: Assessment of Mmu-miR-203 Expression in hELAM-GFP Cells. a)
MicroRNA-Northern analysis of mmu-miR-203 expression activated hELAM-GFP
cells. MicroRNA-Northern membranes were created using RNA from a LPS serial di-
lution series in hELAM-GFP cells. The membranes were hybridised with LNA probes
complementary to mmu-miR-203 and mmu-let-7f. There was no detection of miR-203
expression at any of the nine LPS doses used, confirming that miR-203 is not expressed
in activated or unactivated macrophages. Mmu-let-7f was used as a loading control.
n=1 b) Transfection of hELAM-GFP cells with a range of pre-mmu-miR-203 doses
confirmed that pre-miR-203 could be processed by macrophages into mature miR-203.
hELAM-GFP cells were transfected for 18hr with a 1 in 2 serial dilution of pre-mmu-
miR-203 from a starting concentration of 120nmol. MicroRNA-Northern membranes
were hybridised with LNA probes complementary to mmu-miR-203 and miR-203 ex-
pression was successfully detected in a dose-dependent manner. Unprocessed pre-
mmu-miR-203 from the purchased stock was loaded directly onto the TBE-Urea gel
as a positive loading control. n=1
It was clear that mmu-miR-203 was not expressed either in unactivated cells or
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cells activated with any of the LPS concentrations tested (Fig 4.9a). It was also
clear that these cells were capable of processing the mmu-miR-203 Pre-miR to gen-
erate the mature form of the miRNA (Fig 4.9b). The unprocessed pre-mmu-miR-
203 reagent displayed two hybridisation bands on the microRNA-Northern membrane,
most likely representing the precursor and mature form of the microRNA, while trans-
fected samples only displayed a single hybridisation band corresponding to the mature
microRNA, indicating that the transfected precursor molecule had been successfully
processed by the cell machinery.
To ensure that manipulating levels of mmu-miR-203 had no obvious effects on
macrophage activation, duplicate sets of cell cultures were set up and transfected with
1) Lipofectamine alone, 2) Lipofectamine + mmu-miR-203 Anti-miR, or 3) Lipofec-
tamine + mmu-miR-203 Pre-miR. A series of transfections with different concentra-
tions of Anti-miR or Pre-miR were performed. Untransfected cultures were also in-
cluded in the analysis. Following transfection, the cells were incubated for 18hr. The
medium was then replaced with macrophage culture medium and cells were activated
with 0.1ng/mL LPS for 6hr. Cells were then harvested and the samples were pro-
cessed for FACS analysis. The mean population fluorescence values for the different
treatments are shown in Figure 4.10.
This analysis revealed that, compared to untreated cells, neither Lipofectamine
alone nor Lipofectamine + mmu-miR-203 Anti-miR or mmu-miR-203 Pre-miR, af-
fected the mean fluorescence value. Similarly, the increase in fluorescence seen upon
activation was not affected by the transfection procedures. The mean fluorescence was
not affected by either of the mmu-miR-203 reagents at concentrations between 7.5
nmol and 120 nmol.
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Figure 4.10: Impact of Mmu-miR-203 Expression on the Mean Population Fluores-
cence of Activated hELAM-GFP Cells. hELAM-GFP cells were plated on square
25-well bacteriological plastic plates and incubated with serial dilutions of anti-mmu-
miR-203 LNAs (1-0.0625ng/mL) and mmu-miR-203 precursors (120-7.5nmol) in
transfection conditions for 18hr. The cells were then activated with 0.1ng/mL LPS
for 6hr prior to harvest for FACS analysis. The fold-change in the mean population
fluorescence value of transfected hELAM-GFP cells was calculated relative to the ac-
tivated control, n=2.
4.2.3.2 Effect of miRNA depletion and over-expression on macrophage activa-
tion
The hELAM-GFP cell line was utilised to assess the effects of microRNA depletion
and over-expression on overall macrophage activation. The RAW264.7 cell line was
used to assess the effects of microRNA manipulation on the expression of individual
activation markers.
FACS analysis of GFP expression Triplicate cultures of hELAM-GFP cells were
transfected with Lipofectamine alone or with Lipofectamine + Anti-miR for mmu-
miR-155, mmu-miR-146a or mmu-miR-142-3p. Controls included untreated cells and
cells transfected with Anti-miR for mmu-miR-203. Cells were transfected for 18hr,
activated with LPS for 6hr, harvested and processed for FACS analysis. The mean
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fluorescence values relative to those of cultures activated by LPS are shown in Figure
4.11.
Figure 4.11: Impact of Anti-miRNA Transfection on the Mean Population Fluores-
cence of Activated hELAM-GFP Cells. hELAM-GFP cells were plated on square 25-
well bacteriological plastic plates and incubated with 1ng/mL of anti-miRs for mmu-
miR-203, -155, -146a and -142-3p in transfection conditions for 18hr. The cells were
then activated with 0.1ng/mL LPS for 6hr prior to harvest for FACS analysis. Data
was normalised against unactivated hELAM-GFP expression. The fold-change in the
mean population fluorescence value of transfected hELAM-GFP cells was calculated
relative to the activated control (LPS only) ±1S.D. of 3 experimental replicates (n=1).
Anti-mmu-miR-203 represented the control transfection.
It is clear that, as with LPS alone and LPS + mmu-miR-203 Anti-miR, specific
depletion of mmu-miR-155, mmu-miR-146a or mmu-miR-142-3p had no significant
effect on the mean fluorescence value. Cells were examined under light microscopy
at 6hr post-activation and no obvious differences were observed between control and
knock-down samples.
RT-QPCR of marker gene expression As depletion of the selected miRNAs clearly
did not inhibit overall macrophage activation, the effects of manipulating selected
miRNA levels on the expression of individual activation marker genes was examined.
Triplicate cultures of RAW264.7 cells were transfected with either Pre-miRs for mmu-
miR-155 or mmu-miR-146a, or Anti-miR for one of a number of miRNAs.
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The miRNAs suppressed were mmu-miR-146a, mmu-miR-155, mmu-miR-15b,
mmu-miR-16c, mmu-miR-191, mmu-miR-21, mmu-miR-27b, mmu-miR-30b, mmu-
miR-322-5p, mmu-miR-378 and mmu-miR-7a. Controls included untreated cells,
Lipofectamine-treated cells and cells transfected with Anti-miR for mmu-miR-203.
Cells were transfected for 18hr, activated with LPS for 6hr, harvested and RNA ex-
tracted. RNA was used to generate cDNA for RT-QPCR analysis of expression of
Tnf-a, Cox2, Cxcl2, Il-6 and Saa3. Expression levels for individual genes and different
treatments at 6hr post-activation were shown relative to the expression levels in cells
treated with LPS only (Fig 4.12).
As expected, both on the basis of established knowledge of miRNA effects and
the analysis of treated hELAM-GFP cells presented here, none of the treatments had
a dramatic effect on the expression of individual genes. However, a number of the
treatments had small but significant effects on gene expression. Knock-down of mmu-
miR-15b had the most widespread effect and resulted in a decrease in expression in
all five genes examined. Knock-down of mmu-miR-191 led to a decrease in Tnf-a,
Il-6 and Saa3. Manipulating levels of mmu-miR-146a and mmu-miR-155 had mixed
effects; over-expression affected some genes while knock-down affected other genes.
Over-expression of mmu-miR-146a resulted in a decrease in the levels of Cox2 and
Cxcl2, while knock-down increased expression of Saa3. Interestingly, over-expression
of mmu-miR-155 resulted in decreased levels of Tnf-a expression, while knock-down
of this miRNA caused an increase in expression levels of the same gene.
Analysis of cellular impedance The xCELLigence system has been previously shown
to accurately quantify physical changes in the activated macrophage population (Fig
3.9). Although no gross changes in macrophage activation morphology were observed
under bright-field microscopy following Pre-miR or Anti-miR treatment, the xCELLi-
gence system was utilised to determine if more subtle physical changes did occur.
RAW264.7 cells were transfected for 18hr with Pre-miR or Anti-miR molecules,
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then activated with LPS. The CI value was measured regularly during transfection and
for 24hr post-activation. Figure 4.13a shows the CI plots for the control samples. The
CI profiles generated by the activated controls (LPS and LPS + mmu-muR-203) are
clearly distinct from the unactivated samples (untreated and Lipofectamine only). LPS
and mmu-miR-203 show very similar plots, demonstrating that transfection with the
ESC-associated mmu-miR-203 did not affect macrophage activation physiology. This
finding concurred with the RT-QPCR, FACS and microRNA-Northern data generated
here. Untreated RAW264.7 cells and the mock transfected cells also show similar
CI profiles, confirming that at the low doses used here Lipofectamine did not cause
macrophage activation.
Figure 4.13b shows that depressing the levels of five of the selected microRNAs
(mmu-miRs -27b, -30b, -322-5p, -378 and -7a) did not cause noticeable changes in the
CI profiles generated, indicating that knock-down of these microRNAs did not affect
adhesion and morphological changes associated with macrophage activation. Figure
4.13c shows that transfection with Pre-miRs for the macrophage-associated microR-
NAs miR-146a and miR-155 did not cause demonstrable change in the CI profile. The
clear difference in activated vs. unactivated CI profiles held up across experiments and
can again be observed in Figure 4.14a. The activated cells show increased CI values
following activation with LPS, then the CI trace tails off as inflammation resolves and
the activated cells begin to die off. Figure 4.14b shows that knocking-down these five
microRNAs (mmu-miR-142-4p, -146a, -155, -15b and gga-miR-16c) did not affect
macrophage activation morphology.
Most interestingly, suppressing levels of mmu-miR-21 and mmu-miR-191 (Fig
4.14c and d respectively), clearly affected the CI response of activated cells. Although
both CI profiles still demonstrated a response to stimulation with LPS, the CI val-
ues generated were clearly lower than the activated control (mmu-miR-203) and were
closer to those of the untreated samples. Analysis of the CI data found that the differ-
ence between the control (anti-mmu-miR-203) and treated samples, anti-mmu-miR-21
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and -191 (Fig 4.14c and d respectively) were statistically significant (P= >0.05 and
>0.01) from 2-24hr post-activation. This data suggested that the knock-down of these
microRNAs dampened the physiological response of macrophages to LPS.
As the knock-down of mmu-miR-21 and -191 appeared to cause lower CI values
during the 18hr transfection period (statistically significant, P= <0.05, at some time-
points) it was decided to look at the effects of microRNA knock-down on normal
macrophage physiology. RAW264.7 cells were transfected with Anti-miRs and Pre-
miRs for 18hr. The cells were then cultured for 5 days and the CI value measured
at regular intervals. Knock-down and over-expression of the selected microRNAs did
not noticeably alter the CI profile compared to the untreated cells (data not shown).
Therefore, it was conlcuded that the effects of miR-21 and miR-191 on macrophage
physiology are linked to LPS activation and do not disrupt the resting macrophage
phenotype under normal culture conditions.
Summary Overall, functional analysis of the selected microRNAs indicated that the
microRNAs mmu-miR-146a, -155, -15b and -191 were able to exert significant effects
on macrophage activation marker gene expression and mmu-miR-191 and mmu-miR-
21 could significantly affect the CI profile. The target genes of miR-146a and -155
in activated macrophages are already known (section 1.4.2.2), but the target genes of
miR-15b and -191 during macrophage activation were unknown.
4.2.4 Target prediction
Although manipulating the selected microRNAs did not result in dramatic effects on
macrophage activation morphology or marker gene expression, altering levels of some
miRNAs had clear effects on CI profiles, most likely representing alterations in mor-
phology or adhesion. It was decided to use target prediction software to further under-
stand these observed miRNA:mRNA interactions.
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Figure 4.12: Expression of Activation Marker Genes in Transfected RAW264.7
Macrophages, measured by RT-QPCR. RAW264.7 cells were transfected with anti-
microRNA LNAs and microRNA precursor molecules for 18hr, then activated with
10ng/mL LPS and harvested for RNA at 6hr post activation. cDNA generated from the
RNA was used in RT-QPCR analysis to measure the expression of the macrophage-
associated genes a) Tnf-a, b) Cox2, c) Cxcl2, d) Il-6 and e) Saa3. The variation in gene
expression during differentiation culture is displayed as mean fold-change (2-ddCt) ±1
S.D. relative to the untransfected, activated RAW264.7 cells (LPS only control). n=3.
The data was normalised against the housekeeping gene HPRT. P-values were calcu-
lated by independent student’s t-tests against the LPS only control, * = P-value < 0.05,
** = P-value < 0.01
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Figure 4.13: Measurement of Cellular Impedance during Knock-down of MicroRNAs
in Activated RAW264.7 Macrophages. The Roche xCELLigence system was used
to measure changes in the electrical impedance (CI value) across the surface of each
well during RAW264.7 cell transfection and activation. RAW264.7 cells were plated
at 20,000 cells per well and microRNAs were knocked-down or over-expressed in
RAW264.7 cells by transfection with complementary LNAs or precursor molecules for
18hr. The cells were then activated with 10ng/mL LPS and the CI value was measured
for 24hr (2min for 1 hr, 15min for 8hr, 30min for 15hr). a) Transfection controls: un-
treated, Lipofectamine only, LPS only, LPS + anti-mmu-miR-203. b) Knock-down of
mmu-miR-27b, mmu-miR-30b, mmu-miR-322-5p, miR-378, mmu-miR-7a. c) Over-
expression of mmu-miR-146a and mmu-miR-155. Each individual data point repre-
sents the mean CI value at that time-point, n=8 ±1 S.D. P-values were calculated by
independent student’s t-tests against the anti-mmu-miR-203 control transfection, * =
P-value < 0.05, ** = P-value < 0.01
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Figure 4.14: Measurement of Cellular Impedance during Knock-down of MicroRNAs
in Activated RAW264.7 Macrophages. The Roche xCELLigence system was used
to measure changes in the electrical impedance (CI value) across the surface of each
well during RAW264.7 cell transfection and activation. RAW264.7 cells were plated
at 20,000 cells per well and microRNAs were knocked-down or over-expressed in
RAW264.7 cells by transfection with complementary LNAs or precursor molecules
for 18hr. The cells were then activated with 10ng/mL LPS and the CI value was mea-
sured for 24hr (2min for 1 hr, 15min for 8hr, 30min for 15hr). a) Transfection con-
trols: untreated, Lipofectamine only, LPS only, LPS + anti-mmu-miR-203. b) Knock-
down of mmu-miR-142-3p, mmu-miR-146a, mmu-miR-155, miR-15b, gga-miR-16c.
c) Knock-down of mmu-miR-191. d) Knock-down of mmu-miR-21. From 2hr post-
activation the difference in CI value between control (anti-mmu-miR-203) and treated
samples (anti-mmu-miR-21 and -191, (c) and (d) respectively) were statistically sig-
nificant: independent student’s t-tests, P= >0.05 and >0.01 across the remaining time-
points. Each individual data point represents the mean CI value at that time-point, n=8
±1 S.D.
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Assessment of microRNA target prediction programs There are several miRNA
target prediction programs available. All of the programs use different algorithms that
assign differing priorities to the various components of the miRNA:mRNA interac-
tion. This can result in noticeable variation between the target prediction lists pro-
duced. There is a school of thought that using multiple target prediction programs in
parallel and looking for consensus across the programs increases the reliability of the
prediction lists.
miRecords, which returns results for 11 target prediction programs was used. By
comparing the target list generated with known miRNA:mRNA interactions for miR-
146a and miR-155 is was possible to assess the accuracy and relevance of the target
prediction programs both individually and collectively.
Individually, none of the 11 target prediction programs screened by miRecords re-
turned any of the known targets of miR-146a and miR-155 in the top 20 predicted
interactions. Collectively the results were slightly better; by adding the requirement
that a minimum of four programs must return a predicted interaction, a list was gen-
erated in which 1 of 3 known miR-146a targets, and 3 of 15 known miR-155 targets
were returned in the top 20 interactions. This finding appeared to support the theory
that increasing the number of programs used increases the reliability of the predictions
returned. However, it was not the same four (out of eleven) prediction programs that
returned consensus results. Therefore, it was concluded that, when searching for new
targets, it is likely that utilising one target prediction program is just as efficient as
combining many, hoping for consensus across them.
miRNA:mRNA target predictions To better understand the observed interactions
between the activation marker genes and the transfected Pre-miRs and Anti-miRs, the
target prediction program miRDB was used. Target gene lists for miR-15b, miR-191
and miR-21 were generated using miRDB, as the knock-down of these microRNAs
had demonstrated statistically significant changes to macrophage activation parameters
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(miR-15b and -191 by RT-QPCR, Fig 4.12 and miR-191 and -21 by CI analysis, Fig
4.14).
None of the five marker genes measured here (Fig 4.12) were predicted as possible
targets for miR-15b or miR-191. This suggested that these microRNAs do not directly
target Tnf-a, Cox2, Cxcl2, Il-6 and Saa3, and that instead the regulatory effects are
exerted indirectly. Next the known targets of miR-15b and miR-191 (using miRTar-
Base confirmed targets) were examined to determine if these microRNAs targeted an
upstream gene that might account for the effects exerted on Tnf-a, Cox2, Cxcl2, Il-
6 and Saa3. None of the known targets of miR-15b or miR-191 are associated with
macrophage biology. Therefore the mechanism by which miR-15b and miR-191 ex-
ert effects on the expression of Tnf-a, Cox2, Cxcl2, Il-6 and Saa3 during macrophage
activation is currently unknown.
MiR-21 is known to target the extracellular matrix protein (ECM) matrix metallo-
proteinase 9 (MMP9), however to date there are no reports of miR-21/MMP9 interac-
tion in (activated) macrophages, despite both genes being expressed during activation.
Therefore the mechanism by which miR-21 affects macrophage morphology is cur-
rently unknown.
Pathway analysis To further investigate the role of miR-15b, miR-191 and miR-
21 in macrophage activation, pathway analysis was performed on the predicted target
genes for these microRNAs. It was expected that, as these microRNAs had shown
measurable effects on macrophage activation, the predicted target genes would be bi-
ased towards roles in biological functions and pathways associated with the immune
system.
The predicted target gene lists generated by miRDB were entered into the ToppFun
section of the ToppGene Suite (https://toppgene.cchmc.org/enrichment.jsp), a gene list
enrichment analysis program. ToppFun identifies signalling pathways, phenotypes,
cellular functions and other biological processes that are represented by the gene list
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entered.
The list of 1050 predicted target genes for mmu-miR-15b contained many genes
that are components of a variety of immune-associated signalling pathways including
B-cell activation, cytokine signalling, Fc receptor signalling, IL-1 and IL-3 signalling,
PI3K-Akt signalling, MyD88-dependent and -independent signalling, indicating that
miR-15b may have an active role within the immune system. Biological pathways
associated with epidermal, fibroblast and neuronal growth and growth factors were
also strongly represented in the prediction list, suggesting a role for miR-15b in tissue
remodelling and homeostasis, possibly as part of the resolution of inflammation and
wound healing. However, these pathways could also be abused during tumourogenesis.
Misregulation of miR-15b is known to be associated with several cancers, and two
cancer pathways were represented in the gene list (pancreatic cancer and renal cell
carcinoma).
Of the 48 predicted target genes for mmu-miR-191 only four genes indicated a role
in the immune response; two genes were associated with enlarged lymph nodes and
another two were associated with T-helper cell differentiation. By comparison almost
a quarter of the gene list was associated with abnormal nervous system development,
perhaps reflecting a role for miR-191 in homeostasis. Most interestingly, the predicted
targets contained several genes associated with components of cellular morphology
(micro-tubules, growth cone, polarized growth and chromatin).
Mmu-miR-21 is predicted to target 196 genes which show enrichment for IFN-g
signalling, as well as chemokine ligands and signalling. MiR-21 is a known macrophage-
associated microRNA (section 1.4.2.2), therefore it is not surprising that many of its
predicted targets are associated with immune system signalling. Many of the predicted
target genes are associated with overall development and tissue development. This
could indicate a role for miR-21 in tissue remodelling and homeostasis.
In summary, the pathway analysis showed that mmu-miR-15b is strongly associ-
ated with immune system signalling and responses, including inappropriate responses
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like cancer. Mmu-miR-21 is also strongly associated with immune system signalling
pathways, while mmu-miR-191 is predicted to target several genes associated with
cellular morphology.
4.3 Discussion
Next generation sequencing At the time that this work was undertaken an advan-
tage of the illumina Genome Analyzer system was its ability to barcode multiple sam-
ples in a single flow-lane on the sequencing chip through the use of indexed 5’ adaptors.
This enabled the 12 sample libraries to be sequenced on a single chip, thereby avoiding
run-specific bias. Ironically the greatest cause of sequencing bias in the profiling data
was later found to be the indexed 5’ adaptors which have different, sequence-specific
amplification efficiencies resulting in unequal amplification between the samples dur-
ing the PCR step. Work published after the creation of the profiling libraries generated
here determined that this phenomenon could be eliminated by adding the indexed 5’
adaptor during the PCR amplification stage, rather than during the adaptor ligation
stage (Fig 4.4) [6, 262]. The repercussion of the barcoding bias for the work described
here was that the data set was unsuitable for large-scale bio-informatics analysis of
miRNA profiles and potential miRNA:target interactions in activated macrophages,
pushing the focus of this chapter onto the functional analysis.
Functional analysis It is clear that the procedures adopted here effectively deplete
endogenous levels of miRNAs and increase levels of selected miRNAs within the phys-
iological range normally found in macrophages, without affecting the activation pro-
cess. It seems that the expression of some miRNAs, directly or indirectly, affects the
expression of other miRNAs. It is interesting to note that the knock-down of both mmu-
miR-142-3p and mmu-miR-146a results in the reduced expression of mmu-miR-155
(Fig 4.7). This outcome was unexpected, as both miR-142-3p and miR-146a nega-
tively regulate the NFkB signalling molecule IRAK1 [163, 285], which would result
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in decreased expression of the NFkB induced miR-155. Therefore it was expected that
the knock-down of mmu-miR-142-3p or mmu-miR-146a would cause increased ex-
pression of mmu-miR-155 via increased NFkB signalling. However, the cross-talk be-
tween mmu-miR-142-3p and mmu-miR-155 has been subsequently confirmed [251].
Given the high degree of cross-talk that exists within the transcriptome during the
macrophage activation response, it is not surprising that microRNAs are also subjected
to cross-talk during this response.
hELAM-GFP cells: It was envisaged that the mean population fluorescence of ac-
tivated hELAM-GFP cells may be altered by the knock-down and over-expression of
microRNAs, especially mmu-miR-146a and mmu-miR-155, which had already been
confirmed to be involved in macrophage activation (section 1.4.2.2). However, FACS
analysis demonstrated that this was not the case (Fig 4.11). It may be that this could
be attributed to the stability of GFP (half-life ~26hr [48]). Because GFP expression in
hELAM-GFP cells is coupled to the NFkB pathway [245], a microRNA knock-down
would have had to dramatically decrease or block the activation of the NFkB path-
way completely in order to cause a demonstrable reduction in the GFP expression.
Given the role of the NFkB pathway as a master regulator in the immune response and
the range of stimuli to which it responds (Fig 1.5), it was most unlikely that a single
microRNA would completely ablate its activation. MiR-155 and miR-146a are both
induced by NFkB activity and regulate its expression through contribution to negative
feedback loops [163]; therefore the knock-down of these microRNAs could have been
expected to increase GFP expression. However, it was more likely that the knock-
down of miR-146a and miR-155 would prolong NFkB activity, rather than increase it;
therefore it is not unreasonable to observe no change in GFP expression. In retrospect,
it may have been more appropriate to assess the mean population fluorescence of the
transfected hELAM-GFP cells at multiple time-points post-activation.
RT-QPCR and CI data: The analysis in this chapter shows that the overall process
of macrophage activation is not affected by either the over-expression of two miR-
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NAs previously associated with macrophage biology (mmu-miR-146a and -155), or
the depletion of three of the miRNAs that are amongst the most highly expressed in
macrophages (mmu-miR-142-3p, 146a & 155). This was equally true whether the
miRNA was constitutively expressed or induced upon activation. This is not unex-
pected as the majority of miRNAs are considered to act in tandem with other miRNAs
in regulating gene expression.
In contrast, our analysis showed that manipulating levels of some of the individual
miRNAs led to changes in the expression of activation marker genes, suggesting ei-
ther direct or indirect interactions between these molecules. RT-QPCR analysis of the
effects of microRNA knock-down on macrophage activation markers showed that the
knock-down of miR-15b significantly down-regulated all five markers of macrophage
activation measured here (Fig 4.12), but miR-15b is neither known nor predicted to
directly regulate any of these genes. However the ability of miR-15b to alter in-
flammatory gene expression as indicated in this data concurs with published data
in which aberrant miR-15b expression is associated with several different malignan-
cies. Interestingly, despite its clear effects on all five marker genes, the knock-down
of mmu-miR-15b did not exert any significant effects on the CI profile of activated
macrophages. This concurs with the pathway analysis of predicted targets, which was
enriched for several immune-related signalling pathways but not for any structural cel-
lular components.
Mmu-miR-191 did significantly alter the CI profile in activated macrophages (Fig
4.14d); again this finding was supported by pathway analysis which showed that mmu-
miR-191-predicted targets are enriched for structural cellular components. However,
the predicted genes were not enriched for any macrophage-associated signalling path-
ways. Therefore it is less clear how anti-mmu-miR-191 significantly alters the expres-
sion of Tnf-a, Il-6 and Saa3.
Saa3 expression was found to be influenced by 4 different microRNAs (anti-mmu-
miR-146a, pre-mmu-miR-155, anti-mmu-miR-15b and anti-mmu-miR-191), but to
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date there are no confirmed miRNA:Saa3 interactions (data from miRTarBase) and
only 3 miRNA:Saa3 interactions are predicted by miRDB. Interestingly one of the mi-
croRNAs predicted to target Saa3 is the short-listed microRNA miR-30b. Knock-down
of miR-30b did cause a small but not statistically significant increase in Saa3 expres-
sion in our data (Fig 4.12e). Four hours post-activation was the earliest time-point at
which Saa3 was detected in this work (Fig 4.2); however maximal expression occurred
at 24hr post-activation. It would be interesting to study the effect of microRNA knock-
down and over-expression on Saa3 over a 24hr activation time-course to determine
wether Saa3 is abnormally regulated throughout the time-course or if it recovers.
Of the two well-characterised macrophage-associated microRNAs, knock-down
and over-expression of mmu-miR-146a caused changes in gene expression that con-
curred with its role as an anti-inflammatory microRNA, namely that over-expression
decreased, while knock-down increased the expression of pro-inflammatory genes. By
comparison the data reported here for mmu-miR-155 showed an opposite trend than
expected from previous reports; over-expression decreased, and knock-down increased
all five marker genes. With regard to TNF-a expression this behaviour was statistically
significant, deviating from previously published data [15, 259].
The knock-down of the known macrophage-associated microRNA mmu-miR-21
did not exert any significant effects on the expression of the marker genes, but was
associated with a slight trend towards increased gene expression. It also significantly
decreased the CI profile of activated macrophages. This data fits with miR-21’s pub-
lished role as an anti-inflammatory microRNA (section 1.4.2.2). Unlike mmu-miR-
191, the predicted targets of mmu-miR-21 were not obviously related to cellular mor-
phology; and it has not been reported to interact with its known EMC target, MMP9, in
macrophages. Therefore it is not yet known the mechanism by which miR-21 caused




The role of the global microRNA
population in macrophage activation
by LPS
5.1 Introduction
While a small number of microRNAs have been shown to have major effects on par-
ticular biological processes, the majority of individual microRNAs are thought to con-
tribute incrementally to altering cellular activity. The miRNA depletion experiments
reported in chapter 4 suggest that the microRNA studied here are more likely involved
in fine-tuning macrophage activation, as opposed to representing key regulators of this
process. On this basis we elected to assess the effects of manipulating the global
miRNA population on macrophage differentiation and activation.
5.1.1 Aims
The aim of this line of enquiry was to assess two systems for the generation of microRNA-
deficient macrophages and then to use these systems to determine the effects of mi-
croRNA ablation on the process of macrophage activation.
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5.2 Results
An initially assessment was made to determine if it was possible to derive activation-
responsive macrophages in the absence of miRNA activity. The basic concept was to
obtain embryonic stem cells (ESCs) lacking functional DGCR8, and establish whether
these cells could be differentiated into macrophages and, if so, to assess the effects on
differentiation/activation.
5.2.1 DGCR8-/- embryonic stem cell line
The DGCR8-/- embryonic stem (ES) cell line has had exon 3 of DGCR8 removed from
the genome (Fig 5.1a). These cells cannot produce functional DGCR8 and conse-
quently are deficient in mature microRNA production [274]. Generation of microR-
NAs in DGCR8-/- cells is arrested at the pri-miRNA stage; the multiple hairpin pri-
miRNAs are not structurally compatible with Exportin-5 which exports single hairpin
pre-miRNAs to the cytoplasm. Consequently the pri-miRNAs are not exported from
the nucleus, preventing non-canonical processing of these molecules in the cytoplasm
(Fig 5.1b). The creation of macrophages from the DGCR8-/- ESCs would represent a
microRNA-free in vitro system. The DGCR8-/- macrophages could then be used to es-
tablish whether, or to what extent, miRNAs are required during the activation process.
5.2.2 Generation of macrophages from wild-type ESCs
To optimise ESC to macrophage differentiation protocols, two wild-type ES cell lines,
E14 [103] and CGR8 [188], were utilised. These were cultured in conditions adapted
from a previously published protocol for the in vitro generation of macrophages from
ESCs [127]. ESCs were first cultured on bacteriological plastic in the absence of
leukemia inhibitory factor (LIF) for 3 days. ESCs are not naturally adherent cells
and are unable to attach to the bacteriological plastic; instead the ESCs form floating
colonies known as embryoid bodies (EBs). LIF is a core component of ESC culture
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Figure 5.1: DGCR8-/- Cells. a) The excision of DGCR8 exon 3 renders the protein
non-functional. Exon 3 was removed from the genome using the Cre/loxP system. b)
The removal of functional DGCR8 from the microRNA biogenesis pathway blocks the
generation of the single hairpin pre-miRNA molecules. This causes accumulation of
pri-miRNAs and an associated deficiency in mature microRNAs within the knockout
cells.
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conditions. It functions to block differentiation and in the absence of LIF the ESCs
form EBs more readily.
The resulting EBs were then plated in quadruplicate on bacteriological plastic
plates containing the macrophage differentiation media. Transfer of the EBs from
the ESC culture conditions into the differentiation culture conditions was designated
day 0 (d0) for experimental purposes. The differentiation media contained rIL-3 as a
general growth factor which is required at the early, pre-haematopoietic stages [70],
and recombinant human CSF-1 to drive myeloid and macrophage differentiation. The
cultures were photographed daily under light microscopy, and the culture media re-
plenished every 5 days for a total of 20 days. The remaining EBs and, where present,
adherent cells were harvested for RNA every 5 days (d0, d5, d10, d15 and d20). The
harvested RNA was used to make cDNA for RT-QPCR. Successful differentiation of
EBs into macrophages was assessed by morphology and marker gene expression.
5.2.2.1 Morphological changes during wild-type EB differentiation
The morphological changes that occur during EB differentiation into macrophages
were assessed visually under light microscopy (Fig 5.2). At d0 of differentiation (day
3 of EB culture) the two wild-type lines (E14 and CGR8) showed similar population
morphology - small rounded EBs, mostly homogenous in size and shape throughout
the culture.
Both WT cultures underwent morphological changes in the differentiation condi-
tions. Firstly the EBs expanded and then the gross morphology of the EBs in the
culture became less uniform (e.g. rounded, elongated or mushroomed. Fig 5.2 d0-
10). Individual EBs within the population then appeared to develop uneven shading
which marked the development of cysts; in some EBs the cysts became very large and
opaque, while in others the cysts were smaller and appeared shaded (Fig 5.3a). The
EBs then attached to the surface of the plate creating dense clusters of cells which
spread outwards as the cell division increased the colony size (Fig 5.3b). These ad-
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Figure 5.2: Morphological Changes during Differentiation of WT and DGCR8-/-
(MicroRNA-Deficient) EBs under Macrophage Culture Conditions. ESCs from the
three cell lines were cultured in the absence of LIF on bacteriological plastic for 3
days, giving rise to the formation of EBs. The EBs were then cultured in macrophage
differentiation conditions on bacteriological plastic for 20 days. The two wild-type cell
lines (E14 and CGR8) differentiated into macrophages; adherent cells were observed
in these cultures and the non-adherent EBs were diminished. The DGCR8-/- cells did
not successfully differentiate into macrophages; adherent cells were not observed in
these cultures; instead the EBs continued to grow in size during the culture period.
n=3
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Figure 5.3: Characteristic Cellular Morphologies Observed during the Differentiation
of EBs to Macrophages In Vitro. ESCs from the three cell lines were cultured in the
absence of LIF on bacteriological plastic for 3 days, giving rise to the formation of
EBs. The EBs were then cultured in macrophage differentiation conditions on bacteri-
ological plastic for 20 days. Distinct cellular morphologies that developed during the
differentiation culture are shown here. a) A cyst. b) Outward growth of a macrophage
colony following attachment of an EB to the culture plate. c) Granular appearance of
macrophages at d20 of differentiation conditions. d) Accumulated cell debris on the
surface of the culture dish in DGCR8-/- cultures at d20 of differentiation conditions.
n=3
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herent cells have a broadly macrophage-like morphology, but are more granular than
BMDMs (Fig 5.3c). Increased granularity in BMDMs is associated with activation.
However the adherent cells did not display other morphological characteristics asso-
ciated with activation (such as appearing darker under light microscopy or increased
spreading across the surface to which the cells are attached). The more granular nature
of these macrophage-like cells concurs with the images seen in Karlsson et al. [127]
and appears to be a characteristic of macrophages derived by this method. Overall, the
morphological changes observed within the WT cultures indicated that the EBs had
been successfully differentiated into macrophage cells.
5.2.2.2 Marker gene expression during wild-type EB differentiation
The expression of pluripotent/ESC markers and myeloid/macrophage markers was as-
sessed by RT-QPCR to characterise the temporal expression of different genes during
the differentiation of WT EBs into macrophages. Nanog and Oct4 were chosen as clas-
sic markers of pluripotency. They are highly expressed in ESCs but silenced early in
differentiation. It was expected that expression of Nanog and Oct4 would be detected
in the EBs but rapidly switched off during the differentiation time-course. C-kit was
selected as an ESC/HSC transitional marker. This gene is expressed in mesoderm and
early haematopoietic progenitors but expression levels decrease during cellular matu-
ration. Therefore, the expression of c-kit was expected to be detected in the EBs and to
decrease as the cells differentiated. Cd34 was selected as a marker for early myeloid
precursors and its expression was expected to rise during the early stages of differen-
tiation but decrease again with cellular maturation. F4/80 and Csf-1r were selected
as myeloid/macrophage markers. Expression of both genes was expected to increase
along the differentiation time-course (sections 1.2.1.3 and 1.2.1.5).
RT-QPCR analysis (Fig 5.4) showed that, in wild-type EBs, expression levels of
Oct4, Nanog and c-kit decreased sharply over the initial five days of culture. There-
after, while the expression of c-kit was maintained throughout the culture period,
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Oct4 and Nanog levels were undetectable. The early myeloid marker Cd34 was most
strongly expressed between 10 and 15 days of culture, while expression of the two
myeloid/macrophage markers, Csf-1r and F4/80, steadily increased in the later stags
of culture.
The expression of these six genes (Nanog, Oct4, c-kit, Cd34, F4/80 and Csf-1r)
was also measured in the adherent cells that had developed within the cultures at d15
and d20 (data for E14 samples displayed in Fig 5.5). Expression of Nanog, Oct4, and
c-kit was not detectable in the adherent cells while expression profiles of Cd34, Csf-1r
and F4/80 were similar to those seen in EBs.
WT EB differentiation summary The morphological changes and marker gene ex-
pression patterns observed here concurred with the expected results for the successful
differentiation of macrophage-like cells. Therefore it was concluded that macrophages
could be successfully differentiated from WT EBs using this method.
5.2.3 Generation of macrophages from DGCR8-/- ESCs
The next step was to determine if DGCR8-/- ESCs could be differentiated into macro-
phages. DGCR8-/- ESCs [274] had been reported to display impaired early differenti-
ation (the cells do not turn off pluripotency markers efficiently) and it was unknown if
this could be overcome by culturing the cells in terminal differentiation culture condi-
tions.
DGCR8-/-ESCs were treated in the same manner as the wild-type cell lines. Briefly:
ESCs were cultured in the absence of LIF to generate EBs; the EBs were then trans-
ferred to differentiation culture conditions (d0); the cultures were photographed daily
under light microscopy, and the culture media replenished every 5 days for a total of 20
days; the remaining EBs and, where present, adherent cells were harvested for RNA
every 5 days (d0, d5, d10, d15 and d20) (full method in section 2.1.5.1). The harvested
RNA was used to make cDNA for RT-QPCR. Successful differentiation of EBs into
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Figure 5.4: Expression of Pluripotency and Differentiation Marker Genes across WT
EBs during Macrophage Differentiation. ESCs from the two wild-type cell lines - E14
and CGR8 - were cultured in the absence of LIF on bacteriological plastic for 3 days,
giving rise to the formation of EBs. The EBs were then cultured in quadruplicate
in macrophage differentiation conditions on bacteriological plastic for 20 days. The
non-adherent cells (ESCs still in EB form and non-adherent progenitor cells) from one
plate were harvested for RNA every 5 days and used to generate cDNA for RT-QPCR
analysis. The gene expression of the following markers was assessed: pluripotency
markers (a) Oct4 and (b) Nanog; (c) ESC/HSC marker c-kit; (d) myeloid marker Cd34;
and macrophage markers (e) F4/80 and (f) Csf-1r. Gene expression was calculated
relative to d0, or the earliest measurable expression of the gene (Csf-1r d5 in E14 and
d10 in CGR8). ±1S.D. of three technical replicates. The data was normalised against
the housekeeping gene b-Actin. n=2, data from one experiment represented here.
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Figure 5.5: Expression of Pluripotency and Differentiation Marker Genes in
Macrophages Derived from Wild-Type Embryoid Bodies. EBs from the the wild-type
ES cell line E14 were plated in quadruplicate and cultured in macrophage differenti-
ation conditions for 20 days. The cultures generated adherent cells which remained
on the plates after harvesting the EBs/non-adherent cells. These adherent cells were
harvested for RNA, which was then used to generate cDNA for RT-QPCR analysis.
The DCGR8-/- cultures did not produce any adherent cells. The gene expression of
the following markers was assessed: pluripotency markers (a) Oct4 and (b) Nanog; (c)
ESC/HSC marker c-kit; (d) myeloid marker Cd34; and macrophage markers (e) F4/80
and (f) Csf-1r. Gene expression was calculated relative to d0, or the earliest measurable
expression of the gene (d5 for Csf-1r). ±1S.D. of three technical replicates. The data
was normalised against the housekeeping gene HPRT. n=2, data from one experiment
represented here.
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macrophages was assessed by morphology and marker gene expression.
5.2.3.1 Morphological changes during DGCR8-/-EB differentiation
Initially, the DGCR8-/- EB cultures appeared similar to the wild-type EBs, demonstrat-
ing a uniform size and rounded morphology. However, the average size of EBs in the
mutant population was slightly smaller than the average size seen in the WT cultures
(Fig 5.2, d0). This difference in EB size is possibly due to the slower proliferative rate
of the mutant cells [274]. The DGCR8-/- cultures did not display any of the character-
istic morphological changes that had been observed in the wild-type cultures (section
5.2.2.1). The population morphology within the DGCR8-/- cultures remained mostly
uniform; EBs were rounded and of approximately equal size throughout the culture
(Fig 5.2, d0-10). The DGCR8-/- EBs grew more slowly than the wild-type EBs, did
not develop cysts and did not attach to the plate surface to form adherent colonies of
cells (Fig 5.2, d20). The DGCR8-/- cultures contained very small quantities of adherent
matter, but did not form adherent colonies and appeared to be cell debris rather than
living cells when examined under light microscopy (Fig 5.3d).
5.2.3.2 Marker gene expression during DGCR8-/-EB differentiation
Although the morphological changes observed suggested that DGCR8-/-EBs could not
differentiate into mature macrophages, the expression of marker genes was monitored
to assess the differentiation process. Oct4 expression showed a steady if slight decrease
with culture, but expression was maintained throughout the incubation period. In con-
trast, levels of Nanog, c-kit and Cd34 were maintained at day 0 levels throughout.
Most interestingly, expression levels of Csf1r and F4/80 increased in the later stages
of culture - similar to wild-type expression profiles, and suggestive of some element of
the macrophage differentiation (Fig 5.6).
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Figure 5.6: Expression of Pluripotency and Differentiation Marker Genes in DCGR8-/-
EBs during Macrophage Differentiation. ESCs from the DCGR8-/-cell line were cul-
tured in the absence of LIF on bacteriological plastic for 3 days, giving rise to the
formation of EBs. The EBs were then cultured in quadruplicate in macrophage differ-
entiation conditions on bacteriological plastic for 20 days. One plate was harvested for
RNA every 5 days and used to generate cDNA for RT-QPCR analysis. The gene ex-
pression of the following markers was assessed: pluripotency markers (a) Oct4 and (b)
Nanog; (c) ESC/HSC marker c-kit; (d) myeloid marker Cd34; and macrophage mark-
ers (e) F4/80 and (f) Csf-1r. Gene expression was calculated relative to d0. ±1S.D.
of three technical replicates The data was normalised against the housekeeping gene
b-Actin. n=2, data from one experiment represented here.
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Summary of DGCR8-/-EB differentiation A comparison of the DGCR8-/- EBs with
the wild-type EBs confirmed a known discrepancy between their ability to differentiate.
The E14 wild-type cells successfully turned off expression of both pluripotency and
early-stage myeloid-lineage markers to differentiate into macrophages. Conversely, in
the case of the DGCR8-/- EBs, the cells were unable to turn off the stem cell pluripo-
tency markers, despite the fact that they were able to express both early- and late-stage
differentiation markers. This indicated that while the DGCR8-/- ESCs cannot suc-
cessfully differentiate into macrophages, the differentiation process is not completely
blocked. Although it not possible to determine from this data at which stage the differ-
entiation process failed, the continued expression of the pluripotency markers suggests
this happened at an early progenitor stage.
Therefore, to study the effects of the global microRNA depletion on macrophage
activation it was necessary to identify another microRNA-free macrophage system
which could be used to investigate the effects of microRNA ablation on macrophage
activation.
5.2.4 Dicer-floxed BMDMs
The second system assessed was designed to eliminate miRNAs at a more advanced
stage of differentiation. This system utilised Dicer-floxed bone marrow derived macro-
phages.
5.2.4.1 Cre/lox recombination
The Cre/lox system is a well established method for genetic manipulation. The protein
Cre is produced by the bacteriophage P1; it recognises and binds to a specific genetic
palindrome called a loxP site. Cre activity causes recombination between the two loxP
sites to which it has bound, excising the intervening portion of genetic information and
subsequently causing a genomic deletion (Fig 5.7). Although common in the bacterial
genome, loxP sites are not a common motif within eukaryotes; therefore the Cre/lox
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Figure 5.7: The Cre/Lox System. The protein Cre causes genetic recombination be-
tween the two loxP sites resulting in the deletion of the intervening genetic sequence.
If the loxP sites flank a gene, recombination causes loss of function. If the loxP sites
flank a stop sequence, recombination causes gain of function.
system has become a powerful and precise tool for genetic manipulation within eu-
karyotic organisms. The insertion of loxP sites into the region flanking a gene or a
stop sequence can be used to cause gain or loss of function of a specific gene product
through the subsequent addition of Cre (either through external addition of the Cre
protein or by cross-breeding with a Cre-expressing organism). The genetic sequence
flanked by the loxP sites is said to be ‘floxed’.
5.2.4.2 Dicer-floxed mouse line
Harfe et al. created a line of Dicer-floxed mice in which loxP sites had been inserted
around the second RNase III site in exon 23 of the Dicer gene (Dicer1bdh mice [99]).
Ablation of Dicer function can be achieved by crossing the Dicer-floxed mice with
mouse strains that have been genetically engineered to express Cre (Fig 5.8a). How-
ever, the complete systemic removal of Dicer, and subsequently microRNAs, within
the early embryo prevents successful (embryonic) differentiation, resulting in embry-
onic arrest and spontaneous abortion [23, 181, 277]. Therefore it is necessary to cross
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the Dicer-floxed mice with lineage-specific Cre-expressing mice to cause Dicer abla-
tion in only the target cells, or to directly expose specific cell types to the Cre protein
in an in vitro system.
The creation of Dicer-free macrophages through a breeding programme was not
considered to be a suitable solution because there are no markers that are exclusive to
mature macrophages; all known markers are also expressed on progenitor cells. Thus
crossing the Dicer-floxed mice with macrophage-restricted-Cre mice would result in
Cre expression within both macrophages and their progenitors. This would render
Dicer non-functional in the progenitors, subsequently preventing the expression of mi-
croRNAs (Fig 5.8b), which could prevent normal differentiation of macrophages both
in vivo and in vitro.
Therefore it was decided to use an in vitro system to remove Dicer via the applica-
tion of an external treatment.
5.2.4.3 Recombinant TAT:Cre
As mentioned previously, standard transfection methods (e.g. lipid- or viral-based) are
not suitable for use with BMDMs 3, [244]. To remove Dicer from BMDMs without
causing cellular activation, it was necessary to find an alternative method for transport-
ing Cre into the cells. The recombinant TAT:Cre system (rTAT:Cre) developed by the
Dowdy Lab presented a solution to this problem ([268], section 2.9).
The recombinant TAT:Cre system utilises the protein transduction domain (PTD)
of the HIV TAT (trans-activator of transcription) protein to shuttle proteins across lipid
membranes. While the complete TAT protein has infectious properties, the PTD rep-
resents only an 11 amino acid portion of the complete protein, and does not confer any
infectious properties in itself [14, 268]. The usefulness of the PTD lies in its ability
to transmit any molecule attached to it across a lipid membrane without the need for
transfection reagents. TAT-fusion proteins rapidly cross the cellular membrane in an
energy- and temperature-independent manner by lipid-raft-mediated macropinocytosis
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Figure 5.8: Dicer-floxed Cells. a) The removal of the second RNase III domain within
Dicer exon 23 by Cre/lox recombination. LoxP sites were inserted into the genome,
flanking the RNase III domain. The addition of Cre excises this section of gDNA,
rendering Dicer non-functional. b) The loss of functional Dicer in the microRNA bio-




The ability of TAT-fusion proteins to cross the cellular membrane without the need
for transfection reagents made the rTAT:Cre system particularly suitable for use with
mature macrophages, as it was not expected to cause cellular activation.
5.2.4.4 Excision of Dicer from Dicer-floxed cells by recombinant TAT:Cre
The initial approach selected was to attempt to generate BMDMs from Dicer-deficient
bone marrow. If successful, these Dicer-deficient BMDMs would be activated with
LPS and compared against WT cells. If it proved impossible to generate functional
BMDMs from the Dicer-deficient bone marrow then an alternative approach would
involve depleting Dicer from mature BMDMs and subsequently activating cells with
LPS.
It was hypothesised that removal of Dicer from BMDMs would be the superior
method, as using a more uniform starting culture would be expected to yield more
uniform results (compared to the mixed progenitor bone marrow population). This
approach would increase the likelihood that any changes seen during macrophage ac-
tivation were due to the removal of Dicer and subsequent loss of microRNA induction,
rather than to an abnormal resting state caused by a prolonged absence of microRNAs
within the cell.
Optimisation of recombinant TAT:Cre system using YFP-reporter cells The pro-
duction of the rTAT:Cre was out-sourced to Dundee Cell Products (www.dundeecell
products.com) who produced the protein in accordance with the protein purification
protocol provided by the Dowdy Lab (section 2.9). To ensure that the rTAT:Cre was
functional, and to determine the most appropriate concentration of rTAT:Cre protein
to use with BMDMs, it was decided to follow the example of Wadia et al., wherein
a GFP-reporter line was used to show the successful activity of rTAT:Cre. The fluo-
rescent marker provided a clear, quick read-out which could be quantitated [268]. A
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similar test system was adopted using BMDMs derived from a line of stop-floxed YFP-
reporter mice to confirm that the rTAT:Cre was functional (R26R-EYFP YFP-reporter
mice [243] were provided courtesy of Tomasz Nowakowski, Dr. John Mason’s Group,
University of Edinburgh.) The activity of Cre upon these stop-floxed YFP-reporter
BMDMs removes the stop sequence upstream of YFP, resulting in expression of YFP
within the affected cells (Fig5.9a), which can be observed by fluorescent microscopy.
In the experiment described in Wadia et al. a final concentration of 1mM rTAT:Cre
resulted in successful excision of the STOP sequence in the GFP-reporter fibroblast
cells [268]. To determine the optimal concentration of rTAT:Cre for successful Cre-
mediated loxP recombination in BMDMs, a range of rTAT:Cre concentrations was
tested on YFP-BMDMs.
Bone marrow from stop-floxed YFP-reporter mice was harvested and differentiated
into BMDMs following the protocol established in chapter 3. The BMDMs were incu-
bated in serum-free media (as recommended by the Dowdy Lab for rTAT:Cre treatment
[268]) with a range of rTAT:Cre concentrations (0, 0.25, 0.5, 1, 1.5 and 2mM) for 8hr.
When the incubation period was over the treated cultures were returned to complete
(+serum) media. The cultures were photographed at 24hr post-rTAT:Cre treatment
under bright-field and fluorescent confocal microscopy by Dr. Sunil Nandi.
In order to ensure a non-biased assessment of successful rTAT:Cre-mediated re-
combination in the cells, a double-blind system was adopted. The cultures were ‘blinded’
by labelling them alphabetically (a-f) in a non-sequential manner relative to the rTAT:Cre
doses used. Therefore Dr. Nandi did not know the treatment conditions of the samples
when taking the photographs. Dr. Nandi then ‘reblinded’ the photographs by rela-
belling them numerically (1-6) in a non-sequential manner in relation to the previous
alphabetical designations. Therefore, when cell counts for fluorescent vs. total cells
were carried out it was not possible to identify the concentration of rTAT:Cre used in
each sample by the label on the photograph. The total cell counts were carried out
using the bright-field images, while YFP-expressing cells were counted using the flu-
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orescent images. The percentage of YFP-expressing cells within the population was
calculated for each concentration of rTAT:Cre, using an average from six images per
concentration. It was found that a concentration of 1.5mM rTAT:Cre gave approxi-
mately 90% recombination rate in BMDMs. Although a 2mM treatment provided the
highest percentage of recombination (>90%), this appeared to represent the plateau
of recombination efficiency, indicating that increasing the concentration of rTAT:Cre
above 1.5mM provided diminishing returns (Fig 5.9b and c).
Optimisation summary Since it had been established that the rTAT:Cre successfully
excised floxed sequences in BMDMs, it was decided to use a final rTAT:Cre concen-
tration of 1.5mM for experiments with BMDMs.
Differentiation of Dicer-floxed bone marrow treated with recombinant TAT:Cre
The data generated here (section 5.2.1) demonstrated that DGCR8-/-ESCs were unable
to differentiate into mature macrophages. To determine if BMDMs could differentiate
in the absence of microRNAs, the rTAT:Cre system was used to remove Dicer from
Dicer-floxed bone marrow in vitro, and the differentiation of untreated and rTAT:Cre-
treated bone marrow was compared.
Experimental conditions Dicer-floxed bone marrow was harvested from six mice
and used to create three pools (two mice per pool) which were then incubated in the
presence or absence of 1.5mM of rTAT:Cre protein for 2hr in serum-free conditions at
37°C. These samples were designated as treated and control samples respectively. The
bone marrow was then transferred into macrophage differentiation culture conditions
for seven days. RNA and DNA samples were harvested immediately after the rTAT:Cre
treatment and at day 7 of culture; adherent and non-adherent cells were harvested
separately.
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Figure 5.9: Optimisation of Recombinant TAT:Cre System using YFP-reporter Cells.
This figure illustrates: a) Cre-mediated excision of the upstream floxed STOP sequence
in the YFP-reporter construct results in the expression of YFP in R26R-EYFP YFP-
reporter mice. BMDMs from R26R-EYFP YFP-reporter mice were plated in serum-
free macrophage culture conditions and treated with a range of rTAT:Cre concentra-
tions (0, 0.25, 0.5, 1, 1.5 and 2mM) for 8hr, n=2. b) The rTAT:Cre-treated cultures
were photographed at 24hr post-treatment under fluorescent confocal microscopy, 6
representative photographs were taken at each rTAT:Cre concentration. c) The per-
centage of successful recombination for each rTAT:Cre concentration was calculated
as a function of YFP-expressing cells.
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Figure 5.10: Morphological Changes during In Vitro Differentiation of rTAT:Cre-
treated Dicer-floxed BMDMs. Bone marrow was treated with 1.5mM of rTAT:Cre,
2hr in serum-free conditions at 37°C, then rTAT:Cre-treated and control bone marrow
samples were plated in macrophage differentiation culture conditions and grown for
7 days. Light microscopy photographs from d1, d3, d5 and d7 of differentiation are
shown here. The images show that fewer adherent cells were present in the rTAT:Cre
samples (x40 magnification). n=6
Morphological and cell index changes The gross cellular morphology of the rTAT:Cre-
treated and control sample populations was monitored by light microscopy during dif-
ferentiation (Fig 5.10). It was found that both cultures displayed the expected se-
quence of morphological changes, from non-adherent to adherent cells (section 3.2.1,
Fig 3.1). However, visual assessment revealed that there were fewer adherent cells in
the rTAT:Cre-treated cultures than in the controls in the initial stages of culture (d3-
4). This discrepancy between the number of adherent cells in the control and treated
cultures had diminished by days 5-6 of differentiation.
The xCELLigence machine was used to record, in real time, any differences in the
CI profiles between the control and rTAT:Cre-treated samples during BMDM differen-
tiation. Control and treated bone marrow samples were added to a 96-well E-view plate
(20,000 cells per well) in macrophage differentiation culture conditions (Fig 5.11). All
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Figure 5.11: Measurement of Cellular Impedance during Dicer-floxed Bone Marrow
Differentiation. The Roche xCELLigence system was used to measure changes in the
electrical impedance (CI value) across the surface of each well during macrophage
differentiation. a) Control and b) rTAT:Cre-treated samples (1.5mM of rTAT:Cre, 2hr
in serum-free conditions at 37°C) were plated at 20,000 cells per well in macrophage
differentiation media. The cells were grown for 7 days and the CI value across each
well was measured at 2hr intervals. Each individual data point represents the mean CI
value at that time-point ± 1 SD of 8 technical replicates. n=3
three pools showed a distinct difference in the CI profiles generated by the control and
treated samples. In the control cultures the CI values increased dramatically after day
3 of culture. By comparison, the CI values in the rTAT:Cre-treated samples only in-
creased slightly after day 4 of culture and the final CI values were all lower than any
of the control samples. It also was observed by light microscopy that the rTAT:Cre-
treated samples contained fewer adherent cells than the untreated control samples (Fig
5.12).
Together, the morphological observations and CI data indicated that the removal of
Dicer from bone marrow impaired BMDM differentiation in vitro.
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Figure 5.12: Photomicrographs of Dicer-floxed Bone Marrow Differentiation on the
Roche xCELLigence System. Bone marrow was treated with 1.5mM of rTAT:Cre,
2hr in serum-free conditions at 37°C, then rTAT:Cre-treated and control bone marrow
samples were plated at 20,000 cells per well in macrophage differentiation media and
grown for 7 days. Photographs of the three biological repeats were taken on d5 of
differentiation. Biological pools 1-3 (n=3) are shown from left to right in a) control
and b) rTAT:Cre-treated samples. The images show that fewer adherent cells were
present in the rTAT:Cre samples. This concurs with the cellular impedance values in
Fig 5.11.
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Marker gene expression analysis by RT-QPCR To better understand how the ab-
sence of Dicer affects the differentiation of BM into BMDMs the expression of a panel
of marker genes (Runx1, Cd34, c-kit, F4/80 and Csf-1r) was compared by RT-QPCR.
Normally, expression of the haematopoietic/myeloid-associated genes Runx1, c-kit and
Cd34 is expected to decrease over the seven days of culture, while expression of the
macrophage markers F4/80 and Csf-1r is expected to increase with differentiation (sec-
tions 1.2.1.4, 1.2.1.3 and 1.2.1.5). It was hypothesised that expression of these genes
in the rTAT:Cre-treated samples would vary from the control samples in some way.
The expression of Runx1, Cd34, c-kit, F4/80 and Csf-1r at d7 was measured by
RT-QPCR. Marker gene expression in the rTAT:Cre-treated duplicate cultures was cal-
culated relative to the matching pair of controls for each biological pool. In general,
the expression of the marker genes in Dicer-floxed BMDMs was similar to that seen in
wild-type BMDMs (Fig 5.13).
PCR confirmation of Dicer knock-down PCR analysis was carried out to confirm
successful excision of Dicer by rTAT:Cre treatment. DNA which had been extracted
from control and treated samples at d0 and d7 of culture was used in the PCR analysis.
Two primer pairs were used during the PCR analysis. The first pair was designed to
amplify a 420bp segment from the WT allele but not to produce a product from the
deleted allele, while the second pair of primers amplified a 471bp product from the
excised allele only. The PCR product was then electrophorised on an agarose gel and
visualised under UV light (Fig 5.14).
As expected, the 420bp WT product was observed in the d0 control samples and
the 471bp recombination product was not. In the rTAT:Cre-treated samples both the
WT and excised products were detected (Fig 5.14a). At d7 the WT product was only
observed in the control samples, and only the excised product was observed in the
treated samples (Fig 5.14b).
The results from the d7 non-adherent populations were similar to those of the d0
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Figure 5.13: Expression of Macrophage Markers during In Vitro Differentiation of
rTAT:Cre-treated Dicer-floxed BMDMs, measured by RT-QPCR. Duplicate cultures
of Dicer-floxed bone marrow from three biological pools were treated with 1.5mM of
rTAT:Cre for 2hr in serum-free conditions at 37°C. Treated and control bone marrow
samples were then plated in macrophage differentiation culture conditions for 7 days.
RNA from adherent cells was harvested at d7 and used to generate cDNA for RT-QPCR
analysis of the macrophage-associated genes a) c-kit, b) Cd34, c) Csf-1r, d) F4/80 and
e) Runx1. Gene expression in rTAT:Cre-treated samples is displayed as mean fold-
change (2-ddCt) ±1S.D. relative to untreated (control) bone marrow, for three technical
replicates. The data was normalised against the housekeeping gene HPRT. P-values
were calculated by paired student’s t-tests against the control sample, * = P-value <
0.05, ** = P-value < 0.01
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samples. The non-adherent control samples contained only the WT product, while in
the treated samples both the WT and excised products had been amplified (Fig 5.14c).
This data shows that the rTAT:Cre treatment had successfully excised the Dicer RNase
III domain from the genome.
Summary of Dicer-floxed bone marrow differentiation It appeared that macrophage-
like cells can be derived from Dicer-depleted bone marrow. The fact that these cultures
contain fewer cells than wild-type cultures may suggest that the ‘missing’ miRNAs are
required for other cellular characteristics such as adhesion or proliferation.
However, it was decided not to use these Dicer-deficient BMDMs for LPS acti-
vation experiments because we could not be confident that any changes in the LPS
response would be the direct result of the impairment of the LPS-induced miRNA
response, rather than a side effect of the abnormal steady-state in which these cells
appear to exist as a result of their differentiation under miRNA-deficient conditions.
Therefore it was decided to remove Dicer from mature BMDMs prior to activation
with LPS, in order to specifically block the generation of activation-induced miRNAs.
Activation of Dicer-floxed BMDMs treated with recombinant TAT:Cre The ap-
plication of Cre to mature BMDMs in culture should block the ability of mature
macrophages to generate new microRNAs upon activation. Due to the stability of
microRNAs (119hr [76]), it is possible that the existing miRNA population might not
be greatly affected by the excision of Dicer. However the generation of those miRNAs
normally activation-induced should be inhibited (Fig 5.8b). Our aim was to establish
the importance of these activation-induced microRNAs for normal macrophage activa-
tion.
Experimental conditions Dicer-floxed bone marrow was cultured under differentia-
tion conditions for 7 days. The resultant BMDMs were treated with 1.5mM of rTAT:Cre
for 8hr in serum-free conditions at 37°C to delete Dicer and then returned to complete
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Figure 5.14: PCR Product Analysis for Dicer Excision during the Differentiation of
Dicer-floxed Bone Marrow into BMDMs. Duplicate cultures of Dicer-floxed bone
marrow from three biological pools were treated with 1.5mM of rTAT:Cre for 2hr in
serum-free conditions at 37°C. Treated and control bone marrow samples were then
plated in macrophage differentiation culture conditions for 7 days. DNA was har-
vested at d0 and d7 for PCR analysis. Two primer pairs were used to assess whether
rTAT:Cre treatment had successfully excised the RNase III domain. Primers for the
WT Dicer sequence produced a product at 420bp. Primers for the deleted Dicer se-
quence produced a product of 471bp. a) d0 cultures. b) d7, adherent cell cultures. c)
d7, non-adherent cultures. 1-3 = biological pool (n=3). C = control/mock incubation.
T = rTAT:Cre-treated. PCR product electrophorised on 1% agarose 1x TBE gel and
visualised under UV light.
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(+serum) media. Control samples were treated in the same way but without the addi-
tion of rTAT:Cre. At 48hr post-treatment the BMDMs were activated with 10ng/mL
LPS; the start of the activation time-course was designated 0hr. DNA, RNA and protein
were harvested from unactivated cells (0hr). RNA was also harvested from multiple
time-points post-activation (1, 2, 6, 12 and 24hr). The RNA was used to generate
cDNA for RT-QPCR analysis and microRNA-Northern menbranes.
Morphological changes during activation of Dicer-floxed BMDMs Following ac-
tivation, morphological changes of individual cells within the population upon acti-
vation were found to be similar in the control and treated cells, although fewer cells
were present in the cultures treated with rTAT:Cre. Both cultures demonstrated in-
creased spreading, granularity and refraction of light (Fig 5.15). These observations
suggest that the loss of Dicer function does not prevent cytoskeletal changes following
activation of BMDMs by LPS.
Marker gene expression analysis by RT-QPCR To determine whether the loss of
Dicer activity resulted in changes to the molecular response seen upon the activation
of macrophages, the expression of known markers of activation was assessed by RT-
QPCR (Tnf-a, Cox2, Cxcl2, Il-6 and Saa3).
All five markers were induced in both the control and rTAT:Cre-treated samples,
providing molecular confirmation of activation (Fig 5.16). The rTAT:Cre-treated sam-
ples showed similar expression patterns to those of the control cultures.
MicroRNA-Northern analysis Loss of Dicer activity was predicted to cause a bot-
tleneck in miRNA production at the pre-miRNA stage and prevent the expression of
mature miRNA sequences. To determine if this was the case, the expression of known
macrophage-associated microRNAs was assessed in control and rTAT:Cre-treated cul-
tures by microRNA-Northern analysis.
In the absence of active microRNA degradation, it was expected that the levels of
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Figure 5.15: Morphological Changes during Activation of rTAT:Cre-treated Dicer-
floxed BMDMs. Dicer-floxed BMDMs were incubated with 1.5mM of rTAT:Cre for
8hr in serum-free conditions at 37°C, then activated with 10ng/mL LPS at 48hr post-
treatment. The morphological changes in control and rTAT:Cre-treated cell cultures
after activation were assessed at multiple time-points post-activation (0, 1, 6, 12 and
24hr). Presented here are representative photographs. Light microscopy at x40 magni-
fication. n=2
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Figure 5.16: Expression of Known Macrophage Activation Marker Genes during
the Activation Response in rTAT:Cre-treated Dicer-floxed BMDMs, measured by RT-
QPCR. Dicer-floxed BMDMs were incubated with 1.5mM rTAT:Cre for 8hr in serum-
free conditions at 37°C, then activated with 10ng/mL LPS at 48hr post-treatment.
cDNA generated from RNA harvested from control and rTAT:Cre-treated cell cultures
at multiple time-points post-activation was used in RT-QPCR to measure the expres-
sion of the macrophage activation markers a) Tnf-a, b) Cox2, c) Cxcl2, d) IL-6, and e)
Saa3. Expression is displayed as the mean fold-change (2-ddCt) ±1S.D. relative to un-
activated (0hr) control. The data was normalised against the housekeeping gene HPRT.
n=6. P-values were calculated by paired student’s t-tests against the unactivated (0hr)
control, * = P-value < 0.05, ** = P-value < 0.01
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constitutively expressed microRNAs (e.g. miR-146a) would remain unchanged in the
rTAT:Cre-treated cells following activation, and that microRNAs normally induced by
macrophage activation (e.g. miR-155) would be absent. In general, for those miRNAs
present in the cultures at T0 the expression levels were maintained throughout the
culture period. Most surprisingly, expression of mmu-miR-155 was induced in both
the control and treated cultures at 6hr post-activation (Fig 5.17).
Summary of Dicer-floxed BMDM activation Some differences emerged in gene
expression between the control and rTAT:Cre-treated macrophages, most notably around
12hr post-activation. However these differences were not statistically significant. Un-
expectedly, increased microRNA expression was observed in the rTAT:Cre-treated
cells following activation. Furthermore, rTAT:Cre treatment did not cause any observ-
able differences in macrophage activation morphology. Combined, this data suggested
that following rTAT:Cre treatment, Dicer-floxed BMDMs were still able to respond to
LPS activation within normal parameters.
It was then necessary to confirm Dicer knock-down to determine if these results
reflected the effect of Dicer ablation on macrophage activation, or if Dicer was still
present in the cells thereby enabling a mostly normal activation response.
PCR confirmation of Dicer knock-down The successful excision of the Dicer RNase
III domain from the genome was confirmed by PCR using DNA extracted from the
treated and control cells prior to activation (0hr). PCR was carried out using two
primer pairs to amplify segments of both the WT and excised Dicer alleles. The ampli-
fied product was then electrophorised on a 1% agarose 1x TBE gel and imaged under
UV light.
Amplification of the rTAT:Cre-treated samples with the Dicer deletion primers cre-
ated a 471bp product, indicating successful excision of the RNase III domain from the
gDNA. This band was not observed in the control samples (Fig 5.18). The reverse pat-
tern occurred when primers for WT Dicer were used. In the control samples a 420bp
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Figure 5.17: MicroRNA-Northern Analysis of MicroRNA Expression in rTAT:Cre-
treated Dicer-floxed BMDMs during Activation. Dicer-floxed BMDMs were incubated
with 1.5mM rTAT:Cre for 8hr in serum-free conditions at 37°C, then activated with
10ng/mL LPS at 48hr post-treatment. RNA was harvested from control and rTAT:Cre-
treated cell cultures at multiple time-points post-activation (0, 1, 2, 6, 12 and 24hr)
and was used to generate microRNA-Northern membranes. The microRNA-Northern
membranes were hybridised with LNA probes complementary to mmu-miRs -142-3p,
-146a, -155, -15b, -191, -21, -30b and -322-5p. T = rTAT:Cre-treated. C = control.
n=1
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Figure 5.18: PCR Product Analysis for the Excision of the Dicer RNase III Domain in
BMDMs Prior to Activation with LPS. Three biological pools of Dicer-floxed BMDMs
were incubated in duplicate with rTAT:Cre for 8hr and harvested for DNA 48hr post-
treatment. Successful excision of the Dicer RNase III domain by rTAT:Cre treatment
resulted in the generation of a 471bp band. This band was observed in the rTAT:Cre-
treated samples but not in the control samples. n=3
product was observed; a product of this size was not observed in the rTAT:Cre-treated
samples. This data shows that at the time of activation (48hr post-rTAT:Cre treatment)
the second RNase III domain of Dicer had been successfully excised. Any protein
made from this modified template would be non-functional.
Western analysis of Dicer expression Because of the unexpected induction of mi-
croRNAs in rTAT:Cre-treated Dicer-floxed BMDMs upon activation with LPS, it was
hypothesised that although new Dicer protein would be functionally inactive, any resid-
ual Dicer protein from before the rTAT:Cre treatment would still be functional and
could participate in the microRNA biogenesis pathway as usual, thus enabling mi-
croRNA generation in the rTAT:Cre-treated cells.
To determine if WT Dicer protein was present in the rTAT:Cre-treated samples
the expression of the Dicer protein was assessed by Western analysis (section 2.6.3).
Protein samples had been harvested at 48hr post-rTAT:Cre treatment, before activation
of the cultures (0hr). These samples were denatured, electrophorised on an 8-16%
tris-glycine gradient gel and transferred to a nitro-cellulose membrane. Expression of
Dicer was assessed using the Li-COR Odyssey system (Fig 5.19).
According to Harfe, et al., [99] the excision of the RNase III domain does not
introduce a premature stop codon; instead a smaller non-functional version of Dicer is
produced. Therefore both WT and non-functional Dicer were expected to be observed
during Western analysis. Dicer is approximately 220kDa and the non-functional Dicer
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Figure 5.19: Western Analysis of Dicer Protein Expression. Dicer protein was de-
tected (designated by the black arrowhead) in the ovary tissue control sample but not
in the BMDM samples (C and T) or the immortalised macrophage control (E). A trun-
cated form of Dicer (expected band 190kDa) was not detected in the rTAT:Cre-treated
samples. Staining: red = Dicer (218kDa), green = b-actin, loading control (42kDa).
Samples: O = ovary tissue control; E = hELAM-GFP control; C = untreated BMDMs;
T = rTAT:Cre-treated BMDMs. n=4
was expected to be approximately 190kDa, because the excised portion of the gene is
~820bp which equates to ~30kDa.
The 220kDa WT Dicer protein was only detectable in the ovary control sample;
it was not apparent in any of the treated or untreated BMDM samples. The smaller
190kDa protein was also not observed in any of the samples. This data suggests that
Dicer protein is present at levels below that detectable by Western analysis using this
antibody, and therefore this approach cannot be used to confirm Cre-mediated deple-
tion of Dicer protein.
Summary of activation of Dicer-floxed BMDMs While PCR analysis indicated that
the second RNase III domain of Dicer had been successfully excised in the rTAT:Cre-
treated cells, these cells still responded to LPS activation within normal parameters
(gene and miRNA expression), suggesting the presence of functionally active Dicer in
these samples.
It was not possible to confirm the expression of wild-type or truncated Dicer protein
in BMDMs by Western analysis. However, the up-regulation of microRNAs following
macrophage activation strongly suggested the continued presence of functional Dicer
protein within the samples.
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5.3 Discussion
Differentiation of DGCR8-/-ESCs The data produced here found that the DGCR8-/-
embryonic stem cell line was able to form embryoid bodies but was not able to differ-
entiate. Instead the cells were found to express both pluripotency markers and dif-
ferentiation markers at the same time. These findings are in agreement with previous
reports. The DGCR8-/- EBs replicated slowly and did not differentiate successfully, the
clearest indication of this deficiency being the inability to form cysts. The slow rate of
replication in comparison to the WT cells is likely to be the reason why the DGCR8-/-
EBs remained smaller throughout the time-course [268]. The expression profiles of
the ESC/HSC and myeloid markers in the EBs suggested that microRNAs are required
for turning off pluripotency markers rather than for turning on differentiation markers.
This is most obvious in the expression of Csf-1r and F4/80 which displayed the same
expression patterns in the DGCR8-/- cultures as in the WT cultures, suggesting that the
DGCR8-/- ESCs are able to some undertake elements of macrophage differentiation in
the absence of miRNAs.
Generation of Dicer-floxed BMDMs To investigate whether miRNAs are specifi-
cally required for the later stages of macrophage differentiation or for macrophage ac-
tivation, we analysed cells where Dicer was removed from either bone marrow or from
BMDMs. Our analysis of the rTAT:Cre-treated stop-floxed YFP BMDMs showed that
the rTAT:Cre was fully functional. The rTAT:Cre entered the cells and caused genomic
recombination which resulted in the expression of YFP. The optimal dose of rTAT:Cre
derived from our data differed slightly from the 0.5mM concentration of rTAT:Cre that
had been used by Wadia, et al. in reporter T-cells [268] possibly due to differences in
efficacy of the rTAT:Cre preparations, or to differences between the two cell types.
PCR analysis confirmed that the Dicer RNase III domain had been successfully ex-
cised from the genome of Dicer-floxed bone marrow cells. Although the Dicer-/- bone
marrow samples did differentiate into macrophages, they demonstrated some deviation
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from wild-type cells. During differentiation the rTAT:Cre-treated bone marrow sam-
ples displayed lower CI values than the control population (Fig 5.11). It may be that,
like the DGCR8-/- cells [274], the Dicer-deficient cells divide more slowly than their
wild-type counterparts, or are less adherent. Both of these possibilities could cause the
lower CI values.
The Dicer-deficient cells also demonstrated dysregulation of marker gene expres-
sion (Fig 5.13). Together this data indicates that microRNAs play a ‘fine-tuning’ role
during bone marrow differentiation into macrophages.
Activation of Dicer-floxed BMDMs This fine-tuning role of microRNAs was also
apparent during the activation of mature BMDMs that had been treated with rTAT:Cre
to remove Dicer activity. The treated samples displayed dysregulation of marker gene
expression when compared to untreated control cells, but also between the treated bio-
logical repeats.
The results from microRNA-Northern analysis of rTAT:Cre-treated BMDMs dur-
ing activation were unexpected. It was found that microRNAs were still present in
macrophages 48-72hr post-rTAT:Cre treatment. Expression of mature microRNAs in
the rTAT:Cre-treated/Dicer-excised cells was lower than seen in WT samples, often
with visible accumulation of pre-miRNA.
When harvesting the BMDMs from the tissue culture plastic, the rTAT:Cre-treated
cells were found to detach from the surface more easily than the control cells. This
observation concurs with the hypothesis that reduced adherence of individual cells
within the population contributed to the lower CI values generated by the xCELLigence
machine. This hypothesis provides a potential avenue for further study as it suggests
that microRNAs (global or specific) may be involved in regulating cellular adherence.
Published work on giant multi-nucleated cells appears to support this hypothesis [237].
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Summary of microRNA-free systems
Overall the results of the experiments undertaken here indicate that, in both macrophage
differentiation and activation, miRNAs are required for canalisation of mRNA expres-






The main aim of this work was to identify the profile of miRNAs expressed during
macrophage maturation and activation and to perform functional analyses of the role of
selected miRNAs in these processes. To do this, it was necessary to establish and char-
acterise in vitro systems for the culture and activation of both primary (BMDMs) and
immortalised (RAW264.7) macrophages (chapter 3). RNA from activated BMDMs
was then harvested at multiple time-points post-activation, and the microRNA expres-
sion profile in these samples established by next generation sequencing of miRNA
libraries. Although it later became apparent that technical issues with the sequencing
procedure (chapter 4) limited the utility of in silico analysis of the data set, differential
expression of a number of microRNAs was confirmed by independent approaches, and
these were selected for further analysis to determine the effects of individual microR-
NAs on macrophage activation. As this analysis suggested that most miRNAs played
a role in ‘fine-tuning’ processes, the requirement for the global microRNA population
in macrophage activation was assessed using DCGR8- and Dicer-deficient systems
(chapter 5). The main findings from these studies, how they fit into the macrophage
activation literature, and ideas for future work are discussed here.
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6.2 In vitro primary and immortalised macrophage cul-
ture
Primary BMDMs were successfully cultured in vitro from bone marrow, and subse-
quently activated with LPS. The effects of LPS activation on macrophage biology
were assessed by the observation of morphological changes, marker gene expres-
sion (mRNA and miRNA) and CI profiling analysis. The data demonstrated that the
BMDMs had been successfully activated with LPS and responded within the expected
parameters; the expression of Tnf-a, Cox2, Cxcl2, Il-6 and Saa3 and miR-155 was
induced in activated macrophages, while expression of the constitutively expressed
miR-146a was up-regulated (Fig 3.7 and Fig 3.13). Activated macrophages demon-
strated morphological changes, most notably cell spreading (Fig 3.5). The CI values
also increased following LPS stimulation (Fig 3.6).
The activation response of the BMDMs was compared against that of an estab-
lished macrophage cell line (RAW264.7 cells). The RAW264.7 cells were shown to be
successfully activated in a similar manner to the BMDMs (induction of Tnf-a, Cox2,
Cxcl2, Il-6 and Saa3 by LPS. Fig 3.10). However the morphological changes observed
(Fig 3.8), and the CI values recorded (Fig 3.9) after RAW264.7 cell activation with LPS
were smaller than those demonstrated by the BMDMs, suggesting that the RAW264.7
cell response is less robust.
A direct comparison of miR-146a and miR-155 expression in the activated pri-
mary and immortalised macrophages across a serial dilution of LPS (Fig 3.15) clearly
showed that the RAW264.7 cell microRNA response was less sensitive to LPS stim-
ulation than BMDMs. In RAW264.7 cells miR-155 was not induced at LPS con-
centrations <1ng/mL, while BMDMs demonstrated a strong induction of miR-155 at
LPS concentrations ≥0.1ng/mL. The assessment of miR-155 and miR-146a expres-
sion over an extended time-course (120hr post-activation, Fig 3.14) demonstrated that
miR-155 expression increased until 24hr post-activation when it appeared to plateau
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before decreasing after 72hr post-activation. This decreased expression was likely the
result of the resolution of inflammation. As a pro-inflammatory miRNA, miR-155
must be turned off after the completion of the activation response. Expression of the
anti-inflammatory miR-146a increased steadily over the 120hr time-course. In con-
trast, miR-155 expression in the RAW264.7 cells was very low and did not appear to
be down-regulated during the time-course. MiR-146a expression in the RAW264.7
cells was lower than in the BMDMs but followed the same expression pattern, i.e.
constitutive expression that continued to increase for the duration of the time-course.
The morphological changes observed and marker gene expression profiles found
in the activated BMDMs and RAW264.7 cells are in agreement with published data
(sections 1.2.3.3 and 1.4.2.2) and confirmed successful activation of these cells. The
Cell Index provided novel data on the phenotypic changes in the macrophage popu-
lation following LPS activation. Several factors can affect the CI profile of a culture,
but it is likely that the increased CI values observed following macrophage activation
were caused by an increased number of focal adhesion points in the cells as they pre-
pared to spread. It was evident that resolution of the cell index response was delayed
in established cell lines compared to BMDMs. MicroRNA-Northern analysis of RNA
from the extended activation time-course demonstrated for the first time that the ele-
vated expression of miR-146a and miR-155 in response to LPS persists past the 24hr
mark. When considered in conjunction with the LPS dose response data, it was clear
that induction of microRNAs in BMDMs was stronger and more sensitive than in the
RAW264.7 cells.
These analyses suggest that the established cell lines represent reasonable model
systems for mature and activated macrophages, although the activation responses are
lower and resolution of the response is delayed compared to the primary cells. Accord-
ingly, since BMDMs could be routinely and reproducibly cultured, this cell type was
used to generate material for miRNA libraries and for NGS. On the other hand, as it is
not possible to transfect primary macrophages, it was decided to use RAW264.7 cells
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for functional analysis of selected microRNAs.
6.3 Effect of microRNA knock-down and over-expression
on macrophage biology
Next generation sequencing was used to characterise microRNA expression profiles
during macrophage activation. RNA was harvested from BMDMs at multiple time-
points post-activation with LPS and used to generate small RNA sequencing libraries.
437 individual microRNAs were detected in LPS-activated BMDMs during the 24hr
post-activation (appendix A). At any one time-point, 5-15% of these microRNAs were
up-regulated compared to unactivated cells, 15-30% were down-regulated and a fur-
ther 15-30% were completely unexpressed. MiR-21 was the most highly expressed
microRNA across all of the time-points and represented 45% of the total reads across
the libraries. The second most highly expressed microRNA, miR-142-3p, contributed
10% of the total reads. Collectively, the top ten most highly expressed microRNAs
accounted for 86% of the total reads. Although the exact distribution later proved to
be unreliable for technical reasons (section 6.7.1), microRNA-Northern analysis of se-
lected miRNAs identified a number that were differentially expressed. These miRNAs
were then used in knock-down and over-expression experiments to assess their effect
on macrophage activation morphology (CI profile analysis, Fig 4.13 and 4.14) and the
expression of known macrophage activation marker genes (Tnf-a, Cox2, Cxcl2, Il-6
and Saa3, Fig 4.12).
MicroRNA-Northern analysis confirmed that Pre-miRs and Anti-miRs were suc-
cessfully transfected in a dose-dependent manner in the RAW264.7 cells, and that en-
dogenous levels of specific miRNAs could be completely depleted or mimicked (Fig
4.7 and Fig4.8). RT-QPCR analysis of activation marker gene expression and CI pro-
file analysis using the Roche xCELLigence system demonstrated that the majority of
the microRNAs studied here did not exert significant effects on macrophage activation.
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Some microRNAs were able to alter marker gene expression or the CI profile, and are
described below.
6.3.1 Functions of miR-146a
As described earlier (section 1.4.2.2), miR-146a is one of the major macrophage-
associated microRNAs. This anti-inflammatory microRNA is constitutively expressed
in macrophages, its expression is increased by macrophage activation with LPS [254]
and plays several roles in the resolution of inflammation and in establishing endotoxin-
induced tolerance [184]. For this reason miR-146a was selected as a microRNA con-
trol when establishing the in vitro macrophage activation systems (chapter 3) and was
found to be expressed in concurrence with the literature (Fig 4.3). The knock-down
and over-expression of miR-146a by transfecting RAW264.7 cells with Pri-miRs and
Anti-miRs (LNAs) produced the expected effects on the five macrophage activation
markers measured here. Increased expression of miR-146a (transfection with Pri-miR)
caused decreased expression of Tnf-a, Cox2, Cxcl2, Il-6 and Saa3, while decreased
expression of miR-146a (Anti-miR) caused a corresponding increase in marker gene
expression (Fig 4.12). MiR-146a is reported to directly target two members of the
MyD88-independent NFkB signalling pathway, IRAK1 and TRAF-6 [254], and it is
likely that, through this action and its subsequent down-regulation of downstream in-
flammatory mediators, miR-146a was able to affect the expression of the five genes
measured here. This data concurs with the anti-inflammatory effects of miR-146a re-
ported in the literature.
Interestingly, knock-down of miR-146a reduced expression of the pro-inflammatory
miR-155 (Fig 4.7). As miR-146a is reported to negatively regulate the NFkB signalling
molecule IRAK1 [163, 285], it might be expected that the knock-down of miR-146a
would have caused increased expression of miR-155 via increased NFkB signalling;
however this was not the case. This cross-talk between miR-146a and miR-155 and
the mechanism behind it has not yet been reported.
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6.3.2 Functions of miR-155
MiR-155 is considered the archetypal pro-inflammatory microRNA in the macrophage
activation response and its expression can be induced via several of the TLR signalling
pathways (section 1.4.2.2). MiR-155 was selected as a miRNA marker of success-
ful macrophage activation. MiR-155 was not expressed in unactivated macrophages.
However, its expression was induced by LPS/TLR-stimulation becoming faintly de-
tectable by microRNA-Northern analysis at 2hr post-activation, and robustly detectable
by 4hr post-activation. Expression of miR-155 continued to increase until 24hr post-
activation (Fig 4.3). This concurred with previous reports that miR-155 is an LPS-
responsive gene in macrophages [185, 194].
Knocking-down miR-155 in RAW264.7 cells (Anti-miR) caused increased expres-
sion of the macrophage activation marker genes Tnf-a, Cox2, Cxcl2, Il-6 and Saa3,
while increased expression of miR-155 (Pre-miR) led to decreased expression of these
genes (Fig 4.12). Because miR-155 is generally characterised as a pro-inflammatory
microRNA [15, 166, 259], these results initially appear somewhat anomalous. How-
ever, miR-155 is reported to contribute to its own negative feedback loop via indirect
regulation of Akt [11]. Therefore it is possible that, in this case, the over-expression
of miR-155 triggered this negative feedback loop, thereby initiating an earlier down-
regulation of the pro-inflammatory marker genes, which resulted in the decreased gene
expression observed here. Furthermore, it has been reported that inhibition of miR-
155 expression results in higher than normal expression of some activation markers
[218]. Therefore, while the gene expression trends observed here during knock-down
and over-expression of miR-155 during macrophage activation were unexpected, they
were not without precedent.
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6.3.3 Function of miR-15b
MicroRNA-Northern analysis showed that expression of miR-15b was increased by
LPS stimulation (Fig 4.5). Knock-down of miR-15b was associated with the signifi-
cant knock-down of all five macrophage activation marker genes measured here (Tnf-
a, Cox2, Cxcl2, Il-6 and Saa3, Fig 4.12) indicating a pro-inflammatory role for this
macrophage during LPS activation of BMDMs. MiR-15b expression is also reported
to be induced by LPS stimulation in vivo in a dose- and time-dependent manner [104],
and inhibition of miR-15b has been found to regulate Tnf-a expression in acute liver
failure [9].
6.3.4 Functions of miR-191
MicroRNA-Northern quantitation showed that the expression of miR-191 was un-
changed during macrophage activation by LPS (it had been previously reported to be
up-regulated during macrophage activation [223]). Knocking-down miR-191 resulted
in the significant down-regulation of the pro-inflammatory genes Tnf-a, Il-6 and Saa3
(Fig 4.12). The mechanism by which this occurs is unclear, as miR-191 is not predicted
to target any of these genes, nor any macrophage-associated signalling pathways. MiR-
191 knock-down also significantly decreased the CI profile of activated macrophages
(Fig 4.14d). Predicted targets for miR-191 were enriched for cellular structural com-
ponents, suggesting possible mechanisms by which miR-191 exerts effects on cellular
morphology. Abnormal miR-191 expression has been identified in a variety of diseases
including several types of cancer, type 2 diabetes and asthma where it is thought to af-
fect proliferation, angiogenesis, migration and apoptosis [52, 79, 183, 258, 260, 279].
This association between miR-191, angiogenesis and migration is particularly inter-
esting in light of the CI data (Fig 4.14d) and predicted target analysis presented here
(pathway analysis in section 4.2.4), which both indicate a role for miR-191 in cel-
lular morphology, suggesting that miR-191 may play a role in activated macrophage
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migration/adhesion.
6.3.5 Functions of miR-21
When the NGS was carried out, miR-21 had just recently been reported as an anti-
inflammatory macrophage-associated microRNA. Induced by LPS/TLR-4/NFkB sig-
nalling, miR-21 negatively regulates NFkB by targeting PDCD4 [232]. Since then,
miR-21 has been widely reported as an anti-inflammatory microRNA [231].
MiR-21 was found to be one of the most highly expressed microRNAs in the NGS
data set (Table 4.2). MicroRNA-Northern analysis showed that miR-21 was consti-
tutively expressed in BMDMs and up-regulated during macrophage activation (Fig
4.5). Although knocking-down miR-21 did not exert any significant effects on the five
macrophage activation markers measured here, it did exert significant effects on the
CI profile. While the miR-21 knock-down sample still responded to LPS activation,
the CI profile was significantly lower than the control sample (Fig 4.14c), suggesting
a possible role for miR-21 in cellular morphology. Although miR-21 is reported to
target MMP9, direct interaction between miR-21 and MMP9 in macrophages has not
been reported. In silico analysis of miR-21-predicted targets did not reveal any ECM-
associated targets that might be directly responsible for the effect of miR-21 on the CI
profile. Several of the predicted genes were associated with tissue development, indi-
cating a possible role for miR-21 in tissue remodelling. This concurs with the reported
role of miR-21 in tumour development [231], and could explain how miR-21 exerts an
effect on the CI profile.
6.3.6 Functions of miRs -142-3p, -16, -27b, -30b, -322-5p, -378, -7a
Although differentially expressed in the culture system, the majority of miRNAs tested
(by LNA knock-down) did not affect macrophage activation or cellular morphology
(gene expression analysis or CI profile analysis, Figures 4.12, 4.13 and 4.14). How-
ever, the fact that these microRNAs are differentially expressed suggests that they are
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involved with aspects of macrophage biology other than a) cellular morphology, or b)
the expression of the pro-inflammatory activation marker genes assessed here.
miR-142-3p MicroRNA-Northern analysis detected constitutive expression of miR-
142-3p that was up-regulated upon macrophage activation with LPS. Knocking-down
miR-142-3p expression was not found to affect macrophage activation; morphology,
CI profile and marker gene expression remained unchanged (Fig 4.12 and Fig 4.14).
Interestingly, knock-down of miR-142-3p caused reduced expression of miR-155 (Fig
4.7).
It has previously been reported that miR-142-3p is constitutively expressed in
blood cells [64, 128] and that miR-142-3p can be induced in vivo in response to
LPS [178]. Subsequent reports have expanded the understanding of the role of miR-
142-3p in haematopoiesis [5, 251] and the immune system [252], where it is sug-
gested that miR-142-3p regulates several aspects of the macrophage activation re-
sponse [121, 251, 285].
Previous reports have suggested that miR-142-3p negatively regulates the NFkB
signalling molecule IRAK1 [163, 285] which would result in decreased expression of
the NFkB-induced miR-155. Therefore it was expected that the knock-down of miR-
142-3p would cause increased expression of miR-155 via increased NFkB signalling.
The data here demonstrated that miR-142-3p unexpectedly caused decreased expres-
sion of miR-155, and that knock-down of miR-155 was also able to negatively regu-
late miR-142-3p. This cross-talk between miR-142-3p and miR-155 has been reported
subsequently [251].
miR-16 Most commonly associated with several types of cancer [31], miR-16 was
up-regulated in the microRNA-Northern analysis following macrophage activation.
The microRNA-Northern analysis concurred with an existing report that expression
of miR-16 was increased in activated macrophages [279]. It has subsequently been
reported that miR-16 participates in regulation of inflammatory molecules during LPS
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activation response [9, 273, 299].
miR-27b MicroRNA-Northern analysis showed that expression of miR-27b was up-
regulated following stimulation with LPS. Previously reported to be up-regulated fol-
lowing macrophage activation [120, 178], it has subsequently been suggested that miR-
27b regulates iNOS expression during microbial infection [299].
miR-30b Expression of miR-30b was unchanged when assessed by microRNA-Northern
analysis. The role of miR-30b during macrophage biology has only recently been re-
ported where it is suggested to influence macrophage differentiation [69] and phago-
cytosis [186].
miR-322-5p Down-regulated in micro-RNA-Northern analysis, the changes in miR-
322-5p expression following macrophage activation have not been reported, although
recently it has been suggested that miR-322 plays a regulatory role in diabetes and
insulin signalling [93, 145, 164].
miR-378 MiR-378 expression up-regulated in microRNA-Northern analysis. At the
time of these studies the expression profile of miR-378 in activated macrophages had
not been reported. Since then, miR-378 has been reported to be associated with
macrophage proliferation [217] and osteoclast biology [58, 125].
miR-7a MicroRNA-Northern analysis showed up-regulation of miR-7a. The expres-
sion profile of miR-7a during macrophage activation had not been reported at the time
of these studies. Subsequently, miR-7a has been reported to play a pivotal role in the
formation of multinucleated giant cells from macrophages during inflammation [237].
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6.3.7 Summary of microRNA knock-down and over-expression
The combined evidence generated here (section 4.2.3.2) suggests that most individ-
ual microRNAs do not exert major effects on macrophage activation or proliferation.
All 12 of the individual microRNAs selected for functional analysis demonstrated dy-
namic expression in activated macrophages, but none of the microRNAs tested were
able to block macrophage activation and only a few of the microRNAs exerted signif-
icant effects on the macrophage activation responses measured here. Knocking-down
miR-15b, miR-146a, miR-155 and miR-191 caused small but significant changes to
the marker gene expression. Knocking-down miR-191 and miR-21 showed a simi-
lar result on CI values, i.e. the macrophage activation response was augmented but
not blocked. Taken together, these findings support a ‘canalising’ role for microR-
NAs whereby microRNAs ‘fine-tune’ biological processes. This fine-tuning effect has
been identified in several different biological systems including the liver [43], the brain
[267], tooth development [174], T-cell development [72], erythropoiesis [157] and the
hypoxic response [114].
6.4 Role of global microRNA population
The microRNA knock-down data presented here suggests that individual microRNAs
act to fine-tune the macrophage response. To investigate the requirement of the global
microRNA population in macrophage differentiation and activation, two microRNA-
free cellular systems were employed: DGCR8-/- ES cells and Dicer-floxed BMDMs.
DGCR8 and Dicer are key components in the microRNA biogenesis pathway and their
deletion blocks the generation of mature microRNAs. The effects of DGCR8 and Dicer
ablation on macrophage biology are discussed below.
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6.4.1 Requirement of DGCR8
Wild-type and DGCR8-/- ES cells were cultured in macrophage differentiation culture
conditions to determine if microRNAs were required for this process. It had been
previously reported that macrophages could be generated from wild-type ESCs under
these conditions [127]. The results reported here showed that mature macrophages
could not be derived from stem cells lacking microRNAs and that these cells retained
expression of stem cell markers. However, there was also evidence that culture condi-
tions could induce certain molecular characteristics of macrophages in DGCR8-/- ES
cells (Fig 5.6). These findings suggest that microRNAs are either required to facili-
tate differentiation, or are required to shut down pluripotency. It is also possible that
microRNAs function in both capacities. The findings also demonstrate that microR-
NAs are not necessary for the initial development of macrophage characteristics during
differentiation.
Although there are no reported studies on the effect of DGCR8 depletion and the
associated loss of microRNAs on macrophage biology, it is apparent that DGCR8 and
the global microRNA population are required for normal biology in many systems
including: differentiation and function of Schwann cells [154], kidney formation and
function [18], skin development [294], osteoclast differentiation and function [249,
250], NK cell function [24], regulatory T-cell function [119] and the development of
T-cell tolerance [133]. Interestingly, the loss of DGCR8 function also appears to block
cancer growth and development [20, 95]. This effect is possibly linked to the report
that DGCR8 knock-down causes cell senescence in primary fibroblasts through loss of
microRNA-mediated suppression of cell-cycle inhibitors [83]. The slower growth rate
of the DGCR8-/- ESCs used in this study may also be caused by this type of interaction.
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6.4.2 Requirement of Dicer
When investigating the role of the microRNA-processing molecule Dicer in macrophage
biology, it was demonstrated that Cre could be used successfully to excise Dicer from
Dicer-floxed bone marrow cells in vitro. These Dicer-deficient bone marrow cells
could be differentiated into macrophages, but showed dysregulation of macrophage
marker genes (Fig 5.13) and produced fewer cells (Fig 5.10) than wild-type bone mar-
row.
It had already been established that Dicer is required for early development, that
its ablation causes embryonic arrest [23], and that individual microRNAs can exert
fine-tuning effects on various stages of haematopoiesis [57]. Concurrent work in the
same time-period as the data presented here reported the requirement of Dicer, and the
global microRNA population, for the maintenance of HSCs [29, 94]. The ablation of
Dicer in C/EBPA+ myeloid progenitors is reported to reduce the number of GMPs and
subsequently monocytes/macrophages in vivo. Furthermore these Dicer-/-GMP cells
demonstrate a resurgence of genes associated with earlier stages of the haematopoietic
pathway [5].
It appears that the loss of Dicer at later developmental stages impairs, rather than
blocks cellular development. For example, the loss of Dicer function in erythroid
precursors causes the cells to become megakaryocytes [29], while loss in later-stage
erythroid cells impairs erythroid maturation [30]. In vivo, lineage-specific Dicer dele-
tion reduces the number and impairs the function of osteoclasts [176] and mast cells
[195] but does not block their maturation entirely. This explains the finding that the
mixed-cell bone marrow population was able to differentiate into BMDMs (Figs 5.10
and 5.13); some of the cells were later progenitors that were sufficiently committed
to the macrophage differentiation pathway that the ablation of Dicer could not prevent
final differentiation.
The data relating to investigation of the effect of Dicer ablation on macrophage
activation was found to be inconclusive as Dicer was excised by Cre, but the cells re-
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sponded within normal parameters to LPS stimulation (Fig 5.16) and continued to pro-
duce microRNAs (Fig 5.17), suggesting that the cells still contained functional Dicer
protein.
Some reports suggest that Dicer activity and the canonical microRNA population
mediate macrophage biology; alveolar macrophages in smokers are known to be more
susceptible to disease and have been reported to display decreased Dicer and global
microRNA expression [92]. Dicer knock-down is reported to promote macrophages to
form multinucleated giant cells [237], while HIV suppresses Dicer activity in mono-
cytes and macrophages [46]. Dicer has also been reported to be required for other
processes within the immune system, including normal NK cell [24], CD8+ T-cell
[297] and mast cell [195] functions, in addition to the development of germinal cen-
tres, B-cell formation and antibody production [286].
6.4.3 Non-canonical microRNAs in microRNA-free systems
As previously reviewed (section 1.3.4), there are non-canonical microRNA biogene-
sis pathways that bypass the need for DGCR8 or Dicer; therefore neither of the sys-
tems used here is truly microRNA-free. Categories of known DGCR8-independent mi-
croRNAs include: mirtrons, small nuclear RNAs (snRNAs), endogenous small hairpin
RNAs, tRNAs and simtrons (Drosha-dependent, DGCR8-independent) [100]. There
are fewer Dicer-independent processing pathways reported. So far miR-451 is the
only miRNA to have been identified as truly Dicer-independent [291]. However, it has
been reported that in the absence of Dicer, pre-miRNAs can be loaded directly onto
AGO. The slicer activity then selectively generates mature 5p miRNAs [134, 290].
Interestingly, it appears that depletion of Drosha (the other half of the micropro-
cessor) blocks a greater number of canonical and non-canonical microRNAs than de-
pletion of Dicer or DGCR8. In the experiments conducted by Kim et al., knocking-out
Drosha essentially blocked the expression of all canonical microRNAs and only a few
non-canonical microRNAs were detected (miR-7706, -3615 and -1245) [134]. This
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suggests that a Drosha-/- system may be the most effective way to achieve a microRNA-
free model.
6.4.4 Global microRNA summary
The data contained here, as well as in some other reports, give differing results on the
requirement of the global microRNA population for cell survival and cellular functions.
It appears that the effect of complete microRNA ablation is dependent not only on the
cell type, but also on the stage of cell maturation. Removal of the global microRNA
machinery can either block cellular development completely, or cause dysregulation
or some degree of abnormality in the response. This suggests that in some conditions
the role of the global microRNA population is the canalisation of biological processes,
while in other conditions it is a crucial regulator.
6.5 Role of microRNAs in macrophage adhesion
It has previously been reported that microRNAs can target ECM proteins in many
different cell systems, most notably in cancer where dysregulation of microRNAs
affects tumour growth and metastasis by influencing cellular adhesion and motility
[111]. In macrophages specifically, miR-107 negatively regulates the expression of
cyclin-dependent kinase 6 (CDK6) which facilitates macrophage adhesion. TLR-4
mediated down-regulation of miR-107 increases macrophage adhesion [101]. MiR-
7a-1 negatively regulates the IL-4-responsive fusion protein Tm7sf4 which mediates
macrophage fusion into giant multinucleated cells [237]. In atherosclerosis, reduced
miR-155 expression is associated with increased expression of the adhesion molecules
ICAM-1 and VCAM-1, as well as increased lipid phagocytosis [41].
The microRNA knock-down data here demonstrated that miR-191 and miR-21
were able to significantly affect the CI value of activated macrophages (Fig 4.14),
strongly indicating that these microRNAs are able to influence aspects of macrophage
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activation morphology. Genes associated with cellular morphology accounted for
approximately 25% of miR-191-predicted targets, and miR-21 is reported to target
MMP9, even if this direct interaction has not been described in macrophages, strongly
supporting the conclusion that miR-191 and miR-21 are associated with macrophage
adhesion. Furthermore, it was observed that Dicer-/-BMDMs detached more easily
from the culture plate than wild-type cells (chapter 5). The findings from both indi-
vidual and global microRNA knock-down experiments support previous reports that
microRNAs are associated with macrophage adhesion. The identification of miR-191
and miR-21 as adhesion-associated microRNAs during macrophage activation adds to
this knowledge.
6.6 Conclusions
Individual microRNAs were successfully knocked-down in macrophages. Four mi-
croRNAs, miR-15b, -191, -146a and -155, were found to significantly alter expression
of macrophage activation markers. MiR-191 and miR-21 were found to exert sig-
nificant effects on macrophage physiology, most likely through regulation of ECM
components. It is thought that miR-191 and miR-21 regulate macrophage adhesion but
the exact mechanisms by which these effects occur are not yet known and provide an
interesting avenue for future work.
The rTAT:Cre system can be used to successfully introduce Cre into BMDMs
in a dose-dependent manner. Ablation of Dicer from bone marrow did not prevent
the generation of BMDMs, while DGCR8-/- ESCs were not able to differentiate into
macrophages. Both systems demonstrated some dysregulation of gene expression.
Given the inconclusive findings on the effect of Dicer ablation on LPS activation of
macrophages, this aspect needs further study.
Overall, it appears that individual microRNAs exert their effects through canalisa-
tion of biological processes, and that removal of the global microRNA population does
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not entirely block the development of (molecular) macrophage characteristics.
6.7 Retrospective assessment of methodology
6.7.1 illumina small RNA sequencing
At the time this work was carried out (2011), the illumina Small RNA sequencing kit
used here was a new product in the next generation sequencing repertoire. The bar-
coded indexed adaptor system supplied by the sequencing service providers (Ark Ge-
nomics) was based on the established illumina multiplexing sequencing kit for mRNA.
The indexed adaptor system was found to have introduced bias into the data set
(chapter 4, Fig 4.6). Other laboratories reported around that time that it was the gen-
eral methodology of the indexed adaptor system itself that had introduced the bias
[6, 262]. When the indexed adaptors were added directly to the RNA samples prior to
amplification by PCR, the nucleotide differences within the indexes caused sequence-
specific amplification bias during the PCR stage. This uneven amplification between
the samples was then carried through the samples to the sequenced libraries.
It was found that ligating standard adaptors to the RNA samples and then adding the
indexed adaptors during the PCR amplification step prevented the induction of index-
specific sequencing bias. illumina and the other NGS platforms took the findings of
these papers into account and redesigned their multiplexing kits appropriately. illumina
now also produces multiplexing kits for small RNA sequencing.
If this work was to be repeated now, a designated small RNA multiplexing kit
would be utilised, or possibly a microRNA array chip, to generate a reliable data set
without inherent bias that could therefore be reliably used during in silico analysis, in
addition to serving as a starting point for laboratory work.
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6.7.2 Assessment of DGCR8- and Dicer-deficient systems
The most obvious challenge with the rTAT:Cre/Dicer-floxed system is how to deter-
mine if any functional Dicer protein remains in the treated cells. Therefore to accu-
rately assess the effect of Dicer ablation on macrophage activation, it would be neces-
sary to identify a system to detect Dicer protein expression in macrophages in order to
measure its turnover in resting macrophages. Once it is established that no functional
Dicer remains in the BMDMs, the effect of Dicer depletion on macrophage activation
can be assessed.
During these experiments, it would have been ideal to have access to Dicer-/- ESCs,
or DGCR8-floxed mice, so that a direct comparison between the two molecules could
have been made. Although both molecules form part of the microRNA biogenesis
pathway, they function at different stages and in different cellular compartments, and
different non-canonical microRNAs remain in each scenario (Fig 1.15).
6.8 Future work
6.8.1 MicroRNA knock-down and over-expression
The data here contains some interesting findings that merit further exploration. The
actions of miR-15b, miR-191 and miR-21 on macrophage activation could be fully
characterised, and the mechanisms by which they exert these effects identified. Mi-
croarrays could be used to assess changes in the transcriptome upon knock-down and
over-expression of these microRNAs. Once the genes regulated by these miRNAs have
been identified, target prediction analysis could be used to suggest miRNA:mRNA in-
teractions between the identified genes. These interactions could then be confirmed by
luciferase reporter assays.
By characterising changes in mRNA expression at multiple time-points post-activ-
ation after manipulating the levels of individual microRNAs, it would be possible to
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determine if gene expression is altered for the entire time-course, or if the gene expres-
sion can recover. Newer technologies such as the CRISPR/Cas9 system [47, 122, 203]
would make it possible to undertake reversible gene silencing, in addition to regular
knock-down experimentation.
6.8.2 Global microRNA population
Future work in the field of microRNA-free systems could focus on characterising the
LPS macrophage activation response in the absence of the global microRNA popula-
tion, via the depletion of Dicer, Drosha or DGCR8, or ideally all three as a comparison.
The EB differentiation experiments could also be repeated, this time to include
Dicer-/- and Drosha-/- ESCs as a comparison against DGCR8 and WT ESCs. If any
macrophage-like cells were generated from the Dicer-/- and/or Drosha-/- ESCs, then
phagocytosis assays and LPS activation could be carried out to discover if the cells can
function as macrophages. How would the activation response of these cells vary from
BMDMs or mature immortalised macrophage cell lines? A comparison between the
activation response of the macrophages derived from the the WT ESCs and the primary
and immortalised macrophages would be interesting, in order to determine whether the
cells are able to phagocytose and respond to LPS within normal parameters. Although
the DGCR8-/- cells did not generate any adherent cells in the experiments conducted
here, it might be interesting to treat them with LPS to determine if they expressed any
activation markers in addition to macrophage markers.
To assess the effect of microRNA ablation on macrophage development in vivo,
the MacGreen mouse, in which the macrophages express GFP, could be crossed with
macrophage lineage-specific Dicer, Drosha or DGCR8-floxed mice. Macrophage de-
velopment and distribution in vivo in the absence of microRNAs could then be as-
sessed.
MicroRNA arrays could be used to accurately assess the remaining microRNA ex-
pression in each system. A comparison of non-canonical microRNA expression across
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Dicer-/-, Drosha-/- and DGCR8-/- models could provide clues regarding any phenotypic
differences observed between models.
6.8.3 Effector functions of secreted microRNAs
The literature presents some evidence of RISC-independent functionality by microR-
NAs. It has been reported that, in cancer, circulating microRNAs (miR-21 and miR-29)
can be taken up by tumour-associated immune cells. The microRNAs then activate the
intracellular, ssRNA-binding TLRs-7/8, causing NFkB signalling and up-regulation of
IL-6 and TNF-a, thus driving tumour growth and metastasis [45, 62]. It would be inter-
esting to investigate which, if any microRNAs are secreted by activated macrophages
and assess what effects they have on other cells of the immune response. Do secreted
microRNAs help to shape the inflammatory response in vivo by creating cross-talk be-
tween cell types? It has been reported that microRNAs can affect endothelial cell
ICAM-1 expression, which is associated with macrophage adhesion and migration
[32, 37, 158].
6.9 End note
Macrophage activation is a highly complex and dynamic process. Therefore it is
not surprising that microRNA regulation of macrophage activation should share these
traits. MicroRNA research is a fast paced, exciting field of study that not only im-
proves our understanding of the intricacies of macrophage biology but also contains
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Appendix A
illumina next generation sequencing
data
A.1 Normalised read counts and fold-change for all
microRNAs
The normalised read counts and fold-change of mean read counts for each time-point
are shown. The 0hr read counts were set as the baseline for expression (value 1.00).
The table contains all 437 microRNAs identified across the six time-points. The table
















A.2 Data loss during NGS analysis
Data loss at each step of NGS data analysis.
Cluster number on flow cell = total number of sequence reads generated in each lane
on the illumina sequencing chip
Dead miRNAs = sequences previously mis-identified as microRNAs
(www.mirbase.org ‘download’ section, ‘deadlist’)
Mature mmu-miR reads = sequences used for data analysis. These sequences were
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B.1 pET 28b TAT v2 Vector Map
Figure B.1: pET 28b TAT v2 Vector Map.
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B.2 rTAT:Cre Sequence
Figure B.2: rTAT-Cre sequence within the pET 28b TAT v2 plasmid
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